An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool by Jajosky, Audrey Nadine
Graduate Theses, Dissertations, and Problem Reports 
2014 
An Overview of Acute Myeloid Leukemia and Cancer Immunology: 
(i) Concepts and Therapeutic Strategies and (ii) RepSox as a 
Candidate Cell-Engineering Tool 
Audrey Nadine Jajosky 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Jajosky, Audrey Nadine, "An Overview of Acute Myeloid Leukemia and Cancer Immunology: (i) Concepts 
and Therapeutic Strategies and (ii) RepSox as a Candidate Cell-Engineering Tool" (2014). Graduate 
Theses, Dissertations, and Problem Reports. 5874. 
https://researchrepository.wvu.edu/etd/5874 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
  
An Overview of Acute Myeloid Leukemia and  
Cancer Immunology:  
 
(i) Concepts and Therapeutic Strategies and  
(ii) RepSox as a Candidate Cell-Engineering Tool 
  
 
 
Audrey Nadine Jajosky 
 
 
 
 
 
Dissertation submitted to the West Virginia University School of Medicine in partial 
fulfillment of the requirements for the degree of  
  
Doctor of Philosophy  
In  
Cancer Cell Biology  
 
 
Michael Ruppert, MD, PhD, Chair  
Linda Vona-Davis, PhD  
Steven Frisch, PhD 
Karen Martin, PhD  
William Tse, MD  
Laura F. Gibson, PhD, mentor  
 
 
Cancer Cell Biology Program  
Morgantown, West Virginia  
2014 
 
 
Key words:  RepSox (E 616452), acute myeloid leukemia (AML), CD34+ AML cells, Tim-3, 
CXCL12 (SDF-1), cancer immunotherapy, TGF-β, c-Myc, CXCR4, CXCR7, γ9δ2 T cells, 
reprogramming, cell engineering, co-culture, cancer stem cells, immunogenicity, 
immunologic synapse, aldehyde dehydrogenase (ALDH), ALK5
  
ABSTRACT 
An Overview of Acute Myeloid Leukemia and Cancer Immunology:   
 
(i) Concepts and Therapeutic Strategies and  
(ii) RepSox as a Candidate Cell-Engineering Tool 
  
Audrey Nadine Jajosky 
This dissertation is intentionally broad in scope and describes the conceptual frameworks, 
research advances, and clinical successes that inspired a therapeutic vision that, in turn, 
prompted specific RepSox experiments (Jajosky, 2014).  The goal of this dissertation is 
to guide and encourage students interested in engineering anti-cancer immune therapies 
by providing perspective and suggestions.  Chapter I provides background on acute 
myeloid leukemia (AML), the cancer stem cell (CSC) theory, and the chemical 
reprogramming tool “RepSox.”  Chapter II describes how tumor cells passively evade 
immune recognition and actively suppress immune cells to escape destruction.  
Immunotherapeutic strategies are described that increase tumor-cell immunogenicity 
and/or sensitize tumor cells to immune-mediated death.  Chapter III reviews immune-cell 
defects induced by cancer-distorted microenvironments.  Tumor cells alter local physical 
and metabolic conditions and distort surrounding stromal cells in ways that impair 
infiltrating immune cells and promote cancer progression.  Strategies are described that 
can reverse immune-cell defects and improve anti-tumor immunity.  Chapter IV highlights 
successful cancer immunotherapies, including patient-specific, FDA-approved, and AML 
leukemic stem cell (LSC)-targeted strategies.  These therapies involve antibodies, 
activated immune cells, and/or immuno-modulatory agents designed to eradicate tumor 
cells, repair and activate dysfunctional immune cells, and reduce cancer-induced immune
  
suppression in tumor microenvironments.  Chapter V describes the features and rationale 
of a therapeutic vision that, in combination with recent clinical and research findings, 
guided this project and identified specific technical obstacles.  Chapter VI is the published 
study – entitled “RepSox slows decay of CD34+ acute myeloid leukemia cells and 
decreases T cell immunoglobulin mucin-3 expression” – which describes how RepSox, a 
“small molecule” reprogramming tool and TGF-β inhibitor, affects AML cells.  The key 
findings are RepSox (1) slows decay of primary CD34+ AML cells from patients with 
diverse AML disease, (2) increases CXCL12 and MYC, and (3) accelerates loss of Tim-3, 
an inhibitory (immune-checkpoint) receptor, from the surface of AML cells.  Thus, RepSox 
may promote in vitro engineering of patient-specific AML LSC-targeted therapies by 
prolonging survival of primitive CD34+ AML cells and increasing AML-cell immunogenicity 
via Tim-3 reduction.  When envisioning the immunologic synapse between antigen-
presenting AML cells and T cells, the actions of RepSox suggest RepSox might promote 
in vitro T-cell activation against primitive (relapse-causing) AML cells which represent the 
most problematic therapeutic target.  Chapter VII discusses the potential therapeutic 
applications of these results in the context of AML and other cancers as well as 
unanswered questions and future research options.  For example, the actions of RepSox 
suggest that its incorporation into pre-existing co-culture methods that exploit TCR 
agonists may enhance the activation of γδ T cells against a patient’s primitive AML cells 
and, thereby, help generate more effective immune-cell therapies.  One goal of this 
dissertation is to encourage students to integrate new findings and conceptual 
frameworks from immunology, regenerative medicine, and cancer research when 
deciding which exciting research agendas to pursue.  
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PREFACE 
Deciding to write a dissertation very broad in scope is consistent with the decision 
made by the Journal for ImmunoTherapy of Cancer to publish in 2014 an overview entitled 
“Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer” 
authored by Raval, et al.  Scientists seem to agree that the exciting anti-cancer 
breakthroughs and opportunities that have emerged recently should be carefully 
described and explained.  This is an ideal time to encourage students to consider getting 
involved in the engineering of anti-cancer immunotherapies.   
In general, researchers are now extremely optimistic, and are eager to recuit new 
cancer fighters.  Fortunately, advances in cancer immunotherapies are truly fascinating 
and, when properly explained, usually generate great excitement.  The pattern is 
encouraging:  new lab observations, conceptual frameworks, and clinical findings have 
suggested novel anti-cancer strategies that have, in turn, prompted scientists to identify, 
and successfully overcome, key technical challenges.  While planning this dissertation, it 
was decided that explaining the reasoning used by cancer researchers could be 
instructive.  Also, to help students fully appreciate current research opportunities, an effort 
was made to explain the context surrounding new concepts and technical advances. 
Although this dissertation is broad, readers should be able to read just the sections 
of interest since topics were designed to be “logically complete.”  Thus, redundancy was 
unavoidable:  some of the same concepts, goals, tasks, and findings are repeated in 
several different locations.  Of note, when discussing these topics at meetings, I found 
that repetition was often needed to eliminate confusion.  Some concepts are, apparently, 
counter-intuitive or “too new or different.”  For example, some were confused about the 
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“paradox” of working hard to keep the most lethal, stem-like leukemia cells alive.  As might 
be expected, some immediately think about killing these lethal cells before considering 
how in vitro tasks that keep them alive can be used to engineer anti-LSC therapies.  
(Coincidentally, to develop anti-ebola therapies, scientists are trying to keep lethal ebola 
viruses alive in vitro.)  Five points that often needed to be explained repeatedly included 
the following:  (1) AML cells can directly function as antigen-presenting cells (when, for 
example, they are co-cultured with γ9δ2 T cells).  (2) Spontaneous de-differentiation (of 
normal cells) is critical for tissue regeneration in primitive animals and for sustaining 
human (malignant) cancer cells – while de-differentiation artificially induced in vitro can 
repair the dysfunctional (non-malignant) immune cells of cancer patients.  (3) At any given 
time, a cancer patient harbors a distribution of malignant cells that includes a distribution 
of CSCs that evolves as the cancer progresses.  That is, the phenotypes of CSCs evolve:  
there is not just a single, static CSC phenotype.  (4)  Human cancer cells are “plastic” and 
can de-differentiate – as well as differentiate and evolve.  Thus, mature cancer cells must 
be eliminated as well as the CSCs.  And, (5) when in vitro chemical cell-engineering is 
used to reprogram mature cells into pluripotent cells, some of the genes/mechanisms 
involved are the same as those activated during the spontaneous (and limited) cellular 
de-differentiation that occurs during injury-induced tissue regeneration.  Overall, this 
dissertation tries to provide perspective and explain the rationale for this project and other 
research agendas.  A key premise:  to fully appreciate the opportunities that are exciting 
cancer researchers, the fascinating context for recent successes should be considered.  
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Chapter I 
 
 
 
 
Background on Acute Myeloid Leukemia, the Cancer Stem Cell Theory, 
and the TGF-β inhibitor “RepSox” 
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Acute myeloid leukemia is a white blood cell cancer involving abnormal, immature 
myeloid cells that rapidly proliferate, continuously evolve, and efficiently disrupt and 
evade immunologic attack.  Accumulation of large numbers of malignant AML cells in the 
bone marrow suppresses normal hematopoiesis.  Due to inadequate numbers of nomal 
white blood cells (i.e. neutrophils, macrophages), red blood cells, and platelets, AML 
patients may present with infections, anemia, or easy bleeding.  Among the acute adult 
leukemias in North America and Europe, AML is the most common (90% of cases).  
Among all cancers of the elderly, AML has one of the highest mortality rates. 
Pathogenesis 
Leukemia may arise via transformation of normal hematopoietic stem cells or de-
differentiation of more committed blood progenitors (Passegué; 2003) as shown in Figure 
1.1.  Transforming events – initiated by genetic or epigenetic alterations – may bestow 
progenitors with stem-cell properties such as enhanced self-renewal.  Regardless of 
cellular origin, leukemia is believed to be sustained by self-renewing leukemic stem cells 
(LSCs) (Lapidot, 1994; Bonnett, 1997). 
Chronic myeloid leukemias often involve activating mutations in tyrosine kinases, 
such as BCR/ABL, TEL/PDGFRβ, TEL/ABL, and TEL/JAK2 (Deguchi, 2002).  In contrast, 
acute leukemias usually involve chromosomal alterations or mutations of transcription 
factors or transcriptional regulators, such as core binding factor (CBF) comprised of runt-
related transcription factor 1 (RUNX1) and CBFβ subunits, retinoic acid receptor α 
(RARα), and the mixed lineage leukemia (MLL) gene (Deguchi, 2002).  Genetic lesions 
often occur in transcription factors that regulate hematopoiesis, leading to maturation 
arrest of myeloid progenitors. 
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Figure 1.1. Cellular hierarchy within normal hematopoiesis and leukemic disease.  
During normal blood cell development, self-renewing hematopoietic stem cells (HSCs) 
give rise to progressively lineage-restricted progenitor cells whose progeny generate 
mature white blood cells, red blood cells, and platelets.  Acute myeloid leukemia (AML) 
may arise from leukemic transformation of normal HSCs or restricted progenitor cells.  
According to the cancer stem cell (CSC) theory, AML is sustained by self-renewing 
leukemic stem cells (LSCs) that ultimately give rise to more mature leukemic blasts.  
Reproduced with permission from:  Tan, B. T., Park, C. Y., Ailles, L. E., et al. (2006). The 
cancer stem cell hypothesis: a work in progress. Laboratory Investigation, 86(12), 1204. 
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Two-hit model of AML 
Gilliland and colleagues proposed the 2-hit model of AML in which leukemic 
transformation involves cooperation between two types of mutations:  class I mutations 
that promote growth and/or survival and class II mutations that block differentiation and/or 
enhance self-renewal (Dash, 2001; Gilliland, 2001).  Class II mutations generally occur 
early and are believed to help initiate disease, while class I mutations occur late and likely 
promote leukemic progression.  Class I mutations activate signal-transduction pathways 
often through constitutive activation of tyrosine kinase surface receptors such as fms-
related tyrosine kinase 3 (FLT3) and c-KIT (Gilliland, 2001).  In contrast, class II mutations 
affect transcription factors or other transcriptional regulators.  Examples of class II 
alterations include overexpression of homeobox (HOX) genes, mutations in 
hematopoietic transcription factors such as C/EBPα, MLL gene rearrangements, and 
creation of fusion genes such as t(8;21) RUNX1-ETO, t(15;17) PML-RARα, and inv(16) 
CBFβ-MYH11 (Gilliland, 2001).  Study of human disease and experimental evidence from 
mouse models support the 2-hit hypothesis.  Combinations of class I and class II 
mutations, such as internal tandem duplication of the FLT3 receptor (FLT3-ITD) and 
nucleophosmin (NPM1) mutation, coexist in AML patients (Golub, 1995; Reilly, 2005; 
Matsuno, 2003).  Mouse studies show that hematopoietic progenitors carrying either 
class I or class II mutations often trigger aberrant myeloid development or myelo-
proliferative disorders (Kelly, 2002), while both mutations cooperate to generate leukemia 
(Schessl, 2005; Grisolano, 2003).   
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Subtypes 
 AML is a heterogeneous disease arising from a variety of pathogenic mechanisms.  
Along with clinical history, AML is diagnosed by examining the morphology, 
cytochemistry, immunophenotype, and molecular genetics of cells in the bone marrow.  
According to the French-American-British (FAB) classification system (see Table 1.1), 
AML is divided into nine subtypes based on the myeloid lineage(s) involved and their 
degree of differentiation.  The newer World Health Organization (WHO) classification 
system (see Table 1.2) also incorporates cytogenetic and molecular genetic features 
which provide additional prognostic value (Swerdllow, 2008).  The “Immunoscore,” 
another classification system under development, proposes that the immune-cell infiltrate 
within a patient’s tumor can predict prognosis and response to therapy (Galon, 2012; 
Fridman, 2012). 
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Table 1.1. The FAB classification of AML.  Reproduced with permission from:  
Lowenberg, B., Downing, J. R., & Burnett, A. (1999). Acute myeloid leukemia. New 
England Journal of Medicine, 341(14), 1052. Copyright Massachusetts Medical Society. 
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Table 1.2. The 2008 WHO classification of AML.  Reproduced with permission from:  
http://www.cancernetwork.com/articles/acute-leukemias/page/0/2 
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Treatment 
 Standard treatment for AML includes induction chemotherapy followed by 
consolidation therapy.  The goal of induction chemotherapy is to eradicate the majority of 
leukemic blasts and induce remission.  With the standard “7 + 3” induction regimen of 
cytarabine for 7 days along with daunorubicin for the first 3 days, 70-80% of younger 
(< 60) and 50% of older (> 60) adults achieve complete remission (Lowenberg, 1999).  
The goal of consolidation therapy – intensive chemotherapy, such as high dose 
cytarabine, or hematopoietic stem cell transplant (HSCT) – is to eliminate “residual” 
leukemia cells and, thereby, prevent relapse.  If patients cannot tolerate additional rounds 
of intensive chemotherapy, they may receive a HSCT.  Sources of HSCs for transplant 
include the bone marrow or mobilized peripheral blood of the patient (autologous) or a 
donor (allogeneic).  With allogeneic-HSCT, a post-remission strategy with the lowest rate 
of relapse, donor T cells attack residual leukemia cells via a graft-versus-leukemia (GvL) 
immune reaction (Thomas, 1999; Jenq, 2010).  A major complication of allogeneic HSCT 
is graft-versus-host disease (GvHD) (Thomas, 1999).  Acute promyelocytic leukemia 
(APL; also known as M3 subtype), characterized by a translocation between 
chromosomes 15 and 17 [t(15;17)], is unique in its treatment with all-trans retinoic acid 
(ATRA) which induces APL cells to mature (Tallman, 1997).   
 Although more than half (50%-70%) of AML patients achieve complete remission 
after induction chemotherapy, the majority (70%-80%) will relapse and die of disease 
(Lowenberg, 1999; Döhner, 2010).  Patients with poor prognosis, or those who fail to 
respond to standard therapy, may undergo experimental therapies in clinical trials.  
Immunotherapies (discussed in Chapter IV) may be most effective in the setting of 
minimal residual disease (MRD) when leukemic disease burden is low.  Of note, LSCs 
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are often enriched during MRD (Gerber, 2012), suggesting they are more likely to escape 
conventional chemotherapy than bulk leukemic blasts – potentially due to their quiescent 
nature (Terpstra, 1996) or the activity of drug efflux pumps (Wulf, 2001).  Thus, by design, 
immunotherapies should target both the LSC population that sustains disease and the 
more mature leukemic blast population which (like melanoma cells) may be able to de-
differentiate into stem–like tumor cells when exposed to therapeutic stresses or 
microenvironmental stresses like chronic inflammation (Landsberg, 2012).  Beyond initial 
control of disease, immune strategies have the potential to provide “cures” via generation 
of memory T and B cells that can provide long-term protection (Kalos, 2011; Porter, 2011). 
Leukemic stem cells (LSCs) 
Background 
Cancer stem cells (CSCs) were first identified in AML (Lapidot, 1994).  Similar to 
normal hematopoiesis, AML is arranged as a hierarchy originating from LSCs (aka 
“leukemia-initiating cells”) that self-renew and give rise to more mature leukemic blasts 
(Bonnett, 1997; Hope, 2004).  Experimentally, only a small subset of AML cells generates 
colonies in vitro (McCulloch, 1983; Griffin, 1986) and initiates disease when transplanted 
into immunocompromised mice (Lapidot, 1994; Bonnett, 1997).  These findings support 
a hierarchical organization of AML, similar to normal hematopoiesis (Bonnett, 1997; 
Hope, 2004).  In mice, disease-initiating cells generate the diverse spectrum of AML cells 
found in patients and can reconstitute disease in secondary recipients, demonstrating a 
capacity for self-renewal (Lapidot, 1994; Bonnett, 1997).  Based on clonal tracking studies 
that identify cells descending from a single progenitor, the LSC compartment has been 
shown to contain subsets of LSCs which differ in self-renewal potential (Hope, 2004).  
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Like normal HSCs, LSCs can display short-term or long-term repopulating 
capacity/potential (Hope, 2004).  Therapeutically targeting LSCs in vivo is challenging:  
LSC populations may be quiescent (Terpstra, 1996), poorly immunogenic (Costello, 
1999), immune- and death-resistant (van Stijn, 2003; Barrett, 2010; Lion, 2012), and 
phenotypically diverse (Eppert, 2011; Goardon, 2011).  Furthermore, in response to 
stresses imposed by the tumor microenvironment, immune system, or cancer therapies, 
mature leukemia cells may de-differentiate into LSCs.  Within any given AML patient, 
multiple pools of LSCs which differ in molecular and phenotypic traits may coexist 
(Goardon, 2011).  Cancer-cell diversity and plasticity suggest that, for some patients, 
combination therapies may be needed to  (1) attack both LSCs and more mature leukemic 
blasts, (2) target multiple tumor antigens (to prevent emergence of escape variants), and 
(3) reverse tumor-cell immune evasion, immune-system suppression, and cancer-
induced dysregulations of the tumor microenvironment.   
LSCs dynamically interact with the surrounding bone marrow niche, as shown in 
Figure 1.2.  LSCs alter local physical and metabolic conditions, convert stromal cells into 
cancer-associated fibroblasts (CAFs), suppress infiltrating immune cells, and recruit 
immunosuppressive cells that support the growth and survival of LSCs by,  for example, 
promoting “immune escape.”  
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Figure 1.2. Reciprocal interactions between leukemic stem cells and the tumor 
bone marrow microenvironment.  Within the bone marrow microenvironment, leukemia 
cells alter physical and metabolic conditions as well as interact with surrounding stromal 
cells and infiltrating immune cells.  Leukemic cells deplete local oxygen and nutrients, 
convert stromal cells into tumor-promoting CAFs, and suppress infiltrating immune cells 
to promote disease progression.  In reaction to microenvironmental stresses like immune 
selection pressures, more mature leukemia cells may dedifferentiate into LSCs as a pro-
survival mechanism.  The bone marrow microenvironment also nurtures leukemic cells 
and protects them from chemotherapy. 
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Clinical significance 
LSCs that survive conventional chemotherapy may trigger relapse of disease.  
Clinical observations support the CSC theory of AML:  CD34+CD38-ALDHint AML cells 
were enriched during MRD, and persistence of this AML subset after induction 
chemotherapy was highly predictive of patients who would subsequently relapse (Gerber, 
2012).  AML LSC gene expression signatures generated by independent research groups 
correlate with patient outcomes (Eppert, 2011; Gentles, 2010).  Using a signature of 52 
genes upregulated in CD34+CD38- LSC-enriched fractions (as opposed to more 
differentiated CD34+CD38+ and CD34- fractions), high LSC scores were associated with 
worse overall, event-free, and disease-free survival than low LSC scores in multiple AML 
patient cohorts (Gentles, 2010).  Rather than relying solely on immunophenotype, Eppert 
and colleagues generated a 42-gene LSC signature using AML LSC-enriched fractions 
functionally verified to initiate disease in mice (Eppert, 2011).  Likewise, high LSC scores 
were generally associated with shorter overall and event-free survival as well as lower 
rates of complete remission than low LSC scores (Eppert, 2011).  These studies suggest 
that AML LSCs are not simply artifacts of xenotransplantation but have clinical relevance.  
These LSC signatures may also help identify poor-risk cases of AML, drivers of LSC 
function, and potential LSC targets. 
AML LSC markers 
Across disease subtypes, disease-initiating AML LSCs were originally reported to 
reside exclusively within the CD34+CD38- fraction of AML cells when assayed in severe 
combined immune deficiency (SCID) mice with B- and T-cell defects and non-obese 
diabetic (NOD)/SCID mice carrying additional NK-cell defects (Lapidot, 1994; Bonnett, 
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1997).  Studies utilizing more immunodeficient mouse strains, such as NOD/SCID/IL-2 
receptor γ chain-deficient and NOD/SCID/β2 microglobulin-null mice that lack NK-cell 
activity, show that disease-initiating LSCs can also reside within the more mature 
CD34+CD38+ or CD34- fractions previously believed to be non-tumorigenic (Taussig, 
2008; Taussig, 2010; Sarry, 2011).  Because LSC immunophenotypes vary both within 
(Goardon, 2011) and across (Eppert, 2011) patients, engineering of LSC-targeted 
therapies may require patient-specific strategies. 
The discovery of cellular and molecular differences between AML LSCs and 
normal HSCs has identified potential therapeutic targets.  Surface antigens upregulated 
on AML LSCs relative to normal HSCs include Tim-3 (Jan, 2011), CD47 (Majeti, 2009), 
CD123 (Jordan, 2000), and CD96 (Hosen, 2007) among others (Horton, 2012).  Of 
interest, several of these receptors, including CD47 (a phagocyte “do not eat me” signal) 
and Tim-3 (a negative regulator of anti-tumor immunity), inhibit immune-cell functions and 
may contribute to the poor immunogenicity of AML LSCs (Costello, 1999; Jaiswal, 2009; 
Majeti, 2009).  Strategies to target surface antigens using antibodies or antigen-specific 
immune cells, such as chimeric antigen receptor (CAR)-modified T cells, are discussed 
in Chapter IV. 
Additional molecular differences between AML LSCs and normal HSCs include 
distinct patterns of ALDH staining (Pearce, 2005) as well as enhanced NFkB activity 
(Guzman, 2001) and apoptotic resistance (van Stijn, 2003; Yoshimoto, 2009) within 
LSCs.  Normal HSCs are Aldefluor-bright (ALDHBR) cells, while AML LSCs display 
intermediate levels of Aldefluor staining (ALDHint) (Pearce, 2005), providing a convenient 
way to isolate and/or monitor both populations.  Strategies to target LSCs now under 
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clinical investigation include inhibitors of NFkB activity (Reikvam, 2009) and anti-apoptotic 
factors of the Bcl-2 family (Bose, 2013). 
CD34 
CD34 is a single transmembrane surface glycoprotein expressed by a spectrum of 
normal (Sutherland, 1992; Larochelle, 1996) and leukemic (Lapidot, 1994; Bonnett, 1997) 
stem and progenitor cells.  Experimental studies suggest CD34 can modulate cell-to-cell 
adhesion, enhance proliferation, and inhibit hematopoietic differentiation (Krause, 1996; 
Nielson, 2008).  CD34 has been proposed to block the differentiation of both normal 
hematopoietic and leukemic progenitors (Fackler, 1995; Krause, 1996).  Of note, during 
normal hematopoiesis, CD34 levels are highest on immature progenitors and decline with 
differentiation (Krause, 1996; Stella, 1995).  Enforced expression of full-length CD34 on 
mouse M1 leukemia cells inhibited their cytokine-induced differentiation into 
macrophages (Fackler, 1995).  Compared to wildtype mice, CD34-knockout mice showed 
delayed myeloid and erythroid differentiation and decreased hematopoietic progenitors in 
embryonic and adult tissues (Cheng, 1996).  Despite these defects, CD34-knockout mice 
developed normally and displayed normal mature blood cell counts (Cheng, 1996; Suzuki, 
1996).  Defects in myeloid and erythroid differentiation within CD34-null embryonic stem 
cells were reversed upon transfection with CD34 (Cheng, 1996).  CD34 is expressed by 
40-60% of AML patients and is most commonly observed within the more primitive M0, 
M1, and M2 subtypes (Borowitz, 1989).  CD34 can sometimes serve as an “LSC marker” 
that is linked to the poor prognosis of AML patients (Geller, 1990; Myint; 1992), although 
conflicting results have been reported. 
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Tim-3 
In cancer patients, Tim-3 has been reported to be expressed by (1) tumor cells 
(Wiener, 2007; Jan, 2011; Kikushige, 2010), (2) dysfunctional antigen-presenting and 
immune-effector cells of the innate and adaptive immune system (Zhu, 2005; Anderson, 
2012; Chiba, 2012; Da Silva, 2014), and (3) endothelial cells within the tumor vasculature 
(Huang, 2010; Wu, 2010).  With the exception of acute promyelocytic leukemia (M3 
subtype), Tim-3 is often expressed by myelodysplastic syndrome (MDS) and AML cells, 
including the CD34+CD38- subset (Kikushige, 2010; Kikushige, 2013).  Tim-3 is generally 
upregulated upon the progression of MDS to AML, suggesting a potential role for Tim-3 
in leukemogenesis (Kikushige, 2013).  Because Tim-3 is not expressed by normal 
CD34+CD38- hematopoietic stem and progenitor cells (Kikushige, 2010; Jan, 2011), 
Tim-3 receptor is an attractive therapeutic target for eliminating AML LSCs (Kikushige, 
2010), restoring the functions of cancer-impaired immune cells (Zhou, 2011; Norde, 
2012), and reversing immune suppression mediated by the tumor stroma (Huang, 2010). 
The Tim-3 pathway may promote AML-cell survival.  Galectin-9 and high mobility 
group box 1 (HMGB1) are the ligands of Tim-3 on lymphocytes (Zhu, 2005) and dendritic 
cells (DCs) (Tang, 2012).  Upon toll-like receptor (TLR) stimulation, primary AML cells 
secrete galectin-9, and Tim-3 engagement by galectin-9 may promote survival of AML 
cells through upregulation of the anti-apoptotic factor myeloid cell leukemia 1 (Mcl-1) 
(Kikushige, 2013).  Tim-3 is also expressed by a variety of solid tumors, including 
melanoma (Wiener, 2007), osteosarcoma (Shang, 2013), lung cancer (Zhuang, 2012), 
and cervical cancer (Cao, 2013) where it may promote cancer-cell immune evasion, 
migration, and invasion.  The role of Tim-3 on cancer-impaired antigen-presenting, 
immune-effector, and stromal cells is reviewed in Chapter IV. 
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TGF-β has been shown to induce Tim-3 expression on mast cells (Wiener, 2007; 
Kim, 2012).  As emphasized in this dissertation, treatment of AML cells with the TGF-β 
inhibitor RepSox accelerated the decline in Tim-3 expression (Jajosky, 2014).  Thus, 
these findings suggest a mechanism that might explain how TGF-β can function as an 
immuno-suppressive cytokine in some stages of malignant disease (Gorelik, 2002; 
Wrzesinski, 2007). 
Challenges to developing LSC- targeted therapies 
Engineering anti-LSC therapies in vitro is challenging because LSCs  (1) rapidly 
die or differentiate in culture (Pabst, 2014), (2) are poorly immunogenic (Costello, 1999; 
Majeti, 2009), (3) display diverse immunophenotypes (Eppert, 2011; Goardon, 2011), and 
(4) constitute a “moving target” as they continually evolve in vivo under constant immune-
selection pressures (Horton, 2012).  Furthermore, tumor microenvironments also become 
progressively dysregulated in ways that promote cancer cells and suppress infiltrating 
immune cells (Kim, 2006).  Thus, LSC-targeted therapies may need to be patient-specific 
and administered shortly after diagnosis.  By engineering therapies in vitro – outside of 
the immunosuppressive tumor microenvironment – it is possible to enhance immune-cell 
activation and reverse defects induced by cancer-distorted microenvironments.  Of note, 
as purified Tim-3+ AML cells were cultured, levels of the immune-checkpoint receptor 
Tim-3 gradually declined, and RepSox accelerated this loss of Tim-3 (Chapter VI, Figure 
7).  In cell culture, just the removal of AML cells from the tumor microenvironment may 
eventually eliminate all Tim-3 expression and, in turn, increase AML-cell immunogenicity.  
In general, better ways to maintain a patient’s LSCs in culture could facilitate a 
variety of valuable technical tasks:  the in vitro activation of more relevant (anti-LSC) γδ 
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T cells and other immune cells (by having LSCs serve as antigen-presenting cells), the 
identification of therapeutic targets, and the evaluation of candidate therapies 
preclinically.  Also, when LSCs in a patient specimen are rare (or absent), it may be 
possible to generate LSC “surrogates” via de-differentiation of a patient’s more mature 
(“bulk”) leukemic blasts into stem-like tumor cells.  By analogy, for tissue regeneration, 
patient-derived induced pluripotent stem cells (iPSCs) (Takahashi, 2007) may serve as 
artificial, lab-synthesized substitutes for naturally occurring embryonic stem cells (ESCs).  
LSC surrogates, chemically or genetically engineered in vitro, may serve as relevant 
therapeutic targets by virtue of immunologic cross-reactivity with a patient’s bona fide 
leukemic stem and progenitor cells residing in vivo.  In general, some of the same 
antigens that can serve as therapeutically useful targets may be expressed by a wide 
spectrum of leukemic progenitor cells. 
RepSox and the TGF-β signaling pathway 
 TGF-β influences a variety of cellular processes including differentiation, growth, 
survival, embryogenesis, immune suppression, tissue fibrosis, and epithelial-to-
mesenchymal transition (EMT) (Li, 2006; Watabe, 2009; Wu, 2009; Xu, 2009; Massagué, 
2012; Travis, 2014).  TGF-β-mediated effects are both context- and cell-specific 
(Massagué, 2000).  Figure 1.3 provides an overview of the TGF-β signaling pathway, 
including TGF-β superfamily ligands, surface receptors, and Smad proteins that regulate 
gene transcription (Weiss, 2013).  Early in tumor development, TGF-β generally functions 
as a tumor suppressor by inhibiting proliferation, promoting apoptosis, and limiting 
inflammation in the tumor microenvironment (Gold, 1998; Ikushima, 2010; Zammaron, 
2011).  In more advanced disease, however, TGF-β facilitates cancer progression by 
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promoting tumor-cell EMT, invasion, and metastasis as well as angiogenesis and immune 
suppression (Gold, 1998; Xu, 2009; Katsuno, 2013). 
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Figure 1.3. The TGF-β signaling pathway.  TGF-β superfamily ligands (such as TGF-
βs, activins, nodals, and BMPs) bind to type II receptors which recruit, phosphorylate, and 
activate type I receptors.  In the case of TGF-β ligands, activated type I receptors 
phosphorylate Smad 2/3 which complexes with Smad4 and translocates to the nucleus 
to regulate gene transcription.  RepSox selectively inhibits TGF-β receptor 1/ALK5.  © 
2013 Sonia Villapol, Trevor T. Logan, Aviva J. Symes.  Originally published in:  “Villapol, 
S., Logan, T. T., & Symes, A. J. (2013). Role of TGF-β signaling in neurogenic regions 
after brain injury, chapter 1, page 5.” under CC BY 3.0 license.  Adapted with permission 
from: [Derynck, R., & Zhang, Y. E. (2003). Smad-dependent and Smad-independent 
pathways in TGF-β family signalling. Nature, 425(6958), 577-584. DOI: 
http://dx.doi.org/10.1038/nature02006] and [Kandasamy M, Reilmann R, Winkler J, et al. 
TGF-β signaling in the neural stem cell niche: a therapeutic target for Huntington's 
disease. Neurology Research International. 2011. Article ID: 124256. DOI: 
http://dx.doi.org/10.1155/2011/124256]. Available from:  http://dx.doi.org/10.5772/5394.   
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RepSox, a cell-permeable, small-molecule inhibitor of TGF-β receptor 1 [also 
known as activin receptor-like kinase 5 (ALK5)] (Gellibert, 2004), promotes cellular 
reprogramming to pluripotency by replacing Sox2 and c-Myc (Ichida, 2009) and promoting 
mesenchymal-to-epithelial transition (MET) (Li, 2010).  Chemical structures of the other 
TGF-β inhibitors studied are shown in Figure 1.4.  RepSox (also known as “E-616542”) 
is one of the seven small molecules that was used to chemically reprogram mouse 
fibroblasts to pluripotency – eliminating the need for genetic engineering (Hou, 2013).  
The other six factors used were (1) histone deacetylase (HDAC) inhibitor valproic acid 
(VPA), (2) glycogen synthase kinase-3 beta (GSK3-β) inhibitor CHIR99021, 
(3) monoamine oxidase inhibitor Tranylcypromine, (4) cAMP agonist Forskolin, 
(5) S-adenosylhomocysteine (SAH) hydrolase inhibitor 3-deazaneplanocin A (DZNep) 
and (6) “2i treatment” involving dual inhibition of mitogen-activated protein kinase (MAPK) 
signaling (using PD0325901) and GSK3-β (using CHIR99021) (Hou, 2013).  
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Figure 1.4. Chemical structures of TGF-β inhibitors. RepSox is structurally most 
similar to LY364947; however, even among selective ALK5 TGF-β inhibitors, we and 
others (Ichida, 2009) discovered effects unique to RepSox.  One unique effect of 
RepSox’s may be its ability to promote CXCL12, even across diverse cell types, including 
AML cells (Jajosky, 2014) and mouse embryonic fibroblasts (Larsen, 2013). 
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RepSox effects on CXCL12 and MYC 
In this project (Jajosky, 2014) and in other studies (Ichida, 2009) key differences 
between the actions of RepSox and other TGF-β inhibitors were noted which may be due 
to the unique ways RepSox affects CXCL12 and c-Myc.  The RepSox-induced changes 
in gene expression are conserved across cell types (normal fibroblasts and malignant 
blood cells) and animal species (mouse and human).  Based on gene-expression studies, 
RepSox-treated MEFs expressed higher levels of C-X-C motif chemokine 12 (CXCL12) 
and MYC than DMSO-treated controls (Larsen, 2013).  Similarly, in this study, RepSox-
treated AML cells more highly expressed CXCL12 and MYC than controls (Jajosky, 
2014).  Because studies suggest both c-Myc and CXCL12 inhibit differentiation of AML 
cells (Leon, 2009; Salvatori, 2011; Huang, 2006; Tavor, 2008), upregulation of these two 
factors may explain how RepSox slows decay of CD34+ AML cells (Jajosky, 2014).   
CXCL12 – also known as “stromal cell-derived factor 1” (SDF-1) – is a chemokine 
that promotes migration and homing of normal hematopoietic progenitors (Aiuti, 1997) as 
well as metastasis of cancer cells (Müller, 2001) along chemotactic gradients.  CXCL12 
also promotes survival of AML cells (Tavor, 2014; Kim, 2013) and may help maintain them 
in an un-differentiated state (Tavor, 2008).  Exposing primary AML cells and cell lines to 
the chemokine C-X-C motif receptor 4 (CXCR4) antagonist AMD3100 induced 
differentiation as evidenced by changes in morphology as well as expression of myeloid 
differentiation antigens (i.e. increased CD15, CD11b), differentiation-promoting cytokines 
(i.e. increased G-CSF and GM-CSF), and transcription factors (i.e. downregulation of 
HOXA9, HOXA10, and WT1 involved in leukemogenesis and upregulation of C/EBPε, 
ID1, and RUNX3 induced during myeloid differentiation) (Tavor, 2008).  Furthermore, the 
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balance between TGF-β and CXCL12 signaling also influences the cell-cycle status of 
normal hematopoietic progenitors (Chabanon, 2008).   
c-Myc is a transcription factor that facilitates reprogramming of differentiated cells 
toward pluripotency (Takahashi, 2006) and can inhibit the differentiation of a variety of 
both normal and malignant cells (Leon, 2009).  In transgenic mice engineered to 
conditionally express c-Myc within blood cells, inactivation of c-Myc triggered 
differentiation of AML and lymphoma cells, leading to cancer regression (Felsher, 1999).  
During all-trans retinoic acid (ATRA)-induced and 1,25-dihydroxyvitamin D3-induced 
differentiation of AML cell lines, c-Myc levels declined (Salvatori, 2011).  Furthermore, 
exposure to the small molecule c-Myc inhibitor “10058-F4” (which inhibits dimerization of 
c-Myc with transcription factor Max) induced primary AML cells to differentiate (Huang, 
2006).  Thus, c-Myc might help maintain AML cells in an undifferentiated state.  
RepSox is a potent reprogramming tool and the actions of RepSox on normal-cell 
differentiation (Ichida, 2009) seem relevant for maintaining CSCs.  Gene-expression 
studies revealed RepSox-treated MEFs expressed higher levels of components of the 
Wnt, Notch, and Hedgehog signaling pathways than DMSO-treated controls (Larsen, 
2013).  Among TGF-β inhibitors, the unique actions of RepSox may be due to its structure 
(see Figure 1.4), potency, or selectivity.  While RepSox promoted iPSC reprogramming 
in the absence of the HDAC inhibitor VPA, other TGF-β inhibitors, such as LY364947 (or 
E-616451), did not (Ichida, 2009).  Of note, TGF-β neutralizing antibody did not enhance 
reprogramming efficiency as well as RepSox (Ichida, 2009).  Among the different tools 
that can be used to inhibit TGF-β signaling, RepSox may be an especially useful way to 
activate genes involved in stem-cell maintenance, self-renewal, and pluripotency – or to 
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repress pro-differentiation genes.  Comparing TGF-β inhibitors in this project showed that 
RepSox most effectively (1) increased or maintained CXCL12 and MYC mRNA levels and 
(2) slowed decay of CD34+ AML cells (Jajosky, 2014).  Of note, RepSox substitutes for 
c-Myc during reprogramming (Ichida, 2009), and both c-Myc and CXCL12 (aka SDF-1) 
are believed to inhibit the differentiation of AML cells (Huang, 2006; Tavor, 2008). 
Interestingly, genes activated during limb regeneration, such as Sal-like 4 (Sall4), 
are also activated during cellular reprogramming to pluripotency (Neff, 2011).  That is, 
when cell de-differentiation is (“artificially”) induced in vitro, this may involve some of the 
same molecular mechanisms that are responsible for the de-differentiation that occurs 
(“naturally”) in vivo when primitive animals regenerate their amputated limbs. 
As with other cancers that progress, AML persists when the patient’s immune 
system fails to eliminate the malignant cells.  A combination of intrinsic tumor-derived 
factors as well as extrinsic cancer-induced dysfunctions of the immune system and tumor 
microenvironment promotes AML immune escape and disease progression.  Chapter II 
reviews the features of cancer cells (i.e. poor antigen-presentation, low immunogenicity, 
death-resistance) that enable them to passively escape (“hide”) and actively suppress 
(“combat”) immune defenses.  In vitro cell-engineering strategies are described that may 
enhance in vitro immune-cell activation (i.e. improve presentation of leukemic antigens).  
Multi-pronged options are described that might, for example, use systemic agents to 
reduce the death-resistance of leukemia cells in vivo (i.e. inhibit generation of the specific 
anti-apoptotic factors that render a patient’s cancer cells resistant to immune-cell attack).  
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AML immune evasion and immune suppression; 
therapeutic strategies for restoring immunologic function 
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When used alone, even chemotherapies that induce immunogenic tumor-cell 
death are unlikely to prevent relapse since the immune sytems of cancer patients are 
often so dysfunctional by the time treatment is initiated that even when they are stimulated 
by ICD they cannot eliminate immune-evasive and death-resistant CSCs.  Thus, 
chemotherapies may need to be combined with patient-specific immune strategies that 
are specifically engineered to (1) eliminate poorly immunogenic CSCs, (2) repair and 
activate dysfunctional immune cells, and (3) neutralize immuno-suppressive pathways in 
tumor microenvironments.  This chapter describes how malignant cells are able to resist 
immunologic attack by (1) growing rapidly, (2) avoiding recognition, (3) resisting death, 
and (4) suppressing anti-tumor defenses – see Figure 2.1 (Leone, 2012).  Through 
immunoediting, the immune system selects for malignant-escape and antigen-loss 
variants that are poorly immunogenic (Dunn, 2002).  As cancer cells evolve, they become 
poor stimulators – as well as poor targets – of immune cells (Whiteside, 2006).  This 
chapter reviews strategies tumor cells employ to passively “hide” and actively escape 
from innate and adaptive immune cells (Igney, 2002).  Of note, immune evasion has been 
more extensively studied in solid tumors than in blood cancers.  
Avoiding immune detection 
Tumor cells can avoid being recognized by the immune system (1) by migrating to 
immuno-privileged sites, (2) by altering their microenvironments in ways that reduce the 
survival, and impair the function, of immune cells, (3) by disrupting the presentation of 
tumor-cell antigens, and/or (4) by blocking costimulatory signals to antigen-presenting 
and immune-effector cells (Mapara, 2004; Whiteside, 2006; Mellman, 2011; Lion, 2012; 
Leone, 2012).  Tumor cells can successfully grow in immuno-privileged sites such as the 
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central nervous system and can create “metabolically hostile” microenvironments by 
altering local oxygen, pH, and amino acid levels in ways that impair the physical entry, 
survival, and activity of infiltrating immune cells (Calcinotto, 2012; Baginska, 2013).  
Malignant cells can also induce the generation of physical and molecular barriers to 
infiltrating immune cells via the synthesis of dense extracellular matrix and/or expression 
of immuno-suppressive molecules like Tim-3 on tumor-associated vasculature (Huang, 
2010) and/or galectins on surrounding stromal cells (Gieseke, 2010; Sioud, 2011).  
 
Figure 2.1. Tumor cell immune escape strategies.  Tumor cells avoid immune-
mediated destruction through a variety of mechanisms, including poor antigen 
presentation and low immunogenicity, death resistance via high expression of anti-
apoptotic factors, expression of inhibitory receptors, release of immunosuppressive 
factors, and recruitment of immuno-suppressive cell types.  Reproduced with permission 
from: Vesely, M. D., Kershaw, M. H., Schreiber, R. D., et al. (2011). Natural innate and 
adaptive immunity to cancer. Annual Review of Immunology, 29, 252 
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Impaired antigen-presentation 
Steps involved in the processing and presentation of tumor-cell antigens to the 
immune system via HLA class I molecules are reviewed in Figure 2.2.  Normal- and tumor-
cell peptides are presented to T-helper (Th) cells via HLA class I molecules and to 
cytotoxic T cells via HLA class II molecules.  Antigen-presenting cells (APCs), including 
DCs and monocytes/macrophages, normally present antigens to effector T cells via HLA 
class II molecules.  Because myeloid leukemias arise from the same lineage as DCs and 
other APCs, AML cells are also able to present leukemic peptides to T cells on HLA class 
II complexes (van Luijn, 2010).  Unfortunately, AML cells may behave like the immature 
DCs that promote immune tolerance (due to poor antigen-presentation) instead of 
functioning like the mature dendritic cells that promote immune clearance (Lutz, 2002; 
Panoskaltsis, 2005; Dudek, 2013).  Although converting AML cells into DCs is being 
explored for the development of therapeutic cancer vaccines, caution must be taken:  the 
differentiation of AML cells into indoleamine 2,3-diosygenase (IDO)-expressing DCs has 
been shown to impair maturation of normal DCs and inhibit T-cell proliferation, potentially 
restricting their use (Curti, 2010).   
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Figure 2.2. Processing and presentation of antigens via MHC class I molecules.  
Proteins are degraded within cells by the proteasome, loaded onto MHC class I molecules 
within the endoplasmic reticulum (ER), and translocated through the Golgi apparatus to 
the plasma membrane where peptide-MHC I complexes can be recognized by cytotoxic 
T cells.  Reproduced with permission from: Parcej, D., & Tampé, R. (2010). ABC proteins 
in antigen translocation and viral inhibition. Nature Chemical Biology, 6(8), 574. 
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Regarding the ways AML cells can escape anti-tumor immunity, evolving AML cells 
may acquire the ability to disrupt the presentation and processing of tumor antigens, 
downregulate expression of immuno-stimulatory receptors and/or their ligands, and/or 
shed immune-receptor decoys (Hoves, 2009; Lion, 2012; Schmiedel, 2013; Elias, 2014).  
Evolving molecular changes can alter expression, and disrupt presentation, of tumor 
antigens which, in turn, can inhibit immune-cell activation (Leone, 2012).  Like many other 
cancer cells, AML cells show reduced expression of HLA class 1 molecules compared to 
the non-malignant white blood cells (WBCs) from healthy donors which, in turn, impairs 
effective presentation of leukemia-associated antigens (Garrido, 2010; Vollmer, 2003; 
Vago, 2009).  In addition, tumor-generated peptides may be poorly immunogenic or fail 
to fit in the HLA class 1 groove.  AML peptide-HLA complexes may not be recognized by 
T cells or may be delivered to T cells in the absence of sufficient costimulatory signals 
(i.e. CD80 and CD86) which, in turn, promotes T-cell anergy, an unresponsive state 
(Vollmer, 2003).  Persistence of class II-associated invariant chain peptide (CLIP) within 
HLA class II molecules impairs presentation of leukemic antigens while downregulation 
of CLIP enhances AML cell immunogenicity which, in turn, promotes activation of Th cells 
(van Luijn, 2010).  Additional tumor-cell defects in antigen-processing machinery include 
mutations or deficiencies of proteasome subunits, including LMP2 and LMP7, and 
proteins that load peptides onto MHC class 1 molecules such as TAP and tapasin 
(Seliger, 1997; Johnsen, 1999; Leone, 2012). 
Promoting immune tolerance  
Immunologic tolerance is the inability to mount an immune response against an 
antigen.  Central tolerance – aka “natural” or “self tolerance” which is normal and 
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protective – is established during development when T cells that can attack normal, self 
antigens (and potentially trigger autoimmune diseases) are deleted in the thymus.  
Unfortunately, malignant cells generate a peripheral tolerance to tumor antigens by 
inducing T-cell anergy, by triggering T-cell apoptosis, and/or by deviating Th1 cytotoxic 
T-cell-mediated responses toward Th2 B-cell-mediated responses that are less effective 
against cancer cells (Mapara, 2004).  Secretion of TGF-β is one way tumor cells distort 
immune-cell responses by directing Th1 cytotoxic T-cell responses toward Th2 humoral 
responses (Maeda, 1996).  AML cells also recruit, or induce formation of, regulatory 
T cells (Tregs) that suppress cytotoxic T cells.  Through an IDO-dependent mechanism, 
AML cells promote conversion of CD4+CD25- T cells into CD4+CD25+ Tregs (Curti, 2007).  
Finally, tumors can permanently delete tumor-reactive T-cell clones by expression of 
death-inducing ligands (Mapara, 2004) or by chronic (repetitive) antigen stimulation which 
triggers activation-induced cell death (Lu, 2008). 
Avoiding immune destruction 
Resisting death 
Tumor cells resist immune-cell-mediated killing via the death receptor (Fas-
mediated) and/or granule exocytosis (perforin- and granzyme-mediated) pathways 
(Igney, 2002; Otten, 2004; Reed, 2003).  Tumor cells overexpress anti-apoptotic factors 
(FLIP, Mcl-1, Bcl-2), resist pro-apoptotic signals, and display mutations or defects in 
apoptotic pathways (Chiu, 1995; Reed, 2003).  Tumor cells also neutralize death-inducing 
stimuli by shedding soluble receptors that act as decoys for death ligands like TRAIL and 
FasL (Chamuleau, 2011; Reed, 2003).  Strategies that can sensitize AML cells to T-cell 
or NK-cell killing include targeting anti-apoptotic factors that induce immune resistance.  
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In a mouse model of colon cancer, treatment with a Nanog inhibitor decreased Mcl-1 
levels and sensitized tumor cells to T-cell-mediated lysis (Noh, 2012).  Small-molecule 
inhibitors of Bcl-2, TRAIL-receptor agonists, and IAP antagonists are currently being 
evaluated as anti-cancer agents in clinical trials (Reed, 2003; Weyhenmeyer, 2012). 
Suppressing immune cells 
Malignant cells express soluble and membrane-bound immuno-suppressive 
factors that disable (by inducing defects) or eliminate cancer-cell-reactive immune cells 
(Whiteside, 2006; Gajewski, 2006).  Immune cells can become dysfunctional when cancer 
cells (1) secrete soluble factors, (2) express immune-checkpoint receptors and/or their 
ligands, (3) recruit, and/or induce formation of, immuno-suppressive cells, and (4) distort 
stromal and immune cells within cancer-cell microenvironments (Huang, 2010; Gieseke, 
2010; Mellman, 2011; Sioud, 2011).  Immuno-suppressive factors can inhibit immune-cell 
activation, maturation, proliferation, survival, cytotoxicity, and proinflammatory cytokine 
secretion as well as recruit immuno-suppressive cells and unfavorably polarize immune 
responses (Spranger, 2013). 
Cancer cells can express a variety of immuno-suppressive factors including TNF-
family ligands, immune-checkpoint receptors and their ligands (Kikushige, 2010), small 
molecules, enzymes, and cytokines (Whiteside, 2006; Vesely, 2011).  Cancer-cell 
expression of TNF family ligands (such as FasL, TRAIL, TNF) triggers T-cell apoptosis 
upon binding to TNF family receptors (Whiteside, 2002).  By increasing cAMP, small 
molecules like prostaglandin E2, histamine, and epinephrine inhibit anti-tumor immune 
responses by decreasing IL-2 and IFN-γ production by T cells as well as IL-1β, IL-12, and 
TNFα production by monocytes and macrophages (Uotila, 1996).  Expression of the 
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immuno-suppressive enzymes IDO and arginase I by cancer cells, Tregs, and myeloid-
derived suppressor cells (MDSCs) impairs T-cell functions.  By depleting tryptophan, IDO 
inhibits T-cell proliferation (Uyttenhove, 2003).  Likewise, by depleting local L-arginine, 
arginase restricts T-cell proliferation and polarizes monocytes toward a suppressive 
M2-like phenotype (Mussai, 2013).  Cancer-cell secretion of cytokines like TGF-β, IL-10, 
and GM-CSF inhibits the proliferation of T cells and the release of pro-inflammatory 
cytokines (Bergmann, 1995; Krüger-Krasagakes, 1994).  
AML cells also directly inhibit T-cell activity by expressing coinhibitory receptors 
such as Tim-3 (Kikushige, 2010; Jan, 2011) and CTLA-4 (Laurent, 2007) as well as their 
ligands such as PD-1 ligand (Norde, 2011).  By expressing higher levels of ligands for 
inhibitory NK-cell receptors than activating NK-cell receptors, AML cells impair NK-cell-
mediated lysis (Lion, 2012; Verheyden, 2008; Baessler, 2009; Baessler, 2010).  AML 
expression of CD200 and RANKL inhibits NK-cell activity (Coles, 2011; Schmiedel, 2013) 
and T-cell activity (Coles, 2012).  AML cells also escape NK-cell-mediated killing by 
secreting MICA and MICB ligands as well as by shedding NKG2D-receptor decoys that 
absorb activating NK-cell ligands (Weiss-Steider, 2011; Groh, 2002).   
Therapies that target immune-checkpoint receptors and immuno-suppressive 
factors in the tumor microenvironment are reviewed in Chapter IV.  In addition to tumor-
cell-derived and immune-cell-derived factors, CAFs and endothelial cells within the tumor 
vasculature may also play an important role in immune suppression (Huang, 2010; 
Gieseke, 2010; Sioud, 2011).  Thus, for some cancer patients, effective multi-pronged 
therapies may need to systemically modulate the tumor-sustaining support cells in 
addition to targeting the tumor cells. 
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Strategies to enhance tumor-cell immunogenicity 
It is believed most cancers do, initially, trigger adaptive immune responses – 
evidenced by the presence of circulating tumor-reactive antibodies and immune cells.  
Over time, however, immunogenic cancer cells are eliminated, favoring the outgrowth of 
immune-escape variants (Dunn, 2002).  When considering how to target AML cells, 
possible immunologic strategies include increasing AML-cell immunogenicity and/or 
rendering AML cells less death-resistant (more susceptible to immunologic attack).  
Increasing the immunogenicity of AML LSCs may be important for eradicating therapy-
resistant “minimal residual disease” cells that can trigger relapse (Gerber, 2012).  AML 
LSCs are problematic because they are especially death-resistant and are better able to 
escape immune recognition and destruction than more mature leukemic blasts (Costello, 
2000).  As expected, poorly differentiated AML subtypes (M0) have been found to be less 
immunogenic than the more differentiated subtypes (M4-M5) as evidenced by weak in 
vitro alloimmune recognition of the poorly differentiated AML cells by T cells and their 
reduced expression of costimulatory molecules (Costello, 1999).  In general, CSCs only 
weakly stimulate immune cells; thus ex vivo activation of a patient’s immune cells may 
require manipulation of stem-like cancer cells to improve their immunogenicity.  Potential 
strategies to increase AML-cell immunogenicity – the ability to stimulate an adaptive 
immune response – include enhancing antigen-presentation by leukemia cells, blocking 
receptors like the “do not eat me” signals involved in immune escape, and inducing 
immunogenic tumor-cell death (Majeti, 2009; Lion, 2011; Rosenblatt, 2012).  
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Improving antigen-presentation by leukemia cells 
AML cells can directly activate, and present antigens to, immune cells in vitro – at 
least γ9δ2 T-cells (Gertner-Dardenne, 2012).   That is, antigen-presentation and immune-
cell activation by AML cells can occur simultaneously.  Perhaps AML-cell immunogenicity 
and antigen-presentation are best envisioned in the context of the immunologic synapse 
between AML and immune cells.  Of note, in co-culture systems, TCR agonists clearly 
enhance the direct activation of T cells by AML cells (Gertner-Dardenne, 2012).  
Presumably, a variety of other factors (cytokines, antibodies, immuno-stimulatory 
compounds, and agents known to modulate antigen-presentation pathways, etc.) can 
also enhance in vitro immune-cell activation by improving antigen-presentation, immune-
cell function, and/or tumor-cell immunogenicity. 
Of note, cytokine-induced differentiation of leukemia cells into DCs has been 
shown to improve the presentation of leukemia cell antigens to T cells (Cignetti, 1999; 
Charbonier, 1999; Harrison, 2001; Woiciechowsky, 2001; Choudhury, 1999).  Exposing 
AML cells to the TLR 7/8 agonist resiquimod, for example, enhanced their expression of 
MHC molecules, production of pro-inflammatory cytokines, and ability to stimulate 
allogeneic T cells (Smits, 2010).  Silencing STAT3 in AML cells upregulated HLA class II 
molecules along with costimulatory and proinflammatory mediators (like IL-12) while 
decreasing expression of the coinhibitory molecule PD-L1 and improving activation of 
CD8+ T cells (Hossain, 2014).  Stimulation with CD40 and IFN-γ increased AML 
immunogenicity and expression of costimulatory molecules (Costello, 1999).  Exposure 
to the histone deacetylase inhibitor (HDAC) chidamide increased AML expression of the 
cancer testis antigen PRAME and susceptibility to T-cell-mediated cytotoxicity (Yao, 
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2013).  In addition, inhibiting nonsense-mediated messenger RNA decay improved the 
immunogenicity of cancer cells by inducing expression of novel immunogenic tumor 
antigens (Pastor, 2010).  Proteasome inhibitors like bortezomib may also improve the 
immunogenicity of malignant cells by inducing expression of HSP90, a “danger signal,” 
on the surface of myeloma cells (Gavioli, 2002). 
Genetic modification of leukemia cells 
To increase their ability to activate immune cells, AML cells can be engineered to 
express danger signals, costimulatory molecules, or proinflammatory compounds (Lion, 
2011).  Transfection of AML cells with the viral mimetic polyinosinic polycytidylic acid 
[poly(I:C)], a synthetic non-coding synthetic dsRNA analog, enhanced DC activation and 
increased IFN-γ secretion by natural killer (NK) cells (Smits, 2007).  Following transfection 
with poly(I:C), AML cells were also more susceptible to killing by NK cells and 
phagocytosis by DCs, suggesting this dsRNA analog may be a useful vaccine adjuvant 
(Lion, 2011).  Downregulating CLIP expression by AML blasts increased their ability to 
stimulate CD4+ T-cell proliferation (van Luijn, 2010) consistent with the enhanced ability 
of CLIP(-) compared to CLIP(+) AML cells to activate and polarize CD4+ T cells toward 
Th1 cells (van Luijn, 2011).  Modifying AML cells to express the costimulatory ligand CD80 
also enhanced their ability to stimulate T-cell proliferation (Mutis, 1998). 
Inducing immunogenic tumor-cell death 
Cytotoxic chemotherapies are generally believed to suppress the immune system 
through myelotoxicity.  However, radiotherapy and certain chemotherapeutic drugs 
induce immunogenic forms of tumor-cell death characterized by cell-surface changes that 
promote the phagocytosis of dying tumor cells and the release of immuno-stimulating 
 48 
 
compounds – see Figure 2.3 (Tesniere, 2008; Inoue, 2014).  Ionizing radiation 
(γ-irradiation) – as well as chemotherapies that include anthracyclines (daunorubicin, 
idarubicin, mitoxanthrone), the platinum derivate oxaliplatin, and the alkylating agent 
cyclophosphamide – induce immunogenic tumor-cell death (Reits, 2006; Garnett, 2004; 
Casares, 2005; Obeid, 2007; Panaretakis, 2008).  Therapies that induce immunogenic 
cell death (ICD) can serve as in situ “cryptic vaccines” via release of tumor antigens and 
immune-boosting danger signals (Ma, 2010).  After reviewing the chronic lymphocytic 
leukemia (CLL) trials that exploited adoptive transfer of autologous CAR-modified T cells, 
Dr. June speculated that pre-treatment of patients with immunogenic chemotherapies 
may have improved therapeutic outcomes (Kalos, 2011; Porter, 2011).  In addition to 
killing tumor cells, cytotoxic chemotherapies can enhance immune responses by inducing 
transient lymphodepletion, counteracting immuno-suppressive mechanisms (Lutsiak, 
2005), stimulating immune cells, and sensitizing tumor cells to T-cell or NK-cell-mediated 
killing (Ma, 2010).  ICD might explain the “abscopal effect” in which localized radiation 
can also shrink metastatic tumors far from irradiated areas – presumably by stimulating 
the immune system (Kingsley, 1975; Robin, 1981; Wersall, 2006; Ohba, 1998). 
Unfortunately for cancer research, the immunological effects of anti-cancer drugs 
cannot be evaluated in immuno-deficient mice transplanted with human tumors.  One 
method to evaluate ICD involves pre-treatment of tumor cells with various 
chemotherapeutic drugs or cell-damaging agents followed by their subcutaneous 
injection into syngeneic immuno-competent mice.  When inoculated with tumor cells 
undergoing ICD, mice generate anti-tumor immune responses and establish long-term 
immunologic memory which prevents tumor growth upon subsequent challenge with live 
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tumor cells.  In vitro immune-cell activation assays that measure proliferation, cytokine 
release, and cytotoxicity are also available. 
Features of immunogenic cell death (ICD) 
During ICD, tumor-cell antigens are released along with pro-inflammatory stimuli 
such as “find me,” “eat me,” and “danger” signals that stimulate anti-tumor immunity – see 
Figure 2.3.  The molecular characteristics of ICD have been nicely reviewed (Tesniere, 
2008; Kepp, 2011).  In general, pro-inflammatory “danger” signals promote tumor-antigen 
uptake, processing, and presentation – as well as enhance the anti-tumor activity of 
immune cells.  Inducing the ICD of malignant cells is one strategy that can promote 
“immunogenic conversion” of the tumor microenvironment – see Figure 2.4.  Current 
conceptual frameworks for immunology suggest it is worthwhile to “convert” cancer cells 
into a “cryptic vaccine” by inducing release of tumor antigens in an immuno-stimulatory 
context.    
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Figure 2.3. Features of immunogenic tumor cell death.  A variety of chemotherapeutic 
drugs, radiotherapy, and targeted anti-cancer agents induce immunogenic forms of tumor 
cell death.  During immunogenic cell death, tumor cells expose and release a variety of 
danger signals.  For example, heat shock proteins (HSP) and calreticulin translocate to 
the plasma membrane and ATP and HMGB1 are secreted.  In response to these danger 
signals, DCs mature into effective antigen-presenting cells that prime T cells to attack 
tumors.  Reproduced with permission from:  Hou, W., Zhang, Q., Yan, Z., et al. (2013). 
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death 
& Disease, 4(12), 5. 
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Figure 2.4. Comparison of immunosupportive and immunosuppressive tumor 
microenvironments.  Within immunogenic microenvironments, activated immune cells 
recognize and eliminate tumor cells.  In contrast, within non-immunogenic 
microenvironments, tumor cells release immunosuppressive factors (such as TGF-β and 
IL-10) and recruit Treg cells and MDSCs that subvert infiltrating antigen-presenting and 
immune-effector cells; this leads to immune escape and tumor progression.  A major goal 
of cancer immunotherapy is to convert immunosuppressive tumor microenvironments 
that promote tumor escape into immunosupportive tissues that eradicate malignancy. 
Reproduced with permission from:  Monjazeb, A. M., Zamora, A. E., Grossenbacher, S. 
K., et al. (2013). Immunoediting and antigen loss: overcoming the Achilles heel of 
immunotherapy with antigen non-specific therapies. Frontiers in Oncology, 3, 4. 
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“Find me” signals include small molecules such as HMGB1 and ATP that help 
recruit and activate infiltrating immune cells like monocytes.  HMGB1 binds TLR4 on DCs 
and inhibits antigen degradation mediated by fusion of phagosomes with lysosomes, 
thereby favoring the processing and presentation of tumor antigens (Apetoh, 2007).  ATP 
released from cancer cells binds P2RX7 on DCs, leading to inflammasome activation and 
secretion of IL-1β (Ghiringhelli, 2009).  “Eat me” signals stimulate uptake of tumor 
antigens by antigen-presenting cells like DCs.  During ICD, malignant cells express 
surface calreticulin.  When translocated to the plasma membrane, calreticulin functions 
as a receptor for DC engulfment (Obeid, 2007).  During ICD, cancer cells may also 
downregulate expression of “do not eat me” signals such as CD47.  Tumor-cell loss or 
the redistribution of CD47, which normally inhibits phagocytosis by SIRPα-expressing 
macrophages, can promote cancer-cell engulfment due to expression of calreticulin 
(Willingham, 2012).  In response to the cellular stress induced by chemotherapy, cancer 
cells transcriptionally activate heat-shock proteins which, in turn, stimulate DC maturation 
via CD91 (Somersan, 2001) and facilitate chaperoning of tumor antigens to MHC 
molecules for presentation to T cells (Zitvogel, 2008; Binder, 2005). 
While this chapter focuses on factors mediating immune evasion and suppression 
on the tumor-cell side of malignant disease, Chapter III focuses on the cancer-induced 
defects of immune cells and the tumor stroma that prevent immune clearance of cancer 
cells.  Strategies are reviewed for (1) the repair of dysfunctional immune cells (in vitro) –
followed by their activation and expansion and (2) the reversal of the immune suppression 
induced by cancer microenvironments (in vivo).  The ways Tim-3 expression can impair 
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anti-tumor immune responses – when expressed on the surface of tumor or immune cells 
– are also described.   
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Cancer-induced impairments of immune cells and stromal cells; 
therapeutic strategies for repair 
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 When the immune system mounts an attack against cancer, tumor cells “fight 
back” by subverting anti-tumor immune defenses (Zitvogel, 2006).  While Chapter II 
reviewed cancer-cell-derived factors that mediate immune evasion and suppression, this 
chapter describes immune-cell defects induced by cancer-distorted microenvironments.  
Intrinsic immune-cell defects (i.e. anergy, exhaustion, impaired maturation) and extrinsic 
immune-suppressing factors (i.e. TGF-β, IDO, CAFs) are reviewed.  Potential ways to 
repair dysfunctional immune cells and counteract immuno-suppressive factors in cancer 
microenvironments are described.  Tim-3 is highlighted because it disrupts immune 
responses and synapses, and both TGF-β and RepSox affect Tim-3 (Wiener, 2007; 
Jajosky, 2014).  In vivo Tim-3 blockade and the in vitro manipulation of Tim-3 expression 
by malignant cells warrant consideration when designing anti-cancer immune strategies. 
Generation of anti-tumor immune responses 
The immune system eliminates malignant cells via a variety of defenses including 
innate and adaptive immune cells, antibodies, complement proteins, and cytokines.  
Innate defenses are first to respond, followed by more specialized attack by antigen-
specific T and B cells of the adaptive immune system.  The key players of the innate and 
adaptive immune system are outlined in Figure 3.1.  Adaptive immune responses, 
involving antigen-specific T and B cells or antibodies, can be divided into the “activation 
phase” involving tumor-antigen cross-presentation within lymphoid organs (i.e. lymph 
nodes) and the “effector phase” involving tumor-cell lysis in the periphery (Dzivenu, 2003; 
Yao, 2013).  Figure 3.2 provides an overview of important soluble factors and cell-to-cell 
interactions that mediate generation of innate and adaptive anti-tumor immunity.   
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Figure 3.1. Innate and adaptive immune defenses.  The innate immune system is the 
body’s first line of defense against invading pathogens and cancer.  Components of innate 
immunity include phagocytes (i.e. macrophages), NK cells, and complement proteins.  
The adaptive immune system generates antigen-specific anti-tumor responses mediated 
by antibodies, B cells, and T cells.  Unlike innate immunity, the adaptive immune system 
can generate immunological memory that is capable of protecting against re-emergence 
of disease.  Reproduced with permission from:  Dranoff, G. (2004). Cytokines in cancer 
pathogenesis and cancer therapy. Nature Reviews Cancer, 4(1), 13. 
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Figure 3.2. Generation of innate and adaptive anti-tumor immune responses.  Within 
NK cells of the innate immune system, the net input of activating and inhibitory signals 
determines whether or not cancer cells lacking MHC class 1 molecules (“missing self”) 
will be effectively killed.  Within the adaptive immune system, DCs engulf tumor antigens 
and migrate to lymph nodes where they present tumor peptide-MHC complexes to T cells 
(a process called “cross-priming”).  Activated CD4+ TH cells, in turn, help to activate CD8+ 
cytotoxic T cells and stimulate B cells to produce antibodies.  Reproduced with permission 
from:  Dranoff, G. (2004). Cytokines in cancer pathogenesis and cancer therapy. Nature 
Reviews Cancer, 4(1), 14. 
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Activation phase 
Antigen-presenting cells (APCs), such as macrophages and DCs, engulf cancer 
cells or capture antigens released by dying cells.  Immunogenic tumor-cell death, 
illustrated in Figure 2.4, activates APCs through release of pro-inflammatory “find me,” 
“eat me,” and “danger” signals (Tesniere, 2008; Inoue, 2014).  In contrast, non-
immunogenic cell death promotes tolerance.  APCs process and present captured tumor 
antigens on their surface via major histocompatibility complex (MHC) class II molecules 
(Dzivenu, 2003).  After migrating to tumor-draining lymph nodes, DCs cross-present 
malignant peptide-MHC complexes to CD4+ Th cells (Dzivenu, 2003).  Th cells secrete 
cytokines that activate other immune cells.  Th cells can be divided into type 1 (Th1) and 
type 2 (Th2) cells based on the cytokines they secrete.  By secreting interferon-gamma 
(IFN-γ) and IL-2, Th1 cells activate CD8+ cytotoxic T cells and promote cell-mediated 
immunity (Dzivenu, 2003).  In contrast, by secreting IL-4 and IL-5, Th2 cells stimulate 
antibody production by B cells (Dzivenu, 2003). 
Effector phase 
Once activated, cytotoxic T cells recognize malignant cells expressing cancer-
specific or cancer-associated antigens bound to MHC class 1 molecules via their T-cell 
receptor (Dzivenu, 2003).  Cytotoxic T cells lyse cancer cells by releasing perforins and 
granzymes.  Once activated, B cells differentiate into antibody-producing plasma cells.  
Antibodies bind the surface of cancer cells and lead to tumor-cell death through antibody-
dependent cellular cytotoxicity (ADCC) or activation of the complement cascade 
(Dzivenu, 2003).  ADCC involves recruitment of immune cells, such as macrophages and 
NK cells, which engulf or lyse cancer cells (Raval, 2014).  Antibodies can also activate 
 67 
 
the complement cascade which, in turn, induces tumor-cell lysis by perforating the cell 
membrane (Raval, 2014). 
Cancer immunoediting hypothesis 
The cancer immunoediting hypothesis (see Figures 3.3 and 3.4) describes how 
the immune system affects cancer development through its dual host-protective and 
tumor-promoting roles (Dunn, 2002; Dunn, 2004).  Immunoediting of tumors can be 
divided into three phases:  elimination, equilibrium, and escape – see Figure 3.4 (Dunn, 
2002; Dunn, 2004).  During the elimination (“immuno-surveillance”) phase, immunogenic 
tumor cells are eliminated by innate and adaptive immune cells.  If all cancer cells are 
eradicated, disease is cured.  If not, residual “immune-escape variants” remain behind. 
During the equilibrium (“immuno-selection”) phase, tumor outgrowth is prevented, but 
remaining cancer cells continue to evolve under constant immune-selection pressures.  
During the escape (“immuno-subversion”) phase, the poorly immunogenic cancer cells 
that evaded immune destruction grow and expand.   
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Figure 3.3. Immunoselection and immunosubversion during tumor evolution.  By 
eliminating immunogenic tumor cells, the immune system selects for poorly immunogenic 
tumor cells that escape immune recognition.  These immune escape variants 
progressively alter (“hijack”) their microenvironment to suppress immune defenses and 
promote tumor growth.  Adapted with permission from:  Zitvogel, L., Tesniere, A., & 
Kroemer, G. (2006). Cancer despite immunosurveillance: immunoselection and 
immunosubversion. Nature Reviews Immunology, 6(10), 716. 
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Figure 3.4. Three phases of cancer immunoediting:  elimination, equilibrium, and 
escape.  As cancers evolve, tumor cells are recognized and cleared by the immune 
system.  Elimination of all tumor cells cures disease.  If malignant disease persists, the 
immune system may prevent outgrowth of surviving tumor cells for some time.  However, 
tumor cells may continue to evolve and alter surrounding tissues in ways that impair 
immune defenses.  Ultimately, tumor cell “immune escape” variants may emerge and 
cause overt disease.  Reproduced with permission from:  Vesely, M. D., Kershaw, M. H., 
Schreiber, R. D., et al. (2011). Natural innate and adaptive immunity to cancer. Annual 
Review of Immunology, 29, 238. 
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Cancer-induced dysregulation of the immune system 
As cancers progress, immune cells may no longer be recruited to, or activated by, 
malignant cells; and immune-cell function may be inhibited by tumor microenvironments 
(Gajewski, 2006; Spranger, 2013).  Even when patients do not generate an effective anti-
cancer immune response, tumor-reactive immune cells may still exist, but are, 
unfortunately, overwhelmed or suppressed (Gajewski, 2006; Tran, 2014).  
Immunotherapies for cancer aim to trigger de novo immune responses and enhance 
(“rescue”) pre-existing anti-tumor immune reactions that have become silenced (Mellman, 
2011).  Conceptually, this involves stimulating the immune-activation phase and rescuing 
the immune-effector phase.  Remarkably, cancer-induced immune-cell defects can be 
repaired (Hodi, 2010; Reiners, 2013; Vizcardo, 2013), and immuno-suppressive cells, 
enzymes, and soluble factors can be neutralized or eliminated (van den Boorn, 2013).  
Thus, it is possible to convert non-immunogenic tumor microenvironments into anti-
cancer, immuno-stimulating tissues (van den Boorn, 2013). 
Cancer-induced intrinsic immune-cell defects 
Unfortunately, dysfunctional immune cells can accumulate in cancer patients 
(Gabrilovich, 2004; Pinzon-Charry, 2005; Wherry, 2011).  Defects include anergy, 
exhaustion, impaired maturation, deletion, and unfavorable polarization (toward type 2 
humoral immunity rather than type 1 cell-mediated immunity).  Immune-effector cells 
become “tolerant” and are unable to eliminate cancer cells (Crespo, 2013; Wherry, 2011).  
By failing to adequately present antigens and activate T cells, the (immature) DCs actually 
promote T-cell tolerance (Lutz, 2002; Dudek, 2013).  Cancer-induced dysfunctions of 
T cells, DCs, NK cells and macrophages are reviewed. 
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T-cell defects 
In patients with cancer and chronic viral infections, T cells can become 
dysfunctional (i.e. anergic, exhausted) or may be deleted.  T-cell anergy is due to 
incomplete activation (i.e. T-cell receptor ligation in the absence of costimulatory signals 
like CD28 engagement) (Chappert, 2010), while exhaustion arises from chronic over-
stimulation (Wherry, 2011).  Exhausted T cells often express inhibitory immune-
checkpoint receptors (Tim-3 and PD-1) and display impaired cytokine secretion and 
cytolytic activity upon antigen stimulation (Wherry, 2011).  Compared to healthy controls, 
T cells from AML patients formed defective immune synapses with AML cells and had 
(altered) gene expressions consistent with impaired cytolytic activity (Le Dieu, 2009). 
NK-cell defects 
Cancer-cell-induced NK-cell abnormalities include impaired maturation, anergy, 
decreased cytotoxicity, and defective secretion of cytokines like IFN-γ (Das, 2000; 
Richards, 2006; Lion, 2012).  Compared to patients without cancer, NK cells from AML 
patients have decreased expression of activating NK-cell receptors and increased 
expression of inhibitory NK-cell receptors (Costello, 2002; Lion, 2012).  This unfavorable 
balance of stimulatory and inhibitory receptors may prevent effective NK-cell-mediated 
elimination of AML cells. 
DC defects 
In cancer patients, incomplete maturation of DCs is one reason why immune 
responses are impaired (Pinzon-Charry, 2005).  Tumor-derived factors, such as 
gangliosides, VEGF, IL-6, and IL-10, inhibit DC differentiation (Gabrilovich, 2004).  This 
leads to an accumulation of immature DCs and the absence of an adequate number of 
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functional (mature) DCs as well as an accumulation of immature myeloid progenitors 
generally – a combination of adverse effects which, collectively, can substantially impair 
T-cell responses (Gabrilovich, 2004).  Of note, immature (dysfunctional) DCs are among 
the myeloid-derived suppressor cells (MDSCs) that suppress T-cell immunity – see Figure 
3.5 (Gabrilovich, 2009; Khaled, 2013; Ostrand-Rosenberg, 2009).  That is, MDSCs 
include a variety of immature myeloid cells that have not fully differentiated into fully 
functional macrophages, DCs, or granulocytes (Gabrilovich, 2009; Khaled, 2013).  
Because immature DCs present antigen in the absence of appropriate costimulatory 
signals (i.e. CD80 and CD86) and/or proinflammatory cytokines, they, unfortunately, 
induce T-cell tolerance rather than protective anti-tumor responses (Gabrilovich, 2004). 
Macrophage defects 
Tumor-associated macrophages (TAMs) accumulate in tumors, and high tumor 
influx of TAMs is associated with poor prognosis in cancer patients (Solinas, 2009; Tang, 
2013).  TAMs may polarize to type 2 (M2) macrophages that promote tumor growth 
(Solinas, 2009).  While type 1 (M1) macrophages produce IL-12 and enhance Th1 and 
NK cell-mediated immunity, M2 macrophages secrete IL-10 and promote Th2 humoral 
immunity – see Figure 3.5 (Solinas, 2009).  Of note, cell-mediated immunity is believed 
to be more effective than antibodies in controlling tumor growth. 
Strategies to repair dysfunctional immune cells 
Remarkably, dysfunctional immune cells can be repaired (“re-educated” or 
“reprogrammed”) and then activated and expanded to promote tumor-rejection.  Using a 
metastatic melanoma patient’s exhausted CD8+ T cells, reprogramming to pluripotency – 
followed by re-differentiation – generated “rejuvenated” cytotoxic T cells that were 
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functional based on their ability to produce IFN-γ upon encounter with antigen (Vizcardo, 
2013).  Immature DCs can be differentiated into functional APCs using ATRA (Mirza, 
2006; Kusmartsev, 2003).  In a mouse model of breast cancer, type 2 tumor-promoting 
TAMs were re-polarized into type 1 cells with increased tumoricidal activity using a 
combination of microbial stimulus (TLR9 ligand CpG) and anti-IL-10-receptor antibody 
(Giuducci, 2005).  Here, strategies are reviewed that can repair and activate defective 
immune-effector cells in order to stimulate anti-tumor immunity.  Relevant factors include 
proinflammatory cytokines, “danger signals” (like TLR agonists), and antibodies that 
activate costimulatory, and/or block coinhibitory, immune-checkpoint receptors.   
Repairing T cells 
Several strategies have been developed to reverse T-cell tolerance. Examples 
include targeting immune-checkpoint receptors, delivering proinflammatory cytokines, 
and reprogramming T cells to pluripotency (Pardoll, 2012; Vizcardo, 2013). 
Modulation of immune-checkpoint receptors   
Antibodies that activate costimulatory receptors or inhibit immune-checkpoint 
receptors can stimulate T cells.  For example, inhibiting the PD-1 signaling pathway can 
rescue exhausted T cells in the setting of cancer and chronic viral infection (Barber, 2006; 
Zitvogel, 2012).  Co-expression of PD-1 and Tim-3 identifies “exhausted” killer T cells in 
mice with AML (Zhou, 2011), and co-blockade of PD-1 and Tim-3 more effectively 
stimulates anti-tumor immunity than either therapy alone (Sakuishi, 2010).  In clinical 
trials, PD-1 blockade induced tumor regression in patients with advanced melanoma or 
lung and kidney cancers (Brahmer, 2012; Topalian, 2012).  Treatment with ipilimumab, a 
CTLA-4 blocking antibody, restored T-cell anti-tumor immunity and improved survival of 
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melanoma patients (Hodi, 2010).  Antibody activation of the costimulatory receptor OX40 
(Weinberg, 2011) and blockade of the coinhibitory receptor LAG-3 (Goldberg, 2011) can 
also promote anti-tumor immunity. 
Cytokine stimulation 
Exposure to cytokines, including IL-15, IL-17 and IL-2, can prevent, or reverse, 
T-cell anergy induced by tumors and chronic viral infections (Boussiotis 1994; Gu, 2007; 
Teague, 2006).  Using a mouse model of T-cell tolerance, in vitro exposure to IL-15 
rescued “tolerant” T cells; furthermore, adoptive transfer of rejuvenated T cells was 
effective in treating mice with leukemia (Teague, 2006). 
Induction of homeostatic proliferation   
Lymphopenia-induced homeostatic T-cell proliferation can reverse tumor-induced 
T-cell anergy and promote tumor rejection (Kline, 2008; Brown, 2006).  Lymphopenic 
conditioning of patients prior to receiving adoptively transferred T cells improves the 
persistence and expansion of infused T cells (Dudley, 2002; Rosenberg, 2008).  
Presumably, lymphopenic conditioning depletes Tregs and supports engraftment and 
homeostatic proliferation of therapeutic (functional) T cells. 
Repairing NK cells 
Following exposure to IL-15, NK cells from AML patients show increased 
expression of activating receptors and improved cytotoxicity (Szczepanski, 2010).  IL-15 
may also promote NK-cell maturation (Richards, 2006).  Anti-KIR antibodies block 
inhibitory NK-cell receptors and promote NK-cell-mediated killing of tumor cells 
(Romagne, 2009; Velardi, 2009; Alici, 2010).  NK-cell-mediated cytotoxicity against non-
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Hodgkin’s lymphoma tumor cells improved with the use of bispecific antibodies that could 
crosslink the CD16A receptor on NK cells with the CD30 receptor on non-Hodgkin’s 
lymphoma cells (Reiners, 2013).  Targeted anti-cancer therapies can also promote the 
anti-tumor activity of NK cells.  For example, imatinib increases DC-mediated NK-cell 
activation (Borg, 2004).   
Role of Tim-3 expression in immune-cell dysfunction 
Tim-3 inhibits the pro-inflammatory or anti-tumor activities of a variety of immune 
cells, including T, NK, dendritic, and monocytic cells.  The endothelial and stromal cells 
that surround tumors also mediate immune suppression.  Tim-3-expressing endothelial 
cells may function as an immunological barrier shielding tumor cells from infiltrating T cells 
by directly suppressing their activity (Huang, 2010).  Tumor cells may convert stromal 
cells into galectin-9-expressing CAFs capable of suppressing T-cell responses (Gieseke, 
2013; Sioud, 2013).  Similar to the adverse consequences of Tim-3 expression by 
immune and stromal cells, Tim-3 expression by tumor cells can also promote immune 
escape or suppression by, for example, disrupting cancer-cell/immune-cell synapses. 
Cytotoxic T cells  
Tim-3 promotes T-cell tolerance in the setting of cancer and chronic viral infections 
(Sánchez-Fueyo, 2003).  High Tim-3+ T cells do not respond to stimulation:  they are 
unable to proliferate or produce cytokines.  Thus, high Tim-3+ T cells are known as “non-
effector” or “exhausted” T cells (Golden-Mason, 2009; Hastings, 2009).  In lymphoma 
patients, T-cell dysfunction (“exhaustion”) was found to be mediated, in part, by increased 
Tim-3 expression by T cells (Yang, 2012).  In the context of chronic viral infections, Tim-3+ 
T cells displayed impaired secretion of the cytokines IFN-γ and TNF-α and were more 
 76 
 
prone to apoptosis (Jones, 2008; Golden-Mason, 2009; Jin, 2010; Ju, 2009).  Tim-3 
expression on the surface of CD8+ T cells impairs their cytotoxicity by inhibiting the 
degranulation needed for the secretion of perforin and granzymes (Sakhdari, 2012).  
Cytokine production by Th1 cells in mice is enhanced following treatment with Tim-3 
blocking antibodies (Sabatos, 2003).  In the presence of Tim-3 blocking antibodies, CD4+ 
T cells showed enhanced secretion of the proinflammatory cytokines IFN-γ, IL-2, IL-17, 
and IL-6 (Hastings, 2009).  In vitro, the Tim-3 ligand galectin-9 blocks differentiation of 
naïve T cells into Th17 cells while inducing their differentiation into suppressive Tregs (Seki, 
2008).  Unfortunately, over-expression of Tim-3 can emerge as malignant disease 
progresses, and Tim-3 can promote immune tolerance by (adversely) altering the 
malignant, immune, and stromal cells of cancer patients.  Tim-3 blockade can restore 
anti-tumor immunity by inducing therapeutically beneficial changes in multiple cell types.  
Regulatory T cells (Tregs) 
Suppressive Tregs inhibit anti-tumor immunity, and in a mouse model of colon 
cancer, most intratumoral FOXP3+ Tregs were found to express Tim-3 (Sakuishi, 2013).  
Tim-3+ Tregs that co-express PD-1 are highly suppressive (Sakuishi, 2013).  As an anti-
cancer strategy, the benefit of simultaneously blocking both the Tim-3 and PD-1 signal 
transduction cascades likely arises not only from the reversal of T-cell exhaustion, but 
also from the inhibition of Treg-cell function (Sakuishi, 2013).  It seems Tim-3 identifies 
those Tregs that very strongly suppress anti-tumor immune responses (Sakuishi, 2013). 
Monocytes and Macrophages 
Tim-3 expression by monocytes and macrophages has not been well studied in 
cancer.  Blocking Tim-3 receptors on monocytes increased their secretion of IL-12, a 
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cytokine that promotes Th1 and NK-cell-mediated immunity (Zhang, 2012).  In mice with 
sepsis, Tim-3 blockade increased macrophage activation (accompanied by increased 
mRNA expression of proinflammatory cytokines and TLRs) and exacerbated sepsis, 
suggesting Tim-3 can limit macrophage activity (Yang, 2013).  Of note, activation of the 
Tim-3-galectin 9 pathway has also been shown to promote macrophage bactericidal 
activity (Sada-Ovalle, 2012). 
Dendritic cells  
In mice with lung or colon cancer, Tim-3 was over-expressed on tumor-infiltrating 
DCs compared to the DCs residing within normal tissues and the DCs of healthy mice 
(Chiba, 2012).  These high Tim-3-expressing DCs enable tumors to evade immuno-
surveillance by suppressing the sensing of nucleic acids associated with by tumor-
induced inflammation (Chiba, 2012; Jinushi, 2012). 
Natural killer cells (NK cells)  
Although Tim-3+ NK cells from healthy donors were mature and fully functional, 
Tim-3 may suppress NK-cell-mediated cytotoxicity upon encounter with target cells 
expressing Tim-3 ligands (Ndhlovu, 2012).  Relative to NK cells from healthy donors, NK 
cells from melanoma patients displayed elevated Tim-3 expression along with reduced 
cytotoxicity, IFN-γ secretion, and proliferation (da Silva, 2014).  Among melanoma 
patients, Tim-3 expression on NK cells was generally higher during advanced stages of 
disease and in patients with poor prognostic factors (da Silva, 2014).  Furthermore, Tim-3 
blockade reversed NK-cell exhaustion and improved cytotoxicity against melanoma cell 
lines (da Silva, 2014).  
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Natural killer-T (NKT) cells  
Tim-3+ NKT cells in the liver are functional:  they can proliferate and produce 
cytokines when stimulated.  When liver NKT cells are activated by exogenous bacterial 
antigens, Tim-3 expression is upregulated and IFN-γ is secreted.  IFN-γ induces 
production of galectin-9 by Kupffer cells in the liver which, in turn, induces apoptosis of 
Tim-3+ NKT cells and reduces the inflammatory response.  That is, in some molecular 
and cellular contexts, Tim-3 expression on NKT cells leads to NKT-cell apoptosis which, 
in turn, limits the NKT-cell immune response (Kinjo, 2005; Mattner, 2005; Kinjo, 2006; 
Mengshol, 2010). 
Tim-3 blockade to stimulate immune-cell activity 
Because Tim-3 restrains anti-tumor immunity, preclinical studies are evaluating the 
use of Tim-3 blockade to promote immune-mediated tumor-rejection.  Along with PD-1 
blockade (Sakuishi, 2010) and CD137 activation (Guo, 2013), Tim-3 blockade reverses 
T-cell exhaustion and promotes anti-tumor immunity in mice.  Co-blockade of Tim-3 and 
Tim-4 also improved vaccine-induced anti-tumor immune responses by stimulating NK 
and T-cell activity in mice with melanoma (Baghdadi, 2013).  Based on these successful 
animal trials, Tim-3 blocking antibodies are in preclinical development. 
Cancer-induced extrinsic immune suppression 
 Tumors recruit, and induce the formation of, suppressive immune cells.  Because 
inhibitory (aka “regulatory”) immune cells normally dampen immune responses, they may 
be recruited and “hijacked” by tumors to promote immune escape (Zitvogel, 2006).  Under 
normal physiologic conditions, inhibitory cells (like Tregs) are useful because they limit 
chronic inflammation, maintain peripheral tolerance to self antigens, and prevent 
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autoimmune disease (Hori, 2003; Vignali, 2008).  But, in the context of malignant disease, 
Figure 3.5 shows how Tregs, tolerogenic DCs, tumor-associated (M2) macrophages, 
MDSCs, and CAFs facilitate tumor progression by suppressing the immune system.  
Regarding the generation of inhibitory immune cells, tumors impair the maturation of 
myeloid cells into functional anti-tumor effector cells and skew development of immune 
responses toward those that are antibody-based and away from the more effective, cell-
mediated responses (Gabrilovich, 2004; Pinzon-Charry, 2005; Solinas, 2009).  Tumors 
also secrete TGF-β which can convert T cells into Tregs by inducing FoxP3 expression 
(Liu, 2007).  Regarding the adverse role played by support cells in tumor-cell 
microenvironments, cancers distort local stromal and endothelial cells in ways that 
suppress the infiltrating immune cells (i.e. by inducing expression of Tim-3 or galectins) 
(Huang, 2010; Mellman, 2011; Gieseke, 2013; Sioud, 2013). 
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Figure 3.5. Proposed mechanisms of immune suppression by immune cells and 
cancer-associated fibroblasts.  Adapted with permission from:  (1) Kerkar, S. P., & 
Restifo, N. P. (2012). Cellular constituents of immune escape within the tumor 
microenvironment. Cancer Research, 72(13), 3126. and (2) Baitsch, L., Fuertes-Marraco, 
S. A., Legat, A., et al. (2012). The three main stumbling blocks for anti-cancer T cells. 
Trends in Immunology, 33(7), 365. 
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Reversing immune suppression 
Strategies to reverse immuno-suppression include eliminating suppressive cells or 
their secretions, inducing immature (“tolerogenic”) cells to differentiate into functional 
cells, and repolarizing (“re-educating”) immune responses from tumor-promoting to 
tumor-rejecting responses.  Inhibitory immune cells can be depleted using targeted 
therapies or systemic agents with immunological effects (Zou, 2006; Vanneman, 2012).  
Targeting Tregs  
Therapeutic strategies for targeting Tregs have been previously reviewed (Zou, 
2006).  Daclizumab, a CD25-targeting monoclonal antibody, depletes Tregs (which are 
classically CD4+CD25+FoxP3+) and improves anti-tumor immunity in preclinical studies 
(Kline, 2008) and in clinical trials (Rech, 2009; Rech 2012).  Denileukin difitox (OnTak), 
an IL-2-diphtheria toxin fusion protein, reduces Tregs and induces tumor regression in 
patients with melanoma (Telang, 2011).  Glucocorticoid-induced tumor-necrosis factor-
receptor related protein (GITR)-stimulating antibodies reduced the tumor-suppressor 
activity of Tregs in vitro (Shimizu, 2002) and promoted tumor regression in mice (Ko, 2005). 
Targeting tolerogenic DCs  
Therapeutic targeting of immature tolerogenic DCs can involve eliminating them, 
inhibiting their formation or expansion, or promoting their differentiation into functional 
DCs (that can present tumor antigens, secrete proinflammatory cytokines, express 
costimulatory ligands, and activate T cells).  In mice with AML, treatment with agonistic 
CD40 antibodies – which are known to activate host APCs like DCs – reversed T-cell 
tolerance and prolonged survival (Zhang, 2013).  CD40 ligation also restored T-cell 
antimicrobial immunity (Tuma, 2002).  All-trans-retinoic-acid (ATRA) differentiated 
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immature myeloid cells into mature DCs (as well as macrophages and granulocytes) and 
improved anti-tumor immunity in tumor-bearing mice upon vaccination (Kusmartsev, 
2003).  Because immature DCs are a type of MDSC, see the “Targeting MDSCs” section 
for other ways to therapeutically target these cells. 
Targeting tumor-associated macrophages (TAMs)   
Therapeutic targeting of TAMs (including strategies to inhibit recruitment to tumors, 
impair survival, increase M1-like tumor-killing activity, and reduce M2-like tumor-
promoting activity) have been extensively reviewed (Tang, 2012).  Therapies may seek 
to reduce the number of TAMs or shift (“repolarize”) macrophage behavior from tumor-
promoting to tumor-rejecting agendas (Biswas, 2010).  Combining the TLR9 agonist CpG 
with IL-10-receptor-blocking antibodies reprogrammed M1-like TAMs to potent M2-like 
anti-tumor effectors (Guiducci, 2005).  CD40 agonistic antibodies (Buhtoiarov, 2006; 
Buhtoiarov, 2011; Beatty, 2011) and IL-12 (Watkins, 2007) also enhanced the anti-tumor 
activity of M1-like TAMs.  Exposure to histidine-rich glycoprotein (Rolny, 2011) and 
inhibition of STAT3 and STAT6 signaling (Kortylewski, 2005; Cheng, 2003) reduced M2-
like TAM tumor-promoting activity and inhibited tumor growth. 
Targeting myeloid-derived suppressor cells (MDSCs)   
Strategies that target MDSCs – by inducing differentiation, preventing expansion, 
inhibiting function, or eliminating them – have been extensively reviewed (Gabrilovich, 
2009).  Typically, the goal is to reduce the number of MDSCs or alter their function.  ATRA 
(Mirza, 2006; Kusmartsev, 2003) and 25-hydroxyvitamin D3 (Lathers, 2004) promote 
MDSC differentiation into mature macrophages or DCs.  Nitroaspirin (De Santo, 2005), 
sildenafil (Serafini, 2006), and biphosphonate (Melani, 2007) inhibit MDSC activity.   
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Inhibiting stem-cell-factor-mediated signaling reduces MDSC expansion (Pan, 2008).  
Some chemotherapy drugs like gemcitabine eliminate MDSCs (Suzuki, 2005). 
Targeting suppressive metabolic enzymes   
Anti-cancer therapies are being developed to not only eliminate inhibitory immune 
cells, but also to reduce their immuno-suppressive secretions.  Enzymes like IDO and 
arginase impair the anti-tumor activity of NK and T cells by depleting tryptophan and 
arginine – amino acids needed for T-cell proliferation and function.  Inhibiting IDO and 
arginase activity improves anti-tumor immunity in preclinical models (Uyttenhove, 2003; 
Liu, 2010; Raber, 2012) and is now being investigated in clinical trials.  In normal 
physiologic settings, IDO limits the activation of T cells and NK cells in the placenta 
(Frumento, 2002; Munn, 2002).   
General non-targeted strategies  
The physical removal of malignant cells has been shown to reduce immuno-
suppression.  Removal of primary tumors restored humoral and cell-mediated anti-tumor 
immunity in mice with breast cancer despite persistence of extensive metastatic disease 
(Danna, 2004).  Presumably, surgery not only eliminates cancer cells and the immuno-
suppressive factors they secrete, but also a variety of inhibitory immune cells that have 
infiltrated the tumor.  Removing both tumor cells and tumor-promoting immune cells may 
tip the balance toward effective anti-tumor immunity.  Perhaps this means leukemia 
patients are most likely to respond to immunotherapy in the setting of MRD.  Of note, 
lymphodepleting regimens (that reduce the number of Tregs) promote expansion of 
adoptively transferred T cells by inducing their homeostatic proliferation (Dudley, 2002; 
Rosenberg, 2008).  Thus, the numbers of cancer and immune-effector cells – or the 
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immune-effector/immune-suppressor cell ratio – may determine whether malignant cells 
can persist or will be eliminated.  
Overall, in addition to inducing immunogenic tumor-cell death, some standard 
(“conventional”) anti-cancer therapies may have additional immuno-stimulatory effects 
(Zitvogel, 2008).  For example, chemotherapeutic agents like cyclophosphamide can 
partially deplete or inactivate Tregs (Ghiringhelli, 2004; Lutsiak, 2005).  
Cancer-associated fibroblasts 
The conceptual frameworks that are driving cancer research include theories and 
models that integrate diverse scientific findings and viewpoints.  This is especially true for 
the study of cancer microenvironments.  Experiments that are clarifying how local 
surroundings support tumor cells have been inspired by provocative models of tumor-
microenvironment interactions (Infanger, 2013).  For example, some propose that the 
physiologic mechanisms that so effectively protect cancer cells had originally evolved to 
promote wound-healing and regeneration (Oviedo, 2009).  In this conceptual framework, 
some patterns of inflammation are critical.  In response to injury, tissue repair in primitive 
animals occurs in adverse acidic, hypoxic, inflammatory microenvironments that trigger 
mechanisms that promote the survival and proliferation of critical stem-like (normal) cells 
that regenerate tissues.  Cancer-induced inflammatory states resemble those triggered 
by injury, and they may trigger the same cell-protection mechanisms that evolved to 
protect normal stem cells to, unfortunately, promote CSC survival (Landsberg, 2012).  In 
this discussion, (from among many synonyms) the terms “normal stromal fibroblast” and 
“CAF” are used.  As shown in Figure 3.6, tumor microenvironments convert, or reprogram, 
normal stromal fibroblasts into stromal cells with a CAF phenotype.  These CAFs, in turn, 
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alter the phenotypes of immune cells in ways that promote tumor-cell survival via immune 
evasion and tolerance.  Of note, the terms “mesenchymal stem cells” and “multi-potent 
mesenchymal stromal cells” are other names that are sometimes used for the cells that 
give rise to normal stromal fibroblasts.  For simplicity, this discussion uses an example 
involving “the reciprocal-interactions model for CAF creation,” the galectin-9/Tim-3 axis, 
and the secretion of pro-inflammatory cytokine IL-6 to illustrate one way the interactions 
of cells and molecular factors may cause immune cells to become dysfunctional in cancer 
patients.  The “reciprocal-interactions model” proposes that tumor cells attract 
macrophages and, together, these cells convert, or reprogram, normal stromal fibroblasts 
into CAFs via pro-inflammatory cytokines like IL-6 (Haviv, 2009; Anton, 2012).  A study 
of ovarian cancer cells found that tumor cells can reprogram normal stromal fibroblasts 
into CAFs by altering fibroblast expression of miRNAs, and these changes could be either 
duplicated or reversed in vitro by transfecting fibroblasts with the appropriate miRNAs and 
miRNA inhibitors (Mitra, 2012).  So, targeting tumor stromal cells with miRNAs and 
miRNA inhibitors may be a valuable therapeutic strategy.  Of note, implicit in both “the 
reciprocal-interactions CAF model” and the original therapy-engineering vision of this 
project is the expectation that greater insight into inflammation and regeneration-related 
mechanisms can help us manipulate cells and engineer effective cancer therapies in vitro.  
Over the course of evolution, the protection of vital stem-like cells has been a priority.  
Animals that can generate and protect critical (normal) stem-like cells in response to injury 
and inflammation have a survival advantage. But, for cancer patients, the unfortunate 
protection of lethal, stem-like tumor cells is a problem that needs to be reversed. 
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Figure 3.6. Role of AML-impaired stromal cells in immune suppression.  A potential 
model for how AML-distorted CAFs suppress anti-tumor immunity is shown.  Leukemia 
cells recruit immune cells such as tumor-associated macrophages which release pro-
inflammatory cytokines (i.e. IL-6).  The pro-inflammatory tumor microenvironment triggers 
conversion of bone marrow stromal cells into CAFs.  CAFs may suppress infiltrating 
immune cells through production and release of immunosuppressive factors and 
enzymes as well as cell-to-cell contact (i.e. galectin-9-Tim-3 interactions).  Adapted with 
permission from: Sioud, M. (2011). New insights into mesenchymal stromal cell-mediated 
T-cell suppression through galectins. Scandinavian Journal of Immunology, 73(2), 80. 
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Figure 3.6 is a deliberately simplistic depiction of how CAFs may induce immune-
cell defects at the molecular level.  IL-6 and Tim-3 are highlighted in this diagram because 
these two factors have been found to play key roles in AML disease (Sugiyama, 1996; 
Kikushige, 2010).  Furthermore, the IL-6 secreted by AML cells may trigger generation of 
CAFs in cancer patients (Cirri, 2011).  A more realistic model would acknowledge that 
interactions are likely to be bi-directional and feedback loops may act so quickly it may 
be difficult to identify cause-and-effect sequences.  In addition to IL-6 and Tim-3, many 
other cytokines (like IFN-γ) and antigens (like MUC-1) may promote immune-system 
dysfunction. Overexpression of the immune-checkpoint receptor Tim-3 (Kane, 2010) is 
used here as one potentially informative, and therapeutically relevant, example.  Of note, 
Tim-3 is expressed not only by the malignant cells of diverse cancers, but is also 
expressed on the surfaces of microglial, mast, monocytic, macrophage, dendritic, and 
T (cytotoxic, helper, and regulatory) cells (Nakae, 2007; Wang, 2011).  Tim-3 ligands 
include galectin-9 and phosphatidylserine (Zhu, 2005; DeKruyff, 2010). 
Tim-3 is considered a critically important factor in AML pathogenesis because it is 
a surface antigen expressed by highly evolved AML LSCs (Kikushige, 2010).  In general, 
tumor cells can evolve in response to immune-selection pressures, and coexpression of 
Tim-3 and PD1 increases, for example, as AML disease progresses (Zhou, 2011).  
Blocking both the PD1/PDL1 and Tim-3/galectin-9 axes can reduce AML tumor burden 
and mortality (Zhou, 2011).  In mice with advanced AML, CD8+ T cells co-expressing PD1 
and Tim-3 synthesized less IFN-γ, TNF-α, and IL-2 than T cells which did not express 
PD1 or Tim-3 when exposed to AML cells expressing the ligands PDL1 and galectin-9 
(Tim-3 ligand) (Zhou, 2011).  In galectin-9 knock-out mice, AML progressed more slowly 
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and fewer Tregs accumulated compared to wildtype mice (Zhou, 2011).  In PD1 knock-out 
mice, Tim-3 was upregulated on T cells as AML progressed, and Tim-3-expressing CD8+ 
T cells showed impaired cytokine secretion compared to wildtype mice (Zhou, 2011).  
Administering a Tim-3 blocking antibody to mice with human AML reduces their tumor 
burden and eliminates the primitive AML cells that can reconstitute AML in secondary 
recipients (Kikushige, 2010; Zhou, 2011; Kikushige, 2012). 
In general, immunotherapy seeks to eliminate tumor cells – especially the relapse-
causing CSCs – and overcome, or reverse, immune and/or stromal-cell defects that 
prevent effective anti-tumor immunity.  Chapter IV reviews examples of promising anti-
cancer immunotherapies, including adoptive transfer of a patient’s ex vivo-modified 
antigen-presenting and immune-effector cells, antibodies, vaccines, and agents that 
modulate immune-checkpoint receptors such as CTLA-4 and Tim-3.  These strategies 
are designed to target tumor cells, dysfunctional immune cells, and/or the immuno-
suppressive tumor microenvironment.  Conventional therapies such as radiotherapy and 
chemotherapeutic agents that induce immunogenic tumor cell death (aka “cryptic 
vaccines”) can also be considered immune therapies.  Of course, the ultimate benefit of 
some therapies is the induction of a protective immunologic “memory” involving immune 
cells that prevent re-emergence of disease by providing constant tumor-cell surveillance.  
“Memory T cells,” for example, have induced long-term remissions – perhaps lifelong 
cures – in some leukemia patients. 
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Anti-cancer immunotherapy:  strategies and recent successes 
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Cancer immunotherapy is now a broad and rapidly expanding field (Raval, 2014).  
This chapter highlights recent technical advances and clinical successes achieved by new 
patient-specific and FDA-approved anti-cancer therapies, reviews AML immuno-
therapies in preclinical development, and discusses rational therapeutic combinations.  
Key features of effective anti-tumor immune responses involving innate and adaptive 
immune defenses are reviewed in Chapter III.  Review articles are recommended that 
comprehensively address topics that are only briefly summarized in this dissertation. 
Introduction 
To save some cancer patients, combination strategies may be required that include 
immunologic components that can overcome cancer-cell immune-evasion and death-
resistance, activate and repair immune cells, and neutralize immuno-suppressive factors 
in the tumor microenvironment (see Figure 4.1).  Chapter II reviews strategies that 
increase the immunogenicity of cancer cells (making them more susceptible to 
immunologic attack), improve the presentation of leukemic antigens, overcome cancer-
induced and immune-mediated death-resistance of cancer cells, and induce 
immunogenic tumor-cell death (ICD).  Immunotherapies should (1) unleash pre-existing, 
tumor-reactive immune cells that are suppressed and/or (2) trigger de novo anti-tumor 
immune responses.  Strategies to restore anti-tumor immune cells that have been 
silenced include removing the inhibitory “brakes” on exhausted immune cells (to restore 
their function) by blocking immune-checkpoint receptors like PD1 (Pardoll, 2012; Yao, 
2013).  Strategies to trigger de novo immune responses include inducing immunogenic 
tumor-cell death which can be considered a form of “vaccination in situ” (Tesniere, 2008; 
Inoue, 2014).  Immunogenic – as opposed to tolerogenic – forms of cell death can release 
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new, previously unexposed leukemic antigens or present previously non-immunogenic 
antigens in a new, immune-stimulatory context that is enhanced by “danger” signals.  ICD 
can trigger antigen-presenting cells (APCs) to uptake and cross-present leukemia-cell 
antigens to T cells and, thereby, stimulate anti-tumor immunity.  Ideally, therapies should 
stimulate both the activation and effector phases of the innate and adaptive immune 
cascades, including both the cellular and humoral arms (Yao, 2013).  While the activation 
phase of adaptive immune responses involves tumor antigen cross-presentation to T cells 
in lymphoid organs, the effector phase involves tumor-cell lysis in the periphery.  
Chapter III reviews strategies to repair and activate antigen-presenting and immune-
effector cells as well as eliminate immuno-suppressive cells in the tumor 
microenvironment.  This chapter reviews cancer immunotherapies involving antibodies, 
vaccines, adoptive transfer of immune cells, and leukemia-derived APCs.  These 
strategies can be combined with approaches that enhance immune responses in non-
specific ways such as immunogenic chemotherapies (Obeid, 2007; Zitvogel, 2008; 
Vanneman, 2012). 
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Figure 4.1. Three-pronged anti-cancer immunotherapeutic strategy.  To achieve 
lasting anti-tumor immunity, targeting of (i) tumor cells, (ii) the immune system, and (iii) 
the immunosuppressive tumor microenvironment may be required.   Tumor cells may 
need to be altered to increase antigen presentation and decrease death resistance.  
Dysfunctional antigen-presenting and immune-effector cells may need to be repaired to 
become activated, responsive, and functional.  Finally, the tumor microenvironment may 
need to be targeted to neutralize immunosuppressive factors and eliminate 
immunosuppressive cell types. 
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Anti-cancer immunotherapeutic strategies 
Adoptive transfer of immune-effector cells 
Studies of allogeneic hematopoietic stem cell transplantation (HSCT) show that 
donor T and NK cells can induce potent graft-versus-leukemia (GvL) immune responses 
that have cured some patients (Ruggeri, 2002; Bleakley, 2004).  However, HSCT carries 
the risk of graft-versus host disease (GvHD).  Using a patient’s own NK or T cells 
(“autologous” cells) eliminates the risk of immune incompatibilities.  Recently, cancer 
patients have experienced dramatic remissions after being treated with their own cancer-
reactive, tumor-infiltrating T cells that were isolated, expanded ex vivo, and re-infused as 
therapy (Tran, 2014).  Alternatively, a patient’s NK or T cells can be genetically 
engineered to express receptors that target (bind) antigens on the patient’s tumor cells 
(Kalos, 2011; Porter, 2011).  Immune cells to be used as therapy may also be genetically 
modified in other ways to increase their survival, proliferation, trafficking toward malignant 
cells, activity, and persistence (resistance to immune suppression) (Kershaw, 2013). 
CAR-modified T cells:  Of historic significance, adoptive transfer of autologous 
chimeric antigen receptor (CAR)-modified T cells induced rapid and sustained remissions 
in patients with advanced B cell leukemias (Brentjens, 2011; Brentjens, 2013; Kalos, 
2011; Kockenderfer, 2012; Porter, 2011) and lymphomas (Kockenderfer, 2012).  In a 
clinical trial, each chronic lymphocytic leukemia (CLL) patient’s T cells were genetically 
engineered to express “second-generation” CARs composed of an extracellular CD19-
targeting domain fused with intracellular CD137 costimulatory and T-cell receptor ζ 
domains (Kalos, 2011; Porter, 2011).  The antibody-binding domain directly recognizes 
antigens on the tumor-cell surface rather than peptide-MHC complexes, enabling T-cell 
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activation without the need for antigen-presentation (Gross, 1989; Irving, 1991).  Within 
CLL patients, CAR-modified T cells survived, persisted, killed ~1,000 cancer cells per 
effector, induced remission (>2 years now), and generated memory T cells (Kalos, 2011; 
Porter, 2011).  Of note, tumor-cell death was so extensive, patients experienced “tumor 
lysis syndrome” and “cytokine release syndrome” (readily reversed using tocilizumab to 
block IL-6) along with aplasias of normal B-cells which were managed via immunoglobulin 
injections (Kalos, 2011; Porter, 2011). 
T cells “rejuvenated” through iPSC reprogramming:  In patients with cancer 
(Vizcardo, 2013) and chronic HIV infection (Nishimura, 2013), reprogramming their 
exhausted T cells to pluripotency – followed by re-differentiation back to T cells – 
rejuvenated their cytokine-secreting and cytolytic activities.  “Rejuvenated” T cells 
retained their antigen-specificity and acquired high proliferative potential accompanied by 
elongated telomeres (Nishimura, 2013).  Large numbers of functionally “rejuvenated” 
T cells may be further modified (via genetic engineering, for example) to express CARs 
prior to use as therapy (Themeli, 2013).  Although using a patient’s own (autologous) 
immune cells as therapy eliminates the risk of immune-incompatibilities (such as host 
rejection of foreign cells or GvHD), sufficient numbers of immune cells may not be 
available in severely immuno-compromised cancer patients.  Therefore, researchers are 
exploring ways to generate large numbers of reprogrammed tumor-reactive T cells that 
are universally tolerated by disrupting T-cell receptors or repressing human leukocyte 
antigens (HLA) (Themeli, 2013).  Of note, reprogrammed T cells have not yet been 
evaluated in clinical trials. 
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LSC-targeted antibodies 
 Treatment with antibodies directed against the antigens on AML LSCs (including 
antigens that emerge on highly evolved AML LSCs) – such as Tim-3 (Kikushige, 2010), 
CD47 (Majeti, 2009), CD44 (Jin, 2006), and interleukin (IL)-3 receptor α (IL3Rα or CD123) 
(Jordan, 2000; Jin, 2009) – has eliminated disease and extended survival in mice 
engrafted with AML.  By promoting tumor-cell immune-escape (Jaiswal, 2009), several of 
these receptors may contribute to the poor immunogenicity of AML LSCs (Costello, 2000).  
For example, AML LSCs express CD47, a phagocyte “do not eat me” signal (Jaiswal, 
2009), and CD47-targeting antibodies promote eradication of AML LSCs by facilitating 
their uptake and clearance by macrophages (Majeti, 2009).  Gemtuzumab ozogamicin 
(Mylotarg), an anti-CD33 antibody fused to the toxin calicheamicin, is FDA-approved for 
AML patients with relapsed CD33+ disease (Larson, 2002).  Antibodies may facilitate 
tumor-cell clearance by antibody-dependent cytotoxicity mediated by NK cells or by 
activation of the complement cascade.  To enhance tumor-cell killing, antibodies may be 
conjugated with drugs, radioisotopes, cytokines, or toxins.  Fortunately, leukemia-cell 
death, in turn, can stimulate anti-tumor immune responses by enhancing the uptake of 
leukemia antigens and their presentation to immune cells.  
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Immune-modulating antibodies 
Various co-stimulatory and co-inhibitory immune-checkpoint receptors are 
expressed by T cells and interact with their ligands on APCs and cancer cells (see Figure 
4.2).  Both (1) agonistic antibodies that activate costimulatory receptors such as CD28 
and CD137/4-1BB (Melero, 2007) and (2) antagonistic antibodies that block critical 
coinhibitory receptors – such as Tim-3, programmed cell death protein 1 (PD-1), and 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (Pardoll, 2012) – promote anti-
tumor immunity (see Figure 4.3).  Depending on the ligand and cell type(s) targeted, 
immune-modulating antibodies increase the cross-presentation of tumor antigens by DCs 
or other APCs in the lymph nodes and/or the killing of tumor cells by immune-effector (i.e. 
NK, T) cells in the peripheral tissues (see Figure 4.3).  Of note, ipilimumab – an antibody 
that blocks CTLA-4 – is the first agent to ever improve the survival of patients with 
metastatic melanoma (Hodi, 2010).  Adverse side effects of anti-CTLA-4 therapy include 
autoimmune reactions resulting from potent activation of not just tumor-reactive T cells 
but self-reactive T cells as well (Hodi, 2010).  CTLA-4 knock-out mice also suffer from 
severe autoimmune reactions (Tivol, 1995; Waterhouse, 1995).  Co-blockade of the 
coinhibitory receptors Tim-3 and PD-1 improves anti-tumor immunity in mouse models of 
melanoma (Fourcade, 2010), supporting the rationale for combination therapies.  As with 
traditional cancer therapies, immuno-modulating strategies can induce both beneficial 
and undesirable effects that must be carefully considered and anticipated.   
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Figure 4.2. Immune checkpoint receptors and their ligands.  Immunomodulatory cell 
surface receptors are emerging as important therapeutic targets for controlling cancer.  
Numerous co-inhibitory and co-stimulatory ligand-receptor interactions are known.  The 
net effect on immune cell activation or suppression involves integration of all signals.  Not 
only T cells, but also cells of the innate immune system and tumor cells can express 
immune checkpoint receptors (i.e. Tim-3) as well as their ligands (i.e. PD1-ligand).  
Reproduced with permission from:  Pardoll, D. M. (2012). The blockade of immune 
checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 254. 
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Figure 4.3. Targeting immunomodulatory receptors to improve anti-tumor 
immunity.  Agonistic antibodies to co-stimulatory receptors and antagonistic (blocking) 
antibodies to co-inhibitory receptors can be used therapeutically to amplify host immune 
responses against tumors.  Potential areas of therapeutic interventions include:  ligand-
receptor interactions between antigen-presenting cells (i.e. DCs) and T cells within lymph 
nodes during the “priming phase” (a) and ligand-receptor interactions between immune 
effector cells and tumor cell targets in the periphery during the “effector phase” (b).  
Reproduced with permission from:  Yao, S., Zhu, Y., & Chen, L. (2013). Advances in 
targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug 
Discovery, 12(2), 135.  
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Vaccines 
Therapeutic cancer vaccines – used to treat patients after cancer is diagnosed – 
may include whole tumor cells, tumor peptides, APCs, viruses, and immune-stimulating 
adjuvants (Schlom, 2012).  Anti-leukemia cell-based vaccines include inactivated whole 
tumor cells that may be modified ex vivo to improve their antigen-presenting or immuno-
stimulating capacity (Burkhardt, 2013).  Utilizing whole tumor cells (as opposed to a 
limited number of peptides) may trigger immune responses against multiple leukemia-
associated antigens, reduce the likelihood of selecting for “escape variants,” and 
eliminate the need to identify patient-specific immunogenic peptides in advance.  To 
improve their immuno-stimulatory capacity, AML cells may be modified in vitro to secrete 
cytokines like GM-CSF (Ho, 2006; Ho, 2007) and IL-2 (Chan, 2006) or express co-
stimulatory molecules like CD80 (Chan, 2006).   
For peptide vaccines to be effective, the immunizing peptide must be recognized 
by the immune system and be able to stimulate anti-tumor immunity.  The “ideal target” 
for an antigen-specific immunotherapy would (1) be expressed by leukemic but not 
normal cells, (2) be highly expressed by all leukemia cells, including LSCs, (3) be involved 
in leukemia development, maintenance, and progression, (4) be strongly immunogenic, 
and (5) when used clinically, be able to stimulate tumor-rejection (Cheever, 2009).  Of 
note, AML vaccines designed to target leukemia-specific antigens – such as mutated 
nucleophosmin (Greiner, 2005) and leukemia-associated antigens like WT1 (Van 
Driessche, 2012), proteinase 3 (Rezvani, 2008), and RHAMM/CD168 (Greiner, 2005; 
Schmitt, 2008) – are currently under development or are being evaluated in clinical trials.  
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Regarding APC-based vaccines, AML lysates or peptides can be loaded onto DCs 
by peptide pulsing, loading, or fusion with AML cells.  AML cells can also be differentiated 
into DCs using cytokines or calcium ionophores to improve their antigen-presenting 
capabilities (Choudhury, 1999).  Leukemic DCs maintain expression of leukemia-
associated antigens, and their therapeutic potential is being evaluated in clinical trials (Li, 
2004; Li, 2006; Hicks, 2003).  However, if AML cells are converted into immature or IDO-
expressing DCs, they can hinder anti-tumor immunity by promoting T-cell tolerance (Curti, 
2012).  Of course, vaccines can be combined with adjuvants like TLR ligands, cytokines, 
and co-stimulators to enhance immune activation.   
Provenge (Sipuleucel-T), a patient-specific DC-based vaccine for advanced 
prostate cancer, is the first FDA-approved cellular immunotherapy (Kantoff, 2010).  
Provenge is prepared by culturing each patient’s peripheral blood mononuclear cells with 
a fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-
monocyte colony-stimulating factor (GM-CSF) (Kantoff, 2010).  Although the precise 
mechanism of action is unknown, APCs (including DCs) are believed to ingest, process, 
and present portions of the GM-CSF protein to T cells to stimulate their anti-tumor activity.  
Provenge improved survival of prostate cancer patients by 4.1 months (Kantoff, 2010), 
but this survival benefit has been questioned due to possible flaws in the design of the 
clinical trial (Huber, 2012). 
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Targeting the immuno-suppressive tumor microenvironment 
While some therapies are designed to stimulate immune responses, others seek 
to reduce immuno-suppression.  Strategies to inhibit immuno-suppressive cells, factors, 
and enzymes within the tumor microenvironment include (1) eliminating Tregs, (2) blocking 
cytokines like TGF-β, and (3) inhibiting immuno-suppressive enzymes such as 
indoleamine 2,3-dioxygenase (IDO) (Löb, 2009; Qian, 2009) and arginase (Reisser, 
2002).  CD25-targeting antibodies eliminate Tregs in the tumor microenvironment and 
show promise in the treatment of breast cancer (Rech, 2012).  Of note, immune-
checkpoint receptors can not only inhibit the activity of cytotoxic T cells, they may also 
enhance the proliferation and activity of Tregs (Pardoll, 2012).  Thus, the clinical benefits 
of immune-checkpoint-receptor inhibitors may be due not only to activation of cytotoxic 
T cells but also to inhibition of immuno-suppressive Tregs (Pardoll, 2012).  Competitive 
inhibitors or “suicide substrates” have been designed to block the enzymatic activity of 
IDO (Löb, 2009; Qian, 2009) and arginase (Reisser, 2002) which inhibit T-cell activity by 
depleting local amino acids.  Strategies to neutralize immuno-suppressive factors can act 
synergistically with immune-stimulating agendas since they affect different mechanisms. 
Additional strategies 
Immuno-therapeutic strategies reviewed elsewhere include the use of cytokines 
(i.e. IL-2) (Dranoff, 2004), oncolytic viruses (Chiocca, 2002), targeted anti-cancer 
therapies that enhance immune responses (Vanneman, 2012), and “conventional” 
radiotherapies and chemotherapies that induce ICD or modulate the immunogenicity of 
tumor cells (Kono, 2013; Inoue, 2014).   
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Designing and engineering patient-specific immunotherapies for AML 
To save the lives of some cancer patients, multi-pronged therapies may be needed 
that combine patient-specific immune strategies with “conventional” treatments.  An 
immunologic component may be necessary to eliminate the stem-like, relapse-causing 
cancer cells and to provide long-term protection via “memory” immune-effector cells.  The 
immunogenic death of mature “bulk” cancer cells induced by radiotherapies and some 
chemotherapies may act synergistically with immunotherapies.   
Technically, the successful engineering of patient-specific immune strategies has 
been possible because better methods have been developed for maintaining and 
manipulating a patient's tumor and immune cells in vitro.  Recently, two small molecules, 
StemRegenin1 (an aryl-hydrocarbon-receptor antagonist) and UM729 (a pyrimidol 
indole), were found to inhibit differentiation and maintain AML LSC activity in culture 
(Pabst, 2014).  New approaches and tools are being identified and evaluated on an 
ongoing basis so patient-specific, anti-CSC immune therapies might, in the future, be 
developed soon after diagnosis – preferably without genetic engineering.  Figure 4.4 
provides an overview of diverse tools and conditions that may facilitate in vitro cell-
engineering.  One premise of this project is that any cell-manipulation tasks needed to 
generate a desired immune therapy – even the de-differentiation of immune and tumor 
cells – can eventually be accomplished without genetic engineering via the skillful use of 
molecular tools and physical conditions (Hou, 2013).  This optimism is based on the 
observation that normal cells of primitive animals spontaneously de-differentiate before 
their amputated limbs regenerate, and malignant human cells can also de-differentiate.  
That is, even profound cell changes can be induced by physiologic stresses, and these 
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molecular mechanisms are likely to be clarified and (eventually) exploited in vitro for 
therapy-development purposes. 
 
 
Figure 4.4. Potential “candidate tools” inspired by regeneration and cancer 
research that may facilitate in vitro engineering of cancer immunotherapies. 
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Regarding antibody therapies, to develop and evaluate antibodies for an AML 
patient's genetically and immuno-phenotypically unique disease, it may be necessary to 
identify the specific tumor-associated surface antigens on that patient's stem-like AML 
cells.  The engineering and preclinical evaluation of a patient-specific antibody strategy 
may require that adequate numbers of the patient's primitive leukemia cells be maintained 
in vitro long enough to complete all the required technical tasks (Pabst, 2014).  Currently, 
finding tools and conditions that promote the survival and expansion of primary leukemia 
cells remains a priority (Pabst, 2014).  Because specimens from some patients contain 
only small proportions of primitive AML cells, tools may be required to “convert” mature 
AML cells into stem-like AML cells (Noh, 2012) – see Figure 4.5.  When working with the 
cells available in some patient specimens, de-differentiation may be needed.  Fortunately, 
a variety of cell types can be de-differentiated in vitro using just a few defined factors 
(Takahashi, 2006; Takahashi, 2007; Hou, 2013).  As outlined in Figure 4.4, tools and 
conditions that may improve survival of stem-like AML cells – or convert mature AML cells 
into more stem-like cells – include both naturally occurring physiologic factors and 
artificially synthesized compounds.  New candidate tools and conditions for cell-
engineering are being identified as cell-culture methods improve and new insights are 
gained into the molecular mechanisms that induce cellular de-differentiation during tissue 
regeneration and chemical reprogramming.  Perhaps, the potent chemicals used for 
7-factor reprogramming to pluripotency (Hou, 2013) may be useful for engineering AML 
immune therapies.  Of note, RepSox is one of the seven factors, and, conceivably, the 
other six chemicals may also help maintain or manipulate primitive AML cells in vitro in 
useful ways.  Presumably, better ways to generate, or maintain, primitive AML cells in 
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vitro can help bioengineers design antibodies that target/bind antigens on the stem-like 
AML cells responsible for disease-relapse.   
Of note, because TGF-β can increase cell-surface expression of Tim-3 (Wiener, 
2006; Kim, 2012) – which is expressed by the highly evolved LSCs found in patients with 
advanced AML disease – factors like TGF-β may be useful when there is a need to 
evaluate, in vitro, tumor-cell phenotypes in advanced stages of evolution.  In general, 
AML-cell diversity is substantial, and patient-specific strategies may be necessary since 
each patient’s LSC-associated antigens can have unique molecular and cytogenetic 
features at disease onset as well as after evolution-dependent phenotypes emerge as 
disease progresses.  Since there is an evolving distribution of cancer cells within any 
given patient, presumably, any factor that can drive AML cells toward any of the CSC 
phenotypes (Noh, 2012) is potentially useful when engineering antibodies or cells for the 
purpose of targeting relapse-causing AML cells.  
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Figure 4.5. Potential ways pre-existing LSCs or in vitro-derived LSC “surrogates” 
may need to be manipulated for the design of LSC-targeted immunotherapies.  
Overview of ways to isolate, generate, and/or manipulate a patient’s pre-existing LSCs or 
dedifferentiated LSC “surrogates” prior to engineering and evaluating LSC-targeted 
therapies. 
 
 
 
The engineering of patient-specific immune strategies that involve antigen-
presenting and immune-effector cells is likely to be more difficult than engineering 
antibodies – except, perhaps, in the special (and remarkable) context of the spontaneous 
activation of γδ T-cells in co-culture systems.  In general, immune-cell engineering may 
involve multiple cells (T cells, NK cells, and APCs as well as tumor cells) manipulated 
individually and during interactions between these cells (like antigen-presentation and 
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immune-synapse formation).  Fortunately, ex vivo cell-manipulations provide unlimited 
options and flexibility.  For example, optimal in vitro antigen-presentation and immune-
cell activation may require using LSC-like cells that are less evolved than those that are 
used to engineer antibodies since the more evolved LSC phenotypes (that appear in 
advanced leukemias) may be less immunogenic (Costello, 1999; Costello, 2000; 
Kikushige; Majeti) and more immuno-suppressive than the less evolved LSCs.  That is, 
different agendas may be facilitated by using cells having specific “task-friendly” 
phenotypes.  Fortunately, factors like TGF-β and RepSox can change the phenotypes of 
cancer cells into phenotypes that may reflect different stages of tumor-cell evolution.  In 
general, cancer researchers are beginning to use in vitro cellular manipulations and 
observations to invent, develop, and evaluate autologous immune-cell therapies.  
Advancing these ambitious agendas seems feasible when considering, for example, that 
even the chemical reprogramming of mature cells to pluripotency has already been 
achieved (Hou, 2013).  Also encouraging, “immune-selection pressures” can 
progressively “convert” populations of tumor cells into more stem-like populations (Noh, 
2012).  That is, using methods that have already developed, a spectrum of cancer cells 
can be generated whose cells exhibit different degrees of “stemness” (Noh, 2012).  
Similarly, a variety of partially reprogrammed intermediates expressing different degrees 
of lineage-commitment genes are generated during iPSC reprogramming (Hochedlinger, 
2009; Mikkelsen, 2008).  Because the underlying “immune-selection” mechanisms that 
drive cancer cells toward a stem-like phenotype (like the Nanog/Tcl1a/Akt pathway) are 
being identified (Noh, 2012; Li), it is possible that, when needed, chemical “conversion” 
of the malignant cells available in specimens into CSCs can be accomplished in vitro 
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(Landsberg, 2012).  Partial, chemical de-differentiation of cancer cells for therapy-
development purposes seems feasible given that chemicals are able to reprogram 
mature, differentiated (albeit normal) cells all the way to pluripotency (Hou, 2013). 
 Although tumor-reactive immune cells are generated in cancer patients, they often 
become suppressed and dysfunctional through “exhaustion,” anergy, or senescence 
(Wherry, 2011).  T-cell exhaustion is a dysfunctional state in which T cells are unable to 
attack cancer cells and cannot be activated by tumor antigens (Sakuishi, 2010) – perhaps 
due to ineffective immunologic synapse formation.  Before attempting to stimulate an AML 
patient’s immune system, immune cells that are dysfunctional may need to be repaired 
so they can respond to immune-stimulating agents.  In patients with cancer (Sakuishi, 
2010) and chronic viral infections (Blank, 2007; Day, 2006; Jin, 2010), exhausted immune 
cells are often characterized by expression of immune-checkpoint receptors like Tim-3 
(Jin, 2010) and PD-1 (Blank, 2007; Day, 2006; Jin, 2010).  Of note, the “exhausted” T-cell 
clones from patients with cancer (Sakuishi, 2010) and chronic viral infections (Blank, 
2007; Day, 2006; Jin, 2010) can, ex vivo, be restored to normal function – and expanded 
– by first reprogramming them into pluripotent cells and then re-differentiating them into 
CD8+ cytotoxic T cells (Vizcardo, 2013; Nishimura, 2013).  In addition to reprogramming, 
blockade of the immune-checkpoint receptors Tim-3, PD-1, and CTLA-4 (when these 
receptors are expressed) also enhances anti-tumor immune-cell function (Fourcade, 
2010; Hodi, 2010; Sakuishi, 2010).   
As cancers progress, Tim-3 on the surfaces of a variety of different cells can 
increase and play key roles in multiple mechanisms that adversely affect a patient’s ability 
to eliminate tumor cells.  Remarkably, Tim-3 contributes to immune-cell dysfunction and 
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cancer-cell immune-evasion when expressed by leukemic stem cells (Kikushige, 2010), 
endothelial cells (Huang, 2010), and cancer-impaired antigen-presenting (Chiba, 2012) 
and immune-effector (Ndhlovu, 2012) cells.  Because Tim-3 impairs anti-tumor immunity 
when expressed by tumor cells, Tim-3 expression was evaluated on RepSox-exposed 
AML cells.  Also, because reprogramming to pluripotency restores cancer-impaired 
immune cells (Vizcardo, 2013), it was reasoned that reprogramming tools (like RepSox) 
might (used alone or in combination with other factors) “convert” immune cells toward 
stem-like phenotypes and help restore their functionality.  In general, “converting” either 
immune cells or tumor cells into more primitive phenotypes may be needed at different 
stages of AML therapy-engineering.  In advanced AML disease, expression of Tim-3 on 
LSCs (Kikushige, 2010) and overexpression of Tim-3 on immune cells (Zhou, 2011) may 
help explain both the resistance of primitive AML cells to immune attack and the 
dysfunction of immune cells.  However, in view of the diversity of AML cytogenetic and 
immunophenotypic subtypes, the surface antigens that impair immune responses may 
vary by patient, and patient-specific approaches may be needed despite the apparently 
frequent, and consistent, involvement of Tim-3.    
The engineering of immunotherapies for AML patients may require not just 
improving in vitro cell-survival (Pabst, 2014) but a variety of other tasks needed to “invent,” 
produce, and evaluate multi-pronged strategies.  For example, studies in humans and 
animals suggest that the inherent death-resistance of primitive tumor cells contributes to 
their ability to resist immune-cell attack (Costello, 1999; Costello, 2000) and trigger 
disease-relapse.  Thus, a necessary component of a multi-pronged immune strategy 
might involve administering a (safe) systemic therapeutic agent that directly reduces the 
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death-resistance of stem-like malignant cells.  Prior studies suggest that inhibiting anti-
apoptotic factors (like Mcl-1) – that are especially problematic (and elevated) in primitive, 
highly evolved malignant cells – can promote immune-mediated clearance of cancer cells 
and improve survival (Noh, 2012).  Chemical inhibitors (Weyhenmeyer, 2012) and cell-
penetrating proteins (CPPs) (Wang, 2012) that deliver agents like siRNAs or microRNAs 
inside death-resistant primitive AML cells may be used to reduce levels of anti-apoptotic 
factors and sensitize tumor cells to cytotoxic T-cell-mediated apoptosis.  As a potential 
treatment for AML patients, a CPP-siRNA conjugate, for example, that can reduce levels 
of a problematic anti-apoptotic factor must be safe and selectively target the AML cells. 
Although therapy-development options for AML patients are unlimited and setting 
priorities is challenging, researchers agree that a key goal is finding better ways to 
maintain and manipulate cancer cells in vitro (Pabst, 2014).  Presumably, molecular tools 
will simplify and expedite in vitro cell engineering so immune therapies might be produced 
and administered soon after diagnosis.  Advances in chemical reprogramming have 
identified promising candidate tools and methods (Hou, 2013) that seem useful for 
engineering patient-specific immune therapies.  The value of manipulating, activating, and 
expanding immune cells in vitro has been demonstrated:  Engineered immune cells have 
eliminated relapse-causing CSCs in human and animal trials as well as in pre-clinical 
studies in vitro.   
Chapter V describes the therapeutic vision that guided this project.  This vision 
emerged after conceptual frameworks for cancer and immunology were integrated with 
specific research findings and the conclusions drawn from clinical successes.  Before 
designing experiments, it was also considered prudent to envision “worst-case scenarios” 
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involving (1) leukemia cells that are highly evolved (immune-evasive and death-resistant), 
(2) dysfunctional immune cells, and (3) distorted cancer microenvironments that support 
malignant cells and impair immune responses.  Technically, the worst possible patient 
specimen would contain none (or few) of the critically important cells:  no CSCs (target 
cells), no activated immune-effector cells (T and NK cells), and no functional antigen-
presenting cells.  Thus, attention was directed to the potential need to complete multiple, 
complex in vitro cell-engineering tasks in order to generate patient-specific, multi-pronged 
immune therapies.  This formidable, intimidating possibility, in turn, was juxtaposed with 
the dramatic cell-engineering advances already achieved by regeneration researchers 
which, in turn, directed attention to useful small-molecule tools like RepSox.  In general, 
the actions of reprogramming tools suggest they may promote cell “stemness” (and the 
survival of primitive cells) via their effects on pluripotency genes.  Thus, RepSox was 
screened for its ability to maintain primitive AML cells and/or alter Tim-3 expression (since 
Tim-3 – when expressed by primitive, highly evolved AML cells that trigger relapse – 
inhibits immune-cell activation and disrupts immune synapses).    
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Chapter V 
 
 
 
 
Guiding therapeutic vision 
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An intentionally broad, and unassuming, therapeutic vision was used to set 
experimental priorities.  This vision was inspired by advances in cancer immunotherapy 
and stem-cell technology (noted in Figure 5.1).  Described here are key research and 
clinical findings and the underlying rationale for a multi-pronged, immune-based strategy. 
 
 
Figure 5.1. Timeline of significant events during thesis. 
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Key features of an ideal anti-cancer immunotherapeutic strategy and underlying 
rationale 
Utilize a multi-pronged approach 
In order to cure leukemia, therapies may require overcoming multiple interrelated 
mechanisms of immune resistance by (1) increasing the poor immunogenicity of leukemia 
cells, (2) activating and repairing dysfunctional antigen-presenting and immune-effector 
cells, and (3) inhibiting immuno-suppressive elements of tumor microenvironments 
(outlined in Figure 4.1).  Of note, perhaps some of these tasks are best visualized as cell-
manipulations designed to improve the activation of immune cells in vitro by enhancing 
the immunologic synapse between leukemia and immune cells.  A variety of therapeutic 
interventions involving activated immune cells, antibodies, and agents that increase 
tumor-cell immunogenicity and/or induce immunogenic tumor-cell death may be needed 
to generate an effective anti-tumor immune response.  Therapies may unleash/reactivate 
pre-existing immune responses (i.e. tumor-reactive lymphocytes that have become 
suppressed) or induce new anti-tumor immune reactions (i.e. by releasing previously 
unexposed tumor antigens or by presenting antigens already being displayed in a new, 
pro-inflammatory context).  The ultimate goal is to eradicate disease-sustaining LSCs and 
induce immunologic memory that protects against relapse.  In clinical trials, skillfully 
designed immune therapies have eliminated quiescent, stem-like tumor cells that sustain 
disease and trigger relapse, and “memory” immune cells have been detected that should 
provide long-term protection by detecting, and responding to, the re-emergence of CSCs.       
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Personalize therapy for each cancer patient 
Patient-specific elements:  Technical breakthroughs are suggesting new and 
diverse ways to repair a cancer patient’s dysfunctional immune cells (Hodi, 2010; Kalos, 
2011; Porter, 2011; Reiners, 2013).  Remarkably, the anti-tumor function of cancer-
impaired immune cells can be restored so these cells can be used therapeutically (see 
Figure 5.2).  Defects in antigen-presentation by DCs can be overcome by ex vivo loading 
with tumor peptides (Kantoff, 2010).  Cytotoxic killing and/or cytokine release by NK and 
T cells can be rescued by immune-checkpoint blockade (Hodi, 2010), reprogramming to 
pluripotency (Vizcardo, 2013; Themeli, 2013), and the physical targeting of immune cells 
against cancer cells using bispecific antibodies (Reiners, 2013).  Fortunately, using the 
patient’s own immune cells as therapy eliminates the risk of host rejection (since 
autologous immune cells are not “foreign”) and graft-versus-host disease (GvHD).  
Especially encouraging, patient-specific anti-cancer immune therapies involving chimeric 
antigen receptor (CAR)-modified T cells have induced long-term remissions in patients 
with advanced leukemia who failed all prior therapies (Kalos, 2011; Porter, 2011).  In 
addition, patient-specific DC vaccines for patients with advanced prostate cancer are now 
FDA-approved (Kantoff, 2010).   
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Figure 5.2. Patient-specific cellular immunotherapy.  Based on patient-to-patient 
differences in targetable AML antigens and immune cell dysfunctions, some components 
of an immune therapy may need to be patient-specific.  Following isolation of an AML 
patient’s immune cells (some or all of which may be dysfunctional), they can be repaired, 
activated, and/or engineered against each patient’s genetically unique tumor prior to use 
as therapy. 
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Personalized elements:  Each patient’s disease is genetically unique and has 
evolved in different settings.  Tumor-cell surface-antigens, molecular defects, and 
mechanisms of immune resistance vary by patient as well as time of diagnosis.  For 
example, cancer-related features can vary in terms of the specific immune-cell defects 
(i.e. anergy, exhaustion; expression of Tim-3, PD-1, or CTLA-4), immuno-suppressive cell 
types (i.e. Tregs, MDSCs, TAMs), and the presence, or functionality, of tumor-reactive 
immune cells.  Ideally, choosing pre-existing – and/or engineering new – therapeutic 
antibodies, immunogenicity-altering compounds, inhibitors of anti-apoptotic factors, and 
immuno-modulatory agents (for in vivo or in vitro use) should be based on patient-specific 
technical insights.   
In vitro cell-engineering using molecular tools 
In some cases, leukapheresis specimens will contain all the cells needed to 
engineer and evaluate a patient-specific immunotherapy:  the LSCs to be targeted, 
normal HSCs to be spared, and the immune-effector cells and/or APCs to be engineered 
before being administered therapeutically.  Multiple tools (see Figure 4.4) may be needed 
to alter cancer cells (see Figure 4.5) and repair dysfunctional antigen-presenting and 
immune-effector cells.  Fortunately, immune-effector cells can be activated ex vivo, away 
from immuno-suppressive tumor microenvironments.  Small molecules and chemical 
engineering methods may simplify and expedite the development of patient-specific 
immunotherapies and, perhaps, completely eliminate the need for genetic engineering. 
As noted, to develop patient-specific immunotherapies, engineering both tumor 
and immune cells may be necessary.  Tumor cells may need to be altered to increase 
immunogenicity and/or maintain or induce “stemness” while immune cells may need to 
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be repaired and activated.  Altering cells by exposure to chemical compounds is simpler 
and faster than genetic engineering and avoids the fears and safety concerns associated 
with genetically modified cells.  In vitro, primary cells can be exposed to environmental 
conditions and chemical factors that directly alter cells or that select for (via “survival of 
the fittest”) a subset of cells of therapeutic interest.  Although tumor and normal cells are 
different, tools used for tissue regeneration and the de-differentiation of normal cells might 
also predictably affect cancer cells.  For example, tools that induce Nanog not only help 
reprogram normal cells into stem cells, they can also induce a “stem-like” phenotype in 
some cancer cells (Ichida, 2009; Noh, 2012).  Furthermore, the effects of chemical 
compounds are often reversible, allowing greater flexibility and control over the 
order/sequence and duration of cellular alterations.  To illustrate how cell-engineering 
tasks can vary by the therapeutic purpose, in order to enhance immune-cell activation in 
vitro, it may be best to increase the immunogenicity of CSCs by changing their phenotype 
to a less-evolved CSC phenotype.  In contrast, when developing antibody therapies, in 
order to know what new antigens might be expressed by highly evolved CSCs, immune-
selection or therapeutic pressures could be used to drive CSCs to more highly evolved 
CSC phenotypes.  Considering the diversity of the cell contents in specimens from 
different leukemia patients, when only mature leukemia cells are present in a patient’s 
specimen, de-differentiation of the available leukemia cells into LSC-like surrogates may 
be necessary in order to develop therapies that can target the relapse-causing LSCs. 
Administering immunotherapies as soon as possible after diagnosis 
Ideally, immune therapies should be administered as soon as possible after initial 
diagnosis since, via “immunoediting,” CSCs can evolve into more problematic CSCs that, 
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for example, might express Tim-3.  That is, as cancers become more advanced, tumor 
cells become more immune- and death-resistant as the immune system selects for 
“immune-escape variants” (Dunn, 2002; Noh, 2012).  Over time, immune cells become 
progressively more impaired and exhausted the longer they are exposed to immuno-
suppressive factors within tumor microenvironments such as soluble factors (like IL-10, 
and TGF-β), enzymes (like arginase, IDO), immuno-suppressive cells (like Tregs, MDSCs, 
TAMs), and immune-checkpoint receptors (like Tim-3, PD-1, CTLA-4).  As malignant 
diseases progress, tumor microenvironments also become progressively more distorted 
as tumor cells disrupt local oxygen and nutrient levels and convert stromal cells into CAFs.   
Encouraging research findings relevant to the therapeutic vision 
 Breakthroughs in the reprogramming of mature (normal) cells to pluripotency – 
which resembles the de-differentiation that occurs during tissue regeneration in primitive 
animals – have identified molecular tools that seem useful for replicating complex in vivo 
processes (Feng, 2009; Ichida, 2009; Hou, 2013).  Although the stimuli and cues that 
trigger or coordinate the cellular de-differentiation that precedes tissue regeneration are 
difficult to dissect and clarify in vivo, advances in iPSC reprogramming have identified 
potent molecular compounds through unbiased chemical screens (Ichida, 2009).  
RepSox, an inhibitor of TGF-β receptor 1, is a potent chemical reprogramming tool that 
replaces Sox2 and MYC – two of the four reprogramming factors that previously required 
viral delivery (Ichida, 2009).  Later, a combination of seven small molecules was found to 
reprogram normal mouse cells to pluripotency without genetic engineering (Hou, 2013).  
Remarkably, in vitro reprogramming of cancer-exhausted T cells to pluripotency – 
followed by re-differentiation into T cells – was found to restore their anti-tumor activity 
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and increase their expansion potential, while retaining their antigen specificity (Vizcardo, 
2013). These technical breakthroughs in cell reprogramming suggest that the cell 
transformations needed to generate anti-cancer therapies might (eventually) also be 
induced in vitro using chemical compounds (Hou, 2013).    
Animal studies have confirmed how combinations of strategies can cooperate to 
more effectively eliminate cancer cells and prolong survival.  In mice with colon cancer, 
survival was dramatically extended when an agent that inhibits the generation of an anti-
apoptotic factor was administered along with the antigen-specific T-cell therapy (Noh, 
2012).  Combining the co-blockade of multiple immune-checkpoint receptors with the 
activation of T-cell co-stimulatory receptors has also improved outcomes (Fourcade, 
2010).  Combining targeted anti-cancer agents with systemic agents that induce 
immunogenic cell death, such as radiotherapies and some chemotherapies (like 
anthracyclines), may also be useful.  In addition, the CSC theory (discussed in Chapter I) 
and studies of MRD cells suggest CSCs must be targeted because they trigger relapses 
as well as initiate disease (Gerber, 2012).  Thus, for AML patients, maintaining – or 
generating – their critical LSC-like cells in vitro can be a vital technical priority.  
Role and implications of the therapeutic vision for this project 
Encouraged by the cell-engineering successes of regeneration researchers, 
RepSox was screened for its ability to maintain and manipulate the primitive CD34+ AML 
cells that often contain the LSCs thought to trigger AML relapse.  Of course, enthusiasm 
for this project increased when patient-specific immune therapies were found to save the 
lives of cancer patients (Kalos, 2011; Porter, 2011; Tran, 2014) and when new chemical 
tools and in vitro methods were developed that could manipulate primary cells in ways 
 141 
 
relevant for therapy-development (Hou, 2013; Pabst, 2014).   
To plan experiments – and the collection and processing of AML specimens – 
patient-specific anti-AML therapies considered promising were envisioned.  Thinking 
“backwards” from an aggressive anti-LSC immune strategy was useful because attention 
was directed to technical obstacles and priorities.  One basic challenge seemed to be the 
need to better maintain and manipulate a patient's AML cells in vitro.  When considering 
the engineering of immune therapies, attention is immediately directed to a variety of 
technical tasks:   ways to generate and evaluate therapies involving antibodies, activated 
immune-effector cells, antigen-presenting cells, and/or agents that can improve the 
immunogenicity or apoptotic susceptibility of tumor cells.  To better activate immune cells, 
tools may be needed to render tumor cells more immunogenic – perhaps by inducing a 
less evolved CSC phenotype.  In contrast, when investigating antigens on highly evolved 
CSCs, immune-selection and therapeutic pressures might be used to “convert” CSCs into 
more highly evolved CSCs that are less immunogenic due to the expression of antigens 
like Tim-3. 
This study was influenced by the CSC theory, new immunologic concepts, recent 
research findings, and recent patient-specific immunotherapies engineered for leukemia 
(Kalos, 2011; Porter, 2011) and prostate cancer (Kantoff, 2010).  Because patient-specific 
treatments may be needed to save the lives of some AML patients, AML cells from 
leukapheresis specimens were used instead of leukemic cell-lines despite the extra time 
and challenges associated with collecting, processing, and maintaining primary cells.  
Also, working with cells from diverse AML patients was considered more important than 
using a cell-line to expedite and simplify the experimental agenda.  Thus, the basic 
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challenge of maintaining and manipulating a patient's primitive cells had to be confronted 
as well as the challenges highlighted by the CSC theory.  Although an AML patient's 
leukemic stem cells (LSCs) represent the critical target conceptually, in the context of 
constant tumor-cell “immunoediting,” the identity of the most recently evolved CSCs is 
impossible to know with any confidence.  Thus, the frustrating paradox:  a patient's CSCs 
are of utmost importance – but, their most recent identity and locations are unknown.  
Also, the CSCs capable of inducing cancer relapses may be a distribution of diverse 
location-specific CSCs with phenotypes ranging from “minimally evolved” to “highly 
evolved.”  That is, CSCs may vary by location as they interact locally with different cancer-
distorted immune cells and microenvironments.  Immune-selection pressures in vivo 
“convert” CSCs into progressively more therapy-resistant and less immunogenic cells.  
This steady “conversion” of cancer cells (into cells that can engraft cancer with 
progressively greater efficiency) has been demonstrated in vitro as well as in animals 
(Noh, 2012).  Thus, it seems prudent to assume it is impossible to know what are the 
most recently evolved (and most lethal) CSCs sequestered in protective niches and, 
therefore, the sooner immune therapies are administered, the better.  However, although 
CSCs are constantly evolving in vivo, human and animal studies suggest immune 
therapies engineered in vitro can successfully eliminate relapse-causing cells (Kalos, 
2011; Porter, 2011).  That is, some leukemia patients have still not relapsed, and this 
success is consistent with evidence of long-term immunologic memory (Kalos, 2011; 
Porter, 2011).  In one animal study, the observation and manipulation of immune and 
tumor cells in vitro inspired a 2-pronged immune strategy that was effective in vivo even 
though the tumor cells used to design and evaluate the immunotherapy were not 
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“conventional CSCs,” but stem-like surrogates (Noh, 2012).  That is, to design, create, 
and preclinically test immunotherapies in vitro, it may not be necessary that the stem-like 
tumor cells used for therapy-development be identical to the most recently evolved CSCs 
in vivo.  Overall, it seems prudent to assume that immune strategies engineered and 
administered soon after the onset of cancer are more likely to be effective by minimizing 
the duration of CSC evolution.  It seems the CSC and immunoediting theories can provide 
practical guidance even though, paradoxically, the phenotype of a patient’s most recently 
evolved CSCs may never be known with certainty. 
By combining such considerations with what is known about AML disease, a multi-
pronged therapeutic strategy was envisioned before specific experiments were planned.  
This vision identified a need for tools and methods that could better maintain primitive 
AML cells in vitro.  Thus, RepSox and other factors were assessed for their ability to 
prolong survival of primitive AML CD34+ cells.  As noted, RepSox had attracted attention 
because of its known actions on normal cells and its role as a potent reprogramming tool 
(Ichida, 2009; Hou, 2013).  In retrospect, considering the actions of RepSox identified in 
prior studies, it is not surprising RepSox can slow the loss of primitive AML cells in vitro.   
Expression of Tim-3 on AML cells was measured because the therapeutic vision 
suggested it is important to (1) understand, identify, and process stem-like AML cells 
[Tim-3 is considered a marker of (highly evolved) LSCs (Jan, 2011)] and (2) determine if 
Tim-3 can be reduced since Tim-3 may be responsible for tumor-cell immune evasion and 
distortion of immunologic synapses between LSCs and immune cells.  If Tim-3 expression 
by tumor cells can be reduced, immune-cell activation in vitro might be enhanced.   
Thus, the therapeutic vision and conceptual frameworks directed attention to 
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specific experiments.  Chapter VI describes the effects of RepSox on primary AML cells.  
When viewed in the context of (1) the relationship between TGF-β and Tim-3 (Gellibert, 
2004) and (2) the de-differentiation of mature cells to pluripotency (Ichida, 2009), RepSox 
was considered potentially useful for confronting two key obstacles:  LSCs rapidly die or 
differentiate in culture (making them difficult to study and manipulate) and highly evolved 
LSCs that express Tim-3 are poorly immunogenic.  In the study described in Chapter VI, 
RepSox is found to slow decay of CD34+ AML cells and accelerate loss of Tim-3, an 
immune-checkpoint receptor that impairs anti-tumor immunity and disrupts immunologic 
synapses.  Thus, used as an in vitro cell-engineering tool, RepSox may facilitate the 
production of patient-specific immune therapies designed to target AML LSCs.  
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Abstract 
Despite initial response to therapy, most acute myeloid leukemia (AML) patients relapse.  
To eliminate relapse-causing leukemic stem/progenitor cells (LPCs), patient-specific 
immune therapies may be required.  In vitro cellular engineering may require (1) 
increasing the “stemness” or immunogenicity of tumor cells and (2) activating or restoring 
cancer-impaired immune-effector and antigen-presenting cells.  Leukapheresis samples 
provide the cells needed to engineer therapies:  LPCs to be targeted, normal 
hematopoietic stem cells to be spared, and cancer-impaired immune cells to be repaired 
and activated.  This study sought to advance development of LPC-targeted therapies by 
exploring non-genetic ways to slow the decay and increase the immunogenicity of primary 
CD34+ AML cells.  CD34+ AML cells generally displayed greater colony-forming and 
aldehyde dehydrogenase (ALDH) activity than CD34- AML cells.  Along with exposure to 
bone marrow stromal cells and low (1-5%) oxygen, culture with RepSox (a 
reprogramming tool and TGF-βR1 inhibitor) consistently slowed decline of CD34+ AML 
and myelodysplastic syndrome (MDS) cells.  RepSox-treated AML cells displayed higher 
CD34, CXCL12, and MYC mRNA levels than DMSO-treated controls.  RepSox also 
accelerated loss of T cell immunoglobulin mucin-3 (Tim-3), a receptor that impairs anti-
tumor immunity, from the surface of AML/MDS cells.  Our results suggest RepSox may 
reduce Tim-3 expression by inhibiting TGF-β signaling and slow decay of CD34+ AML 
cells by increasing CXCL12 and MYC, two factors that inhibit AML cell differentiation.  By 
prolonging survival of CD34+ AML cells and reducing Tim-3, RepSox may promote in vitro 
immune cell activation and advance development of LPC-targeted therapies. 
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Introduction 
Leukemic stem/progenitor cells (LPCs) are believed to sustain disease, persist after 
chemotherapy and radiation, and contribute to post-treatment relapses.  In any given 
acute myeloid leukemia (AML) patient, these disease-causing cells may encompass a 
distribution of diverse immunophenotypes that evolves as disease progresses.  Over 
time, leukemia disrupts the bone marrow (BM), suppresses the immune system, and 
evolves new “immune-escape” and “growth-advantaged” variants [1, 2].  AML LPCs are 
often distinctive at the molecular level because of high levels of T cell immunoglobulin 
mucin-3 (Tim-3) [3, 4] and anti-apoptotic factors [5] as well as low immunogenicity [6].  In 
the setting of minimal residual disease (MRD), immunotherapy may be needed to 
eliminate quiescent LPCs spared by conventional therapies.  Prompt treatment [7] with 
antibodies, inhibitors of anti-apoptotic factors, and/or immune cells that target LPCs – 
while sparing normal hematopoietic stem cells (HSCs) – should improve AML patient 
survival, especially when combined with immune-modulating strategies and 
chemotherapies that cause immunogenic tumor cell death. 
Regarding development of patient-specific LPC-targeted therapies, recent 
technical advances are encouraging.  Notably, immune cell activity – impaired by 
leukemic disease states – can be restored in patients after their immune cells have been 
manipulated in vitro [8, 9].  When treated with their own custom-engineered T cells, 
leukemia patients rapidly entered remission and remain disease-free due to generation 
of long-lived memory T cells [8, 9].  Because their T cells were genetically engineered 
against all CD19+ cells, both normal and leukemic B cells were eliminated.  Although 
tumor cells initially trigger an immune response [10], they suppress immune cell activity 
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by engaging coinhibitory receptors including Tim-3, programmed cell death protein 1 (PD-
1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as well as by secreting 
immunosuppressive factors such as transforming growth factor beta (TGF-β) [11].  
Fortunately, cancer-impaired immune cells can be repaired and activated in vitro [12] and 
in vivo – without genetic engineering – as demonstrated by potent stimulation of tumor-
reactive T cells in metastatic melanoma patients treated with ipilimumab to block CTLA-
4 [13].   
In the setting of AML, Glaser and colleagues [14] have shown that in vitro 
manipulation of AML cells provides relevant insights and predicts promising therapeutic 
effects in vivo.  Furthermore, Noh and colleagues [15] greatly improved survival of mice 
with colon cancer using a two-pronged immune strategy inspired by in vitro study of tumor 
cells that were not conventional cancer stem cells (CSCs), but stem-like surrogates.  By 
decreasing tumor cell resistance to immune attack, adding a Nanog inhibitor to antigen-
specific cytotoxic T cell therapy markedly improved efficacy [15].  In the future, in vitro 
studies of a patient’s tumor and immune cells may help predict the effectiveness of 
candidate therapies if the diversity of AML subtypes requires patient-specific treatments. 
Although LPC surface antigens such as CD123 [16], CD47 [17], and Tim-3 [3, 4] 
are shared by subsets of AML patients, each patient’s LPCs are genetically unique and 
no universal LPC markers have been identified.  Thus, patient-specific therapies may be 
necessary, and some have saved the lives of leukemia patients with no other options [8, 
9].  Engineering patient-specific immune therapies may require insight into how similar 
the primary cells cultured in vitro must be to the LPCs evolving in vivo in order to serve 
as relevant therapeutic targets.  Presumably, when engineering antibodies and/or 
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activated antigen-specific immune cells, the greater the similarity, the greater the 
likelihood of efficacy.  Although LPCs are continually evolving in vivo, working with stem-
like tumor cells (instead of true LPCs) in vitro may be adequate for developing immune 
therapies because of immunologic cross-reactivity. 
Unfortunately, the same LPCs that are hard to eliminate in vivo (MRD cells) are 
difficult to maintain in vitro.  In culture, LPCs tend to rapidly die or differentiate into more 
mature, less relevant cells with phenotypes that may differ from tumor cells that sustain 
disease and trigger relapse.  For the culture of primitive cancer cells, prior technical 
advances provide guidance.  Physiologic BM oxygen levels (1-5% O2) [18], hematopoietic 
cytokines, and BM stromal cells improve survival of AML progenitors [19].  In 
mammosphere [20] and neurosphere [21] assays, 3-D architecture helps maintain and 
expand CSCs, illustrating the diversity of signals that influence CSCs. 
To address the challenge of maintaining LPCs in vitro, we first screened non-
genetic factors that might slow decay of CD34+ AML cells.  In general, a patient’s CD34+ 
AML cells may include bona fide disease-causing LPCs [22], primitive AML cells that are 
similar enough to LPCs to be useful for engineering immune therapies, or AML cells that 
need to be reprogrammed toward a more stem-like phenotype in order to serve as 
relevant therapeutic targets [15, 23].  Unfortunately, a patient’s most recently evolved and 
lethal disease-causing LPCs may be impossible to identify.  Despite an evolving 
therapeutic target, engineering of patient-specific immune therapies will likely advance by 
extending in vitro survival of primitive AML cells as well as normal immune cells and 
HSCs.  Prolonging in vitro survival will facilitate exploring how to increase LPC 
immunogenicity, repair and activate immune cells, improve antigen presentation, and 
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engineer LPC-targeted therapies.  Fortunately, prior studies show in vitro results can 
predict in vivo effects despite the differences in these environments [13, 14]. 
To better maintain primary CD34+ AML cells, we screened factors including low 
O2, co-culture with BM stromal cells, and compounds that agglutinate cells, affect TGF-
β, or promote stem cell maintenance.  Along with low O2 and co-culture with BM stromal 
cells, RepSox, a chemical reprogramming tool [24] and ATP-competitive inhibitor of TGF-
β receptor 1 (TGF-βR1) kinase [25], attracted our attention because it slowed decline of 
CD34+ AML and myelodysplastic syndrome (MDS) cells in culture.  Of clinical relevance, 
CD34+ AML cells often contain disease-causing LPCs that may trigger relapse [22]. 
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Materials and Methods 
Human WBCs 
De-identified leukapheresis specimens were obtained from patients treated at the West 
Virginia University (WVU) Mary Babb Randolph Cancer Center in accordance with 
Institutional Review Board guidelines.  WBCs were isolated by Ficoll-Paque Plus 
(Amersham Biosciences, Uppsala, Sweden) density gradient separation and 
cryopreserved (5x106 cells/mL) in equal volumes of RPMI 1640 medium/10% fetal bovine 
serum (FBS) and freezing solution (80% FBS/20% dimethyl sulfoxide or DMSO).  CD34+ 
cells isolated from the mobilized peripheral blood of healthy donors were purchased from 
AllCells (Emeryville, CA). 
Cell culture 
WBCs were cultured in RPMI 1640 medium (Mediatech, Manassas, VA) containing 2 mM 
L-glutamine (Mediatech), 100 U/mL penicillin, 0.1 mg/mL streptomycin (Sigma-Aldrich, St 
Louis, MO), and 10% FBS (Hyclone, Logan, UT) or serum replacement 1 (Sigma) (also 
referred to as serum-free) as indicated.  Co-cultures included BM stromal cells, adherent 
cells isolated from the BM of patients without evidence of hematologic disease.  BM 
stromal cells constitutively express VCAM-1, fibronectin, and diverse cytokines that 
support hematopoietic progenitors, including IL-7 dependent pro-B cells [26].  Cells were 
cultured at 37°C in 6% CO2 and 1-5% or 21% O2 as noted. 
TGF-β inhibition and neutralization 
TGF-β inhibitors RepSox (E-616452 or SJN 2511; Sigma), SB431542 (Sigma), 
LY364947, and GW788388 (Tocris Bioscience, Ellisville, MO) were dissolved in DMSO 
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and added once at initiation of culture.  TGF-β neutralizing antibody (anti-TGF-β1/2/3) or 
matched mouse IgG1 isotype control antibody (R&D systems, Minneapolis, MN) were 
reconstituted in PBS.  Antibodies (10 μg/mL) were added at initiation of culture and 
subsequently every 3 days. 
Surface immunostaining 
WBCs were suspended in 100μL phosphate buffered saline (PBS)/1% bovine serum 
albumin (BSA).  Samples were blocked with 1μg human IgG (R&D systems) for 20 
minutes at 4°C and incubated with specific or isotype control antibodies for 20 minutes at 
4°C in the dark.  Samples were rinsed 3 times with PBS/1% BSA and analyzed by flow 
cytometry within 4 hours of staining.  Specific and matched isotype control antibodies 
directed against the following human antigens were used:  CD34-PerCP (Becton 
Dickinson, San Jose, CA) and mouse IgG1-PerCP (Dako, Carpinteria, CA); HLA-A/B/C-
PE and mouse IgG1,κ-PE;  CD47-FITC and mouse IgG1,κ-FITC, CD227/MUC1-FITC and 
mouse IgG1,κ-FITC (BD Biosciences, San Jose, CA); and Tim-3-PE and mouse IgG1,κ-
PE (BioLegend, San Diego, CA).  Of note, Aldefluor-stained cells were immunostained in 
Aldefluor assay buffer, which contains ABC-transport inhibitors, to prevent dye efflux. 
Isolation of RNA and RT-PCR 
RNA was isolated from AML cells using the RNeasy Mini Kit with on-column DNase I 
digestion (Qiagen, Valencia, CA).  One-step RT-PCRs were performed in triplicate using 
50 ng of RNA per reaction with the QuantiTect SYBR Green RT-PCR kit (Qiagen) on an 
Applied Biosystems 7500 thermocycler (Foster City, CA).  GUSB served as a loading 
control.  Primers for human CD34, CXCL12, MYC, and HAVCR2 (encoding Tim-3) were 
purchased from Qiagen. GUSB primers (forward: AAACGATTGCAGGGTTTCAC, 
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reverse: CTCTCGTCGGTGACTGTTCA) were synthesized by Invitrogen (Carlsbad, CA).  
Fold changes in relative gene expression were calculated using the 2−ΔΔCT method [27]. 
Carboxyfluorescein diacetate, succinimidyl ester (CFSE) staining 
WBCs were labeled using the CellTrace CFSE cell proliferation kit (Molecular Probes, 
Eugene, OR) according to manufacturer’s instructions.  Briefly, WBCs were incubated 
with 1µM CFSE for 10 minutes at 37ºC.  Staining was quenched using ice-cold media, 
and cells were rinsed and placed in culture.  After six days, cells were analyzed by flow 
cytometry. 
Aldefluor assay 
Aldehyde dehydrogenase (ALDH) activity was measured using the Aldefluor assay 
according to manufacturer’s instructions (Aldagen, Durham, NC).  WBCs were suspended 
in Aldefluor assay buffer and incubated with Aldefluor reagent, a fluorescent substrate of 
ALDH.  An aliquot of each sample was immediately mixed with 
diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH, to serve as a negative 
control.  ALDH+ regions were drawn to exclude > 99% of DEAB-treated cells.  Samples 
were incubated for 40 minutes at 37ºC and analyzed by flow cytometry within 3 hours of 
labeling. 
Flow cytometric analysis 
Samples were analyzed by fluorescence-activated cell sorting (FACS) using a Becton 
Dickinson FACSCalibur.  Data were analyzed using FCS Express software (De Novo 
Software, Los Angeles, CA).  Dead cells, identified by propidium iodide uptake, were 
excluded from analysis.  The Overton histogram subtraction method was used to 
calculate the percentage of stained (i.e. CD34+) cells relative to matched isotype controls 
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[28].  Normalized median fluorescence intensity (MFI) was calculated by subtracting the 
MFI of isotype control antibody-stained cells from the MFI of specific antibody-stained 
cells. 
Immunomagnetic sorting of CD34+ WBCs 
WBCs were co-cultured with BM stromal cells under 5% O2 for 4-8 hours after thawing.  
Following recovery, WBCs were labeled with magnetic beads conjugated to anti-CD34 
antibody recognizing the QBEND/10 epitope (Miltenyi Biotec, Bergisch Gladbach, 
Germany).  WBCs were separated using a Miltenyi Biotec autoMACS according to 
manufacturer’s instructions.  Purity of cellular fractions was evaluated by flow cytometry 
following immunostaining with anti-CD34 antibody recognizing the HPCA-2 epitope 
(Becton Dickinson). 
FACS of Tim-3+ WBCs 
WBCs were co-cultured with BM stromal cells under 5% O2 for 4-8 hours after thawing.  
Following recovery, WBCs were stained with anti-Tim-3-PE antibody (BioLegend) and 
sorted into Tim-3+ and Tim-3- fractions (> 88% pure) using a Becton Dickinson FACSAria 
and FACSDiva 6.2 software.  Tim-3+ cells were gated against matched isotype control 
antibody-stained cells.  Purity of sorted fractions was evaluated by flow cytometry. 
Colony-forming assays 
WBCs were cultured in methylcellulose containing recombinant human stem cell factor 
(SCF), granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony 
stimulating factor (G-CSF), interleukin-3 (IL-3), and erythropoietin (Epo) (MethoCult 
Optimum, Stem Cell Technologies, Vancouver, British Columbia, Canada) according to 
manufacturer’s instructions.  Colony assays, performed in duplicate, were incubated at 
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37°C in 6% CO2 and 21% O2.  Colonies were counted by light microscopy after 14-18 
days of culture. 
Diff-Quik staining 
To evaluate morphology, WBCs were stained using the Diff-Quik Stain Set (Siemens, 
Newark, DE) according to manufacturer’s instructions.  Briefly, slides were sequentially 
dipped in methanol fixative, a solution of Eosin Y, and a solution containing methylene 
blue and Azure A.  Slides were rinsed with deionized water, allowed to dry, and imaged 
by light microscopy under oil immersion. 
Fluorescence in situ hybridization (FISH) 
WVU Hospital Cytogenetics Laboratory analyzed 100-150 interphase cells for t(8;21), 
t(15;17), inv(16), del(6q23), and 11q23 chromosomal abnormalities by FISH.  Probes 
were designed by Abbott Molecular (Des Plaines, IL). 
Statistical analysis 
Differences between groups were compared using paired Student t tests (2-tailed) and 
considered statistically significant when P < 0.05.  Values are displayed as the mean ± 
standard error (SE).  With the exception of FISH, all data are representative of ≥ 2 
independent experiments.  
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Results 
CD34+ AML/MDS cells have greater colony-forming and ALDH activity than CD34- 
cells 
Leukapheresis specimens (Table S1) from AML/MDS patients (P1-8) displayed variable 
CD34 expression (Figure 1A).  To identify LPC-enriched fractions, we compared the 
morphology, colony-forming potential, and ALDH activity of CD34+ and CD34- cells.  
Following immunomagnetic sorting, CD34+ fractions were 75-99% pure (Figure S1) and 
99-100% leukemic by FISH (Figure 1E).  CD34+ AML cells (P1) exhibited rounder nuclei 
and a higher nuclear-to-cytoplasmic ratio than CD34- AML cells (Figure 1B).  CD34+ 
AML/MDS cells generated 35- to 65-fold more colonies (Figure 1C) and generally 
displayed greater ALDH activity (Figure 1D; Figure S2) than CD34- cells.  Of interest, the 
relapsed AML patient (P2) had the highest proportion (85%) of CD34+ cells with ALDH 
activity.  Colonies generated by CD34+ cells were confirmed to be of leukemic origin by 
FISH (Figure 1F).  In culture, CD34+ AML/MDS cells gave rise to CD34- cells, while CD34- 
cells remained CD34- (Figure S3).  CD34+ cells also expanded via self-renewal upon 
stimulation with SCF, G-CSF, and IL-3 (Figure S4A).  In summary, AML/MDS progenitors 
are enriched within CD34+ fractions of leukapheresis specimens. 
RepSox, low O2, and co-culture with BM stromal cells maintain CD34+ AML cells 
Serum-free medium (Figure 2A), co-culture with BM stromal cells (Figure 2B), and low (1-
5%) O2 (Figure 2C) more effectively maintained CD34+ AML cells than serum-containing 
medium, culture without BM stromal cells, and high (21%) O2.  These conditions mimic in 
vitro assays designed to support LPCs [19] and the BM niche where LPCs reside in vivo 
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[18, 29].  To generate 3-D spheroids, leukemic cells were co-cultured with BM stromal 
cells or osteoblasts on low attachment plates (Figure S5).  
Under all culture conditions examined, RepSox maintained higher proportions of 
CD34+ cells than DMSO (Figure 2A-C).  As expected, RepSox inhibited TGF-β-induced 
phosphorylation of Smad2/3 (Figure S6).  Similar proportions of CD34+ cells were 
maintained in media and DMSO; therefore, only DMSO controls are shown.  In summary, 
optimal conditions for maintaining CD34+ AML cells include 1-5% O2, co-culture with BM 
stromal cells, and exposure to RepSox. 
RepSox maintains CD34+ AML cells in a concentration-dependent manner 
Increasing concentrations of RepSox maintained higher proportions of CD34+ AML cells 
(1.6-fold and 2.3-fold increase in the proportion of CD34+ cells, 2µM and 16µM RepSox 
compared to DMSO) (Figure 3A, B).  Enrichment of CD34+ cells plateaued at RepSox 
concentrations greater than 16µM (data not shown).  Effects on CD34 expression were 
also concentration-dependent (3.0-fold and 12.5-fold increase in CD34 MFI, 2µM and 
16µM RepSox compared to DMSO) (Figure 3A, C). 
RepSox slows decay of CD34+ AML/MDS cells 
Next we investigated the effects of RepSox on diverse AML/MDS specimens.  For 
consistency, all specimens were cultured with 16µM RepSox, 10% FBS, BM stromal cells, 
and 5% O2.  Inclusion of serum improved viability even though serum-free conditions 
more effectively maintained the CD34+ subset of cells. 
In culture, the proportion of CD34+ AML/MDS cells declined as cells divided 
asymmetrically and/or differentiated.  Culture with RepSox slowed the mean decline in 
the proportion of CD34+ cells (33% and 54% mean decline, RepSox and DMSO, P1-7) 
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(Figure 4A, B).  That is, RepSox maintained 1.2 to 3.0-fold higher proportions of CD34+ 
cells than DMSO.  RepSox-treated CD34+ cells were confirmed to be of leukemic origin 
by FISH (Figure 4C).  CD34 expression was also 1.9 to 6.5-fold higher on RepSox-treated 
cells than DMSO-treated controls (CD34 MFIs of 30 and 9, RepSox and DMSO, P1-7) 
(Figure 4A).  RepSox did not induce CD34 expression on CD34- AML cells (Figure S3).  
Unlike RepSox, exposure to the TGF-β inhibitors SB431542, LY364947, and GW788388 
(Figure S7A) as well as TGF-β neutralizing antibody (data not shown) did not slow decay 
of CD34+ AML cells.  In contrast to AML/MDS cells, RepSox did not slow decay of CD34+ 
cells from healthy donors (Figure 4A, B). 
We investigated whether RepSox slows decay of CD34+ AML/MDS cells by 
slowing their rate of asymmetric division and/or by inhibiting differentiation.  RepSox-
treated AML cells retained greater CFSE fluorescence (Figure 4D) and incorporated less 
EdU (Figure S8) than DMSO-treated controls, consistent with a slower rate of 
proliferation.  Upon stimulation with IL-3, SCF, and G-CSF, RepSox-treated CD34+ cells 
expanded as effectively as DMSO-treated controls (Figure S4A).  We also evaluated how 
RepSox may affect differentiation of CD34+ cells into CD34- AML cells.  When cultured 
with DMSO, the proportion of CD34+ AML cells (P1) decreased as the proportion of CD34-
CD33-CD14- cells increased (data not shown).  In contrast, RepSox maintained a high 
proportion of CD34+ cells, and no increase in the proportion of CD34-CD33-CD14- cells 
was observed (data not shown). 
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RepSox-treated AML/MDS cells display higher CD34, CXCL12, and MYC mRNA 
levels and similar ALDH activity compared to DMSO-treated controls 
Both c-Myc and C-X-C motif chemokine 12 (CXCL12)/stromal cell-derived factor 1 
(SDF-1) may inhibit differentiation of AML cells [30, 31, 32, 33].  RepSox-treated AML 
cells displayed higher CD34, CXCL12, and MYC mRNA levels than DMSO-treated 
controls (Figure 5A).  CXCL12 and MYC mRNA levels were substantially higher following 
exposure to RepSox than the TGF-β inhibitors SB431542 and LY364947 (Figure S7C). 
ALDH is involved in chemotherapy resistance [34] and normal HSC self-renewal 
[35].  In AML patients, the subset of CD34+ cells with ALDH activity is enriched in long-
term culture-initiating cells [36].  Furthermore, persistence of CD34+CD38-ALDHint AML 
cells after induction chemotherapy is associated with disease relapse [37].  Given this 
clinical relevance, we explored whether RepSox-treated CD34+ cells retain ALDH activity.  
Similar proportions of RepSox- and DMSO-treated CD34+ cells (gated as shown in Figure 
S9) displayed ALDH activity (Figure 5B), demonstrating RepSox equally slows decay of 
ALDH+ and ALDH- subsets of CD34+ cells.  Overall, a subset of CD34+ cells with ALDH 
activity is maintained in our culture system.  The observed pattern of ALDH activity is 
characteristic of leukemic rather than normal stem/progenitor cells [38]. 
RepSox reversibly suppresses AML colony-forming activity 
In addition to CD34 expression and ALDH activity, we compared the colony-forming 
activity (CFA) of RepSox- and DMSO-treated AML/MDS cells.  Normal and AML CD34+ 
cells generated fewer colonies after 6-day culture with RepSox than with DMSO (Figure 
6A).  RepSox did not alter the low CFA of CD34- AML/MDS cells (data not shown).  CFA 
of normal and AML CD34+ cells was reduced with RepSox compared to DMSO included 
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in the colony-forming assay (Figure 6B).  In contrast, CFA of CD34+ MDS cells was higher 
with RepSox compared to DMSO included in the colony-forming assay (Figure 6B). 
Potential reasons for the reduced CFA of AML cells after RepSox exposure include 
death, differentiation, or arrest of colony-forming cells in a quiescent stem-like state.  To 
rule out RepSox-induced death or differentiation of colony-forming cells, we measured 
CFA following RepSox removal.  Removal of RepSox partially rescued AML CFA (Figure 
6C).   
RepSox decreases Tim-3 expression on AML/MDS cells 
Increasing tumor cell immunogenicity is one strategy to improve immune cell activation 
[6].  Therefore, we investigated whether RepSox alters expression of immunomodulatory 
receptors including Tim-3, CD47, human leukocyte antigen (HLA), and mucin-1 (MUC1) 
on AML/MDS cells.  HAVCR2 (encoding Tim-3) mRNA levels were consistently reduced 
in RepSox-treated AML cells compared to DMSO-treated controls (Figure 7A).  A smaller 
proportion of RepSox-treated CD34+ cells expressed Tim-3, a negative regulator of anti-
tumor immunity [39], than DMSO-treated CD34+ cells (mean 27% and 53% Tim-3+ cells, 
RepSox and DMSO, P2-3) (Figure 7B).  To determine whether RepSox promoted 
selective survival of Tim-3- cells or decreased Tim-3 expression, Tim-3+ and Tim-3- 
fractions were separately exposed to RepSox.  Tim-3+ cells converted to Tim-3- cells in 
vitro (Figure 7C).  RepSox accelerated loss of Tim-3 from the surface of FACS-purified 
Tim-3+ AML/MDS cells (64% and 43% mean decline in Tim-3+ cells, RepSox and DMSO, 
P2-3 and P8) (Figure 7 C).  A greater proportion of MDS cells expressed Tim-3 following 
removal from RepSox (Figure S10A) compared to continuous culture with RepSox (Figure 
S10B), suggesting Tim-3 effects are partially reversible.  Exposure to both RepSox and 
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the structurally distinct TGF-β inhibitor SB431542 [40] accelerated loss of Tim-3 from the 
surface of AML/MDS cells (81% and 53% mean decline in Tim-3+ cells, SB431542 and 
DMSO, P3 and P8) without altering viability relative to controls (Figure S11).  Expression 
of CD47 and HLA-A/B/C was not affected by RepSox, while MUC1, an antigen 
contributing to the poor immunogenicity of AML LPCs [41], was not highly expressed by 
AML/MDS cells (Figure S12).   
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Discussion 
Engineering patient-specific anti-cancer immune therapies will advance as in vitro 
techniques improve.  Because primitive relapse-causing tumor cells must be targeted, a 
basic challenge is reducing the in vitro death and differentiation of cancer progenitors.  
LPCs must be maintained in culture long enough to study their molecular characteristics, 
activate immune cells, and/or evaluate potential therapies.  Currently, key technical 
obstacles are being identified and addressed.  Glettig and Kaplan have explored ways to 
better maintain CD34+ hematopoietic progenitors in vitro using co-culture with adipocytes 
[42].  Kellner and colleagues report their “most significant problem” is isolating multiple 
myeloma stem cells so they can be studied [43].  If relevant stem-like tumor cells can be 
adequately maintained in vitro, another challenge may be increasing low tumor cell 
immunogenicity that impedes antigen presentation and immune cell activation.  In the 
setting of AML, abnormal Tim-3 expression on tumor cells and dysregulated antigen-
presenting and immune-effector cells is an especially attractive target because this one 
receptor impairs antigen presentation and promotes both immune suppression and 
immune evasion [44, 45, 46, 47].  Thus, Tim-3 should be considered a potentially serious 
obstacle when engineering immune therapies in vitro. 
In light of these technical challenges, the ability of RepSox to prolong CD34+ cell 
survival and decrease Tim-3 expression seems useful for engineering anti-LPC immune 
therapies.  RepSox is a chemical reprogramming tool with actions linked to maintaining 
stemness and inhibiting differentiation:  two actions relevant for maintaining CD34+ AML 
cells in culture [24, 48].  In mouse embryonic fibroblasts (MEFs), RepSox increased 
mRNA levels of components of the Wnt, Notch, and Hedgehog signaling pathways that 
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promote pluripotency, self-renewal, and stem cell maintenance [48].  Also, as a TGF-β 
inhibitor, RepSox may mitigate immunosuppressive effects induced by TGF-β during 
cancer progression [49].  Thus, RepSox may be a valuable tool for manipulating cancer 
and immune cells because its actions on both normal and cancer cells are potent and 
consistent [24, 48]. 
In addition to their poor survival and low immunogenicity, patients’ tumor cells may 
not be stem-like enough to adequately represent the critical in vivo target:  the most 
recently evolved LPCs capable of triggering relapse.  Thus, primary cells may need to be 
reprogrammed toward more stem-like phenotypes in order to serve as relevant 
therapeutic targets.  Fortunately, technical breakthroughs are encouraging.  The same 
factors that dedifferentiate normal cells may also dedifferentiate tumor cells [15, 23, 50].  
Noh converted tumor cells into a more stem-like phenotype in vitro after identifying a 
mechanism by which immune-selection pressures drove this conversion in vivo [15].  
Furthermore, mouse cells were chemically reprogrammed to pluripotency using seven 
small molecules [51]. 
In this study, the TGF-β inhibitors RepSox and SB431542 reduced Tim-3 
expression on AML cells.  However, only RepSox-treated AML cells displayed 
substantially increased levels of CXCL12 and MYC mRNA, and only RepSox slowed 
decay of CD34+ AML cells.  Slowing decay of CD34+ cells is consistent with prior RepSox 
findings:  RepSox replaces c-Myc during reprogramming [24], RepSox upregulates 
CXCL12 and MYC in MEFs [48], and both c-Myc and CXCL12 promote tumor cell survival 
[32, 52, 53, 54].  Furthermore, c-Myc is downregulated during AML cell differentiation [31], 
and exposing AML cells to a c-Myc inhibitor induces differentiation [33].  
 167 
 
The CXCL12/CXCR4 and/or CXCL12/CXCR7 axes promote survival of LPCs and 
normal CD34+ cells [55, 56].  Activation of the CXCL12/CXCR4 axis is thought to inhibit 
AML cell differentiation because inhibition of CXCR4 by AMD3100 induces AML cells to 
differentiate [32].  Overall, CXCL12 promotes survival of leukemic progenitors both in vitro 
and in vivo [57, 58].  However, the implications of cell surface and intracellular receptor 
levels are still being clarified.  In the case of CXCR7, the CXCL12/CXCR7 axis promotes 
HSC survival even when CXCR7 surface expression is scarce [56].  Conceivably, when 
used as a potential CXCL12 upregulator, RepSox might help clarify the role of intracellular 
CXCL12 levels.  Of note, the balance of CXCL12- and TGF-β-activated pathways affects 
CD34+ cell cycle status [59].  Therefore, as both a TGF-β inhibitor and an apparent 
CXCL12 upregulator, RepSox seems useful for investigating the balance between 
quiescence and cell cycling. 
RepSox may slow decay of CD34+ AML cells by increasing c-Myc which inhibits 
differentiation.  c-Myc blocks differentiation of AML cell lines by increasing microRNA-17 
and microRNA-20a levels which, in turn, decrease p21 and STAT3 [60].  RepSox may 
increase c-Myc by upregulating CXCL12 which signals via CXCR4 to activate NF-κB [61].  
NF-κB can increase expression of microRNA binding protein Lin28 [62] which inhibits 
maturation of the let-7 family of microRNAs [62, 63].  Because let-7 microRNAs repress 
translation of MYC mRNA, reduced let-7 may lead to increased c-Myc expression [63, 
64].  Furthermore, RepSox-treated MEFs expressed higher mRNA levels of Wnt signaling 
components FZD1, FZD4, FZD9, and LEF1 than DMSO-treated controls [48].  Because 
MYC is a target of Wnt signaling [65], RepSox may upregulate MYC via Wnt activation.  
Upregulation of MYC by Wnt/β-catenin signaling has been reported independently by 
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Zhang [66] and He [65], and He highlighted the T cell factor-4 binding sites in the MYC 
promoter.  CXCL12 exposure also increased mRNA levels of the Wnt target genes 
CTNNB1 (encoding β-catenin), CCND1 (encoding cyclin-D1), and MYC (encoding c-Myc) 
in the AML cell line HL60 [67].   
In contrast to the “CD34+ effect” unique to RepSox, Tim-3 reduction on AML/MDS 
cells was reproduced by the structurally distinct TGF-β inhibitor SB431542.  Thus, TGF-
β inhibition may reduce Tim-3 levels, a mechanism supported by reports that TGF-β 
induces Tim-3 expression on mast cells [68, 69].  Of note, the ALDH activity of RepSox-
treated CD34+ AML cells did not change, despite reduced Tim-3 expression, suggesting 
these cells were still stem-like.  Although Tim-3 is an AML LPC marker, reduced Tim-3 
expression may not diminish the disease-initiating or relapse-causing potential of LPCs.  
Indeed, RepSox-treated AML cells engrafted the BM of NOD-scid IL2Rgammanull mice 
(data not shown). 
Tim-3 may be a critical obstacle when engineering AML immunotherapies because 
it impairs anti-tumor immunity [39].  By increasing Tim-3 expression, tumor 
microenvironments restrain the anti-tumor activity of dendritic [70], NK [71], T-lymphocytic 
[39], and monocytic [72] cells.  In turn, blocking Tim-3 signaling with antibodies restores 
the cytotoxicity of CD8+ T cells and improves anti-tumor immunity [12, 73, 74].  
Conceivably, reducing Tim-3 expression on AML cells might increase their 
immunogenicity because Tim-3 binds to, and suppresses, TH cells when expressed by 
endothelial cells [47].   
Immunotherapies involving antibodies, activated immune cells, and/or inhibitors of 
anti-apoptotic factors (responsible for tumor cell immune resistance) may be required to 
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eliminate LPCs that trigger AML relapse.  Although a cancer patient's immune-effector 
and antigen-presenting cells are not malignant, their cancer-induced dysregulations may 
need to be reversed.  Reprogramming exhausted T cells to pluripotency reactivates their 
function, increases their proliferative capacity, and preserves their antigen-specificity 
upon subsequent re-differentiation [75, 76].  Because immune cell suppression and tumor 
cell immune-evasion worsen over time, immune therapies may need to be administered 
shortly after diagnosis to be effective.  Thus, the ability to quickly manipulate a patient's 
diagnostic cells could be an advantage.  Like N-propionylmannosamine [77], resiquimod 
[78], and the MUC1 inhibitor GO-203 [41], RepSox is a chemical that alters leukemia cells 
in vitro within a week.  Prolonging survival of a patient's CD34+ cells in culture by days 
may be sufficient to chemically engineer cells.  Exposing cells to small molecules like 
RepSox is less labor-intensive than genetic engineering and effects may be reversible.  
Of note, culture with a leukemic patient's BM stromal cells, rather than normal BM stromal 
cells, may further enhance maintenance of that patient's CD34+ AML cells because 
cancer-associated fibroblasts have evolved to support tumor growth in vivo [79, 80].  The 
ability to quickly and reversibly alter the primary cells of AML patients in vitro may be 
valuable if sequential cellular manipulations prove useful for therapy development. 
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Conclusion 
RepSox may be useful for developing immunotherapies as a cell culture additive (to slow 
decay of CD34+  AML cells which often contain LPCs) and/or as a cell-engineering tool 
(to decrease Tim-3 expression).  Because Tim-3 expression on the tumor and immune 
cells of cancer patients may adversely affect tumor cell immunogenicity, immune cell 
activation, and antigen presentation, RepSox may improve the anti-tumor actions of 
antigen-presenting and immune-effector cells that become dysregulated in cancer 
patients.  Since the effects of RepSox seem potent and predictable, RepSox warrants 
consideration for manipulating the tumor and immune cells of patients with other cancers.  
Because molecular tools can chemically reprogram cells, RepSox and other molecules 
might eliminate the need for genetic engineering when developing patient-specific 
immune therapies.  Characterizing the actions of RepSox and other tools may promote 
development of immunotherapies by simplifying in vitro engineering of tumor, antigen-
presenting, and immune-effector cells. 
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Figure legends 
Figure 1.  Enrichment of colony-forming and ALDH+ AML and MDS cells within 
CD34+ fractions of leukapheresis specimens.  (A) Flow cytometric analysis of CD34 
surface expression (open histograms) on WBCs isolated from leukapheresis specimens.  
Solid histograms display isotype controls.  (B) Diff-Quik staining of CD34
+
 and CD34
-
 cells 
(P1).  (C) Colony-forming activity of CD34
+
 and CD34
-
 cells (mean ± high and low counts 
from duplicate assays).  *P < 0.05, 108 ± 29 and 3 ± 1, mean colonies generated by 
CD34
+
 and CD34
-
 cells (P1-4).  (D) Summary of the ALDH activity of CD34
+
 and CD34
-
 
cells from the representative experiment shown in Figure S2 (mean difference was NS).  
(E, F) FISH for leukemic alterations in CD34
+
 and CD34
-
 cells isolated from leukapheresis 
specimens as well as colonies generated by CD34
+
 cells.  Abbreviations: NS, not 
statistically significant; FISH, fluorescence in situ hybridization. 
Figure 2.  RepSox, low O2, and co-culture with BM stromal cells maintain CD34
+ 
AML cells.  Flow cytometric analysis of CD34 surface expression (open histograms) on 
AML cells (P1) after 10-day culture with 16µM RepSox or DMSO (vehicle control) in the 
following conditions: (A) with 10% FBS or serum replacement (off stroma, 1% O2), (B) on 
or off BM stromal cells (serum-free, 1% O2), and (C) under 1% or 21% O2 (on stroma, 
serum-free).  Solid histograms display isotype controls. 
Figure 3.  RepSox maintains CD34+ AML cells in a concentration-dependent 
manner.  (A) Flow cytometric analysis of CD34 surface expression (open histograms) on 
AML cells (P1) after 10-day culture with 2-16µM RepSox (on stroma, serum-free, 5% O2) 
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or DMSO (vehicle control).  Solid histograms display isotype controls.  Summary of the 
(B) proportion of CD34+ cells and (C) CD34 MFI of RepSox-treated cells relative to 
DMSO-treated controls from the representative experiment shown in part A. 
Figure 4.  RepSox slows decay of CD34+ AML and MDS cells.  (A) Flow cytometric 
analysis of CD34 surface expression (open histograms) on normal donor (ND) and 
AML/MDS CD34+ cells after 6-day culture with 16µM RepSox or DMSO (on stroma, 10% 
FBS, 5% O2).  Solid histograms display isotype controls.  (B) Summary of the decline in 
proportions of CD34+ cells from the representative experiment shown in part A.  *P < 
0.005, 33 ± 7% and 54 ± 7%, mean decline in CD34+ cells following RepSox and DMSO 
exposure (P1-7).  (C) FISH for leukemic alterations in CD34+ cells (P1) purified by sorting 
after 6-day exposure to RepSox and DMSO.  (D) CFSE staining profiles of RepSox-
treated (open histograms) and DMSO-treated (solid histograms) cells. 
Figure 5.  RepSox-treated cells have increased CD34, CXCL12, and MYC mRNA 
levels and similar ALDH activity compared to DMSO-treated controls.  AML/MDS 
cells were cultured with 16μM RepSox or DMSO for 6 days (on stroma, 10% FBS, 5% 
O2).  (A) qRT-PCR analysis of CD34 (*P < 0.05), CXCL12 (*P < 0.05), and MYC (*P < 
0.005) mRNA levels within RepSox-treated cells relative to DMSO-treated controls.  (B) 
ALDH activity of RepSox- and DMSO-treated CD34+ AML/MDS cells measured by flow 
cytometry (mean difference was NS).  ALDH+ regions were drawn to exclude > 99% of 
DEAB-treated (negative control) cells.  Abbreviations:  ALDH, aldehyde dehydrogenase; 
NS, not statistically significant. 
Figure 6.  RepSox reversibly suppresses AML colony-forming activity.  (A) CFA of 
AML and normal donor (ND) CD34+ cells after 6-day culture with 16μM RepSox or DMSO 
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(on stroma, 10% FBS, 5% O2).  Mean difference between CFA of RepSox- and DMSO-
treated AML cells was NS.  (B) CFA of AML/MDS and ND CD34+ cells grown with 16μM 
RepSox or DMSO included in the colony-forming assay (added once during initiation).  
Mean difference between CFA of RepSox- and DMSO-treated AML cells was NS.  (C) 
CFA of AML cells (P2) following continuous culture with RepSox for 6 days and removal 
of RepSox after 3 days.  Bar graphs display mean colonies ± high and low counts from 
duplicate assays.  Abbreviations:  CFA, colony-forming activity; CFU, colony-forming 
units; NS, not statistically significant. 
Figure 7.  RepSox decreases Tim-3 expression on AML and MDS cells.  AML/MDS 
cells were cultured with 16µM RepSox or DMSO for 6 days (on stroma, 10% FBS, 5% 
O2).  (A) qRT-PCR analysis of HAVCR2 (encoding Tim-3) mRNA levels within RepSox-
treated cells relative to DMSO-treated controls (*P < 0.005).  (B) Flow cytometric analysis 
of Tim-3 surface expression (open histograms) on RepSox- and DMSO-treated CD34+ 
cells (mean difference was NS).  Solid histograms display isotype controls.  (C) Flow 
cytometric analysis of Tim-3 surface expression (open histograms) following culture of 
FACS-purified Tim-3+ AML/MDS cells with 16µM RepSox or DMSO for 6 days (on stroma, 
10% FBS, 5% O2) (mean difference was NS).  Solid histograms display isotype controls.  
Abbreviations:  NS, not statistically significant. 
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Figures 
 
 
 
Figure 1. Enrichment of colony-forming and ALDH+ AML and MDS cells within 
CD34+ fractions of leukapheresis specimens. 
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Figure 2. RepSox, low O2, and co-culture with BM stromal cells maintain CD34
+ AML 
cells. 
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Figure 3. RepSox maintains CD34+ AML cells in a concentration-dependent 
manner. 
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Figure 4. RepSox slows decay of CD34+ AML and MDS cells. 
  
* 
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Figure 5. RepSox-treated cells have increased CD34, CXCL12, and MYC mRNA 
levels and similar ALDH activity compared to DMSO-treated controls. 
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Figure 6. RepSox reversibly suppresses AML colony-forming activity. 
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Figure 7. RepSox decreases Tim-3 expression on AML and MDS cells. 
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Supplemental Methods 
Phospho-Smad 2/3 intracellular staining 
WBCs were serum-starved for 4 hours in RPMI 1640 medium with serum replacement 1 
(Sigma) and subsequently exposed to 10 ng/mL TGF-β (human platelet-derived, R&D 
systems) for 30 minutes with 16μM RepSox or DMSO.  Following stimulation, cells were 
fixed in 2% paraformaldehyde for 10 minutes at room temperature (RT) and chilled on ice 
for 1 minute.  WBCs were permeabilized in cold 90% methanol for 30 minutes on ice and 
stored at -20°C.  Prior to intracellular staining, samples were rinsed with PBS/1% BSA.  
Samples were blocked with 1 μg human IgG (R&D systems) for 30 minutes at 4°C and 
incubated with anti-phospho-Smad-2(S465/467)/3(S423/425) or matched rabbit IgG 
isotype control antibody (Cell Signaling Technologies, Danvers, MA) for 1 hour at RT.  
Samples were rinsed with PBS/1% BSA and incubated with AlexaFluor-488 donkey anti-
rabbit secondary antibody (Molecular Probes) for 1 hour at RT.  Cells were rinsed and 
analyzed by flow cytometry. 
Western blot analysis 
Total cellular protein (25 µg/sample) was separated over 4–20% gradient polyacrylamide 
gels (Bio-Rad, Hercules, CA).  Proteins were transferred to nitrocellulose membranes 
(Whatman, Dassel, Germany) and blocked for 60 minutes in TBS/0.1% Tween-20 (TBS-
T) containing 5% non-fat dry milk.  Blots were incubated with a 1:1,000 dilution of anti-
phospho-Smad2 (Ser465/467) antibody (Cell Signaling) in PBS/5% BSA overnight at 4°C 
with gentle rocking.  Blots were rinsed 3 times with TBS-T for 5 minutes and incubated 
with a 1:5000 dilution of HRP-linked anti-rabbit IgG (Cell Signaling).  Blots were rinsed 
with TBS-T 3 times for 5 minutes, incubated with Immobilon chemiluminescent HRP 
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substrate (Millipore, Billerica, MA), and developed.  MagicMark molecular weight standard 
(Bio-Rad) was used to estimate protein size.  GAPDH served as a loading control. 
Growing and imaging 3-D leukemia spheroids 
Leukemia cells and BM osteoblasts were labeled with CellTracker green CMFDA 
(Molecular Probes) and CellTrace Far Red DDAO-SE (Molecular Probes) fluorescent 
probes and co-cultured on ultra-low attachment plates (Corning, Corning, NY).  For 3-D 
imaging, 2-week old spheroids were collected in a 40μM cell strainer (BD Biosciences) 
and imaged by 2-photon microscopy using a 60X water-dipping objective.  Images were 
deconvoluted using AutoQuant software (Media Cybernetics, Inc., Warrendale, PA) and 
imported into NIS-Elements AR imaging software (Nikon) for 3-D viewing. 
WBC expansion 
WBCs were co-cultured with BM stromal cells in RPMI 1640 medium supplemented with 
serum replacement 1 (Sigma) for 10 days.  To expand cells, recombinant human IL-3 (20 
ng/mL), G-CSF (20 ng/mL), and SCF (100 ng/mL) were added at the initiation of culture 
and 5 days later. 
5-ethynyl-2’-deoxyuridine (EdU) staining 
To measure cell proliferation, the Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit 
(Molecular Probes, Eugene, OR, USA) was used according to the manufacturer’s 
instructions.  WBCs were co-cultured with BM stromal cells for 3 days, 1μM EdU (a 
nucleoside analog to thymidine) was added, and cells were cultured for another 3 days.  
Cells were fixed with 4% paraformaldehyde and permeablized with saponin.  EdU 
incorporation into DNA was detected by a copper catalyzed covalent reaction. 
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Surface immunostaining and flow cytometric analysis for RepSox differentiation 
experiment 
Samples were stained according to standard whole-blood lysis procedure using the 
Becton Dickinson lyse-wash method.  Monoclonal antibodies directed against the 
following human antigens were used:  CD19-PE (4G7), CD33-PerCP-Cy5.5 (P67.7), 
CD3-APC (SK7), CD34-PE-Cy7 (8G12), CD45-APC-Cy7, CD8-FITC (SK1), CD4-PE 
(DK3), CD3-PerCP-Cy5.5 (SK7), CD14-APC (MϕPg), and CD56-PE-Cy7 (NCAM16.2) 
(Becton Dickinson).  The following 3-tube panel was prepared for each sample: isotype 
controls and CD45 (tube 1), CD19/CD33/CD3/CD34/CD45 (tube 2), and 
CD8/CD4/CD3/CD14/CD56/CD45 (tube 3).  Samples were analyzed by FACS using a 
Becton Dickinson FACSCanto II.  A minimum of 30,000 events were acquired and data 
were analyzed using FCSExpress software (De Novo Software).  Initial gating was based 
on forward scatter versus side scatter dot plots to exclude dead cells and debris.  
Thresholds for positivity were set to exclude > 99% of isotype control antibody-stained 
cells.  Positive events were back-gated to ensure that they constituted a discrete 
population on CD45 versus side scatter dot plots to confirm specificity of antigen binding.  
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Supplemental Table and Figure Legends 
Table S1.  Characteristics of leukapheresis specimens.  AML specimens were 
evaluated for t(8;21), t(15;17), inv(16), and 11q23 alterations, while the MDS/MPS 
specimen was tested for 4q12, 5q32, 8p12, and t(9;22) chromosomal abnormalities by 
fluorescence in situ hybridization (FISH).  All samples were screened for FLT3-ITD, 
NPM1, and CEBPA mutations by polymerase chain reaction (PCR).   
a Stage of disease at the time of leukapheresis collection.  
b Measurements obtained prior to leukapheresis.  
c Information not available. 
Abbreviations:  WBC, white blood cell; MLL, mixed-lineage leukemia; ELL, elongation 
factor RNA polymerase II; MDS, myelodysplastic syndrome; MPS, myeloproliferative 
syndrome; del, deletion; inv, inversion; FLT3, fms-related tyrosine kinase 3; ITD, internal 
tandem duplication; NPM1, nucleophosmin; and CEBPA, CCAAT/enhancer binding 
protein α. 
Figure S1.  Purity of CD34+ and CD34- fractions prior to measuring colony-forming 
activity.  AML/MDS leukapheresis specimens were immunomagnetically sorted into 
CD34+ and CD34- subsets.  Purity of fractions was evaluated by flow cytometry after 
CD34 surface staining (open histograms).  Solid histograms display isotype controls. 
Figure S2.  CD34+ AML and MDS cells generally display greater ALDH activity than 
CD34- cells.  ALDH activity of CD34+ and CD34- cells (selected by gating against isotype 
controls) measured by flow cytometry.  ALDH+ regions were drawn to exclude > 99% of 
DEAB-treated (negative control) cells. 
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Figure S3.  RepSox does not induce CD34 expression on CD34- AML cells.  Purified 
CD34- AML cells were cultured with 16µM RepSox or DMSO (on stroma, 10% FBS, 5% 
O2).  After 6 days, CD34 surface expression (open histograms) was evaluated by flow 
cytometry.  Solid histograms display isotype controls. 
Figure S4.  RepSox-treated CD34+ cells expand as effectively as DMSO controls 
upon cytokine stimulation.  AML cells (P1) were cultured with 16µM RepSox or DMSO 
(on stroma, serum-free, 5% O2).  Recombinant human IL-3 (20 ng/mL), G-CSF (20 
ng/mL), and SCF (100 ng/mL) were added at days 0 and 5.  After 10 days, (A) WBCs 
were counted (bar graphs display mean counts ± SE from 2 independent experiments) 
and (B) CD34 expression (open histograms) was evaluated by flow cytometry.  Solid 
histograms display isotype controls. 
Figure S5.  Generation of 3-D spheroids containing leukemic cells and osteoblasts. 
Primary acute lymphoblastic leukemia (ALL) cells (green) and BM osteoblasts (red) were 
labeled with fluorescent probes and co-cultured on low attachment plates to generate 3-
D spheroids.  Spheroids were imaged by 2-photon microscopy (600X magnification) after 
two weeks. 
Figure S6.  RepSox inhibits TGF-β-induced phosphorylation of Smad2/3.  AML cells 
(P1) were serum-starved for 4 hours and cultured (A) ± TGF-β (10 ng/mL) for 30 minutes 
and (B) with 16μM RepSox or DMSO (vehicle control) for 30 minutes prior to TGF-β (10 
ng/mL) exposure for 30 minutes.  Phosphorylated Smad-2/3 expression was evaluated 
by flow cytometry.  (C) Representative immunoblot of AML cells (P6) serum-starved for 4 
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hours then cultured with 16μM RepSox or DMSO for 30 minutes prior to TGF-β (10 ng/mL) 
exposure for 30 minutes.  D, DMSO; RS, RepSox. 
Figure S7.  Unlike RepSox, additional TGF-β inhibitors do not slow decay of CD34+ 
AML cells.  (A) CD34+ AML cells (P1) were cultured with TGF-β inhibitors (LY364947, 
GW788388, SB431542) or DMSO (vehicle control) for 6 days (on stroma, 10% FBS, 5% 
O2).  CD34 surface expression (open histograms) was evaluated by flow cytometry.  Solid 
histograms display isotype controls.  (B) Chemical and physical structures of TGF-β 
inhibitors evaluated.  (C) qRT-PCR analysis of MYC and CXCL12 mRNA levels following 
48-hour exposure of AML cells (P6 and P8) to various TGF-β inhibitors. 
Figure S8.  RepSox-treated CD34+ cells proliferate more slowly than DMSO 
controls.  CD34+ AML cells were cultured (on stroma, 10% FBS, 5% O2) with 16µM 
RepSox or DMSO with and without EdU (added after 3 days).  After a total of 6 days in 
culture, EdU incorporation (open histograms) by CD34+ cells (selected by gating) was 
evaluated by flow cytometry.  Solid histograms display cells cultured without EdU. 
Figure S9.  Gating strategy used to select CD34+ cells.  To select CD34+ cells, regions 
were drawn on side scatter versus CD34 fluorescence dot plots to include anti-CD34 
antibody-stained cells, but exclude > 98% of isotype control antibody-stained cells.  
Regions were converted to gates for subsequent analyses of CD34+ cells. 
Figure S10.  Increased proportion of Tim-3+ cells following removal of RepSox.  
Flow cytometric analysis of Tim-3 surface expression (open histograms) on MDS (P3) 
cells cultured with 16µM RepSox or DMSO (on stroma, 10% FBS, 5% O2):  (A) 
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continuously for 6 days and (B) intermittently for 3 days prior to rinsing and culturing in 
fresh media for 3 additional days.  Solid histograms display isotype controls. 
Figure S11. TGF-β inhibitors RepSox and SB431542 reduce Tim-3 expression on 
AML and MDS cells.  FACS-purified Tim-3+ AML/MDS cells (open histograms) were 
cultured with 16µM RepSox, 2µM SB431542, or DMSO (vehicle control) for 6 days (on 
stroma, 10% FBS, 5% O2).  Solid histograms display isotype controls.  Surface expression 
of Tim-3 and CD3 (T cell marker) was evaluated by flow cytometry. 
Figure S12.  RepSox did not drastically alter CD47, HLA-A/B/C, or MUC1 expression 
on CD34+ AML and MDS cells.  AML (P2) and MDS (P3) cells were cultured with 16µM 
RepSox or DMSO for 6 days (on stroma, 10% FBS, 5% O2).  Surface expression of Tim-
3, CD47, HLA-A/B/C, and MUC1 (open histograms) on CD34+ cells (selected by gating) 
was evaluated by flow cytometry.  Solid histograms display isotype controls. 
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Supplemental Table and Figures 
 
Table S1. Characteristics of leukapheresis specimens. 
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Figure S1. Purity of CD34+ and CD34- fractions prior to measuring colony-forming 
activity.   
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Figure S2. CD34+ AML and MDS cells generally display greater ALDH activity than 
CD34- cells.  
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Figure S3. RepSox does not induce CD34 expression on CD34- AML cells.  
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Figure S4. RepSox-treated CD34+ cells expand as effectively as DMSO controls 
upon cytokine stimulation.  
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Figure S5. Generation of 3-D spheroids containing leukemic cells and osteoblasts.  
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Figure S6. RepSox inhibits TGF-β-induced phosphorylation of Smad2/3.    
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Figure S7. Unlike RepSox, additional TGF-β inhibitors do not slow decay of CD34+ 
AML cells.  
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Figure S8. RepSox-treated CD34+ cells proliferate more slowly than DMSO controls. 
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Figure S9. Gating strategy used to select CD34+ cells. 
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Figure S10. Increased proportion of Tim-3+ cells following removal of RepSox. 
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Figure S11. TGF-β inhibitors RepSox and SB431542 reduce Tim-3 expression on 
AML and MDS cells. 
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Figure S12. RepSox did not drastically alter CD47, HLA-A/B/C, or MUC1 expression 
on CD34+ AML and MDS cells. 
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Purpose 
The goal of this dissertation is to give readers interested in anti-cancer immune 
therapies an overview of historical events, conceptual frameworks, therapeutic options, 
technical challenges, and research opportunities.  Dramatic advances in cell-engineering 
and reprogramming suggest patient-specific anti-CSC immunotherapies can now be 
developed even when CSCs in specimens are rare or missing.  In general, therapeutic 
options are unlimited.  Perhaps this dissertation can help students choose specific 
research agendas from the vast array of exciting opportunities. 
Because immune therapies engineered in vitro have saved the lives of patients 
with a deadly leukemia, cancer researchers are now extremely optimistic.  Historically, 
the evolution of anti-cancer strategies has been remarkable.  Cancer researchers have 
shifted their attention from the chemical warfare agents of World War II to limb 
regeneration in salamanders, stem-cell technologies, and the engineering of immune 
cells as conceptual frameworks for cancer and immunology have evolved.  This is truly 
an exciting time.  Just during the course of this project, achievements (see Figure 5.1) 
have been profound.  A Nobel Prize was awarded for clarifying how mature cells can be 
reprogrammed into pluripotent stem cells capable of regenerating any kind of specialized 
cell (Takahashi, 2006; Takahashi, 2007).  Regarding cancer immune therapies, the FDA 
has approved Provenge, the first patient-specific cellular immunotherapy, to treat patients 
with advanced prostate cancer (Kantoff, 2010) and ipilimumab, an antibody that blocks 
the immune-checkpoint receptor CTLA-4, for the treatment of patients with metastatic 
melanoma (Hodi, 2010).  The lives of leukemia and lymphoma patients have been saved 
by infusing their own T cells after these cells were genetically engineered in vitro to 
specifically attack their cancer cells (Kalos, 2011; Porter, 2011; Kochenderfer, 2012; 
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Brentjens, 2013; Grupp, 2013).  Major investments in cancer immunotherapy are being 
announced, including the National Cancer Institute (NCI)’s launch of the Cancer 
Immmunotherapy Trials Network (http://www.citninfo.org/).  These kinds of achievements 
prompted Science to designate cancer immunotherapy as the 2013 “Breakthrough of the 
Year” (Couzin-Frankel, 2013).   
Recently, the skillful use of RepSox and six other biologically potent chemicals was 
able to reprogram mouse fibroblasts to pluripotency without genetic engineering (Hou, 
2013).  This groundbreaking advance highlights the fantastic potential of in vitro cell 
manipulations and cell-fate control.  Of note, the in vitro chemical reprogramming of cells 
may involve the same de-differentiation mechanisms conserved during evolution to 
generate and protect the primitive (normal) cells needed for tissue regeneration.  These 
mechanisms, unfortunately, might be exploited to sustain populations of malignant cells 
when cancer cells are stressed.  For example, Sall4 (Hou, 2013) – and possibly other 
genes activated during 7-factor chemical reprogramming of (normal) mouse cells to 
pluripotency – are activated during limb regeneration in salamanders (Neff, 2011).  
Furthermore, the same four embryonic transcription factors that reprogram mouse cells 
(Takahashi, 2006) also reprogram human cells (Takahashi, 2007).  Diverse stimuli and 
environmental conditions can activate the same genes and signaling pathways, even 
across species, suggesting convergence on a few key mechanisms maintained over the 
course of evolution.  Fortunately, critical molecular mechanisms are being clarified, and 
potent cell-engineering methods are being developed.  As conceptual frameworks 
improve and additional mechanisms are being discovered, new therapeutic options are 
being identified which, in turn, are directing attention to specific technical obstacles that 
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need to be overcome to engineer these therapies.  Although these technical challenges 
can seem overwhelming, it is reassuring to know immune therapies are now saving the 
lives of cancer patients suffering from diseases recently considered “incurable” (Kalos, 
2011; Porter, 2011; Kochenderfer, 2012; Brentjens, 2013; Grupp, 2013; Tran, 2014).  
Frustrated cancer researchers never abandoned their pursuit of immunologic strategies:  
More than 100 years ago they knew immune responses could (apparently randomly) 
eliminate tumors (Coley, 1893), and now they are rationally designing immune therapies 
that are predictably curing cancer patients. 
Rationale for studying RepSox 
Regeneration research prompted the decision to study how RepSox might affect 
AML cells.  RepSox, an inhibitor of TGF-β receptor 1 (aka ALK5) (Gellibert, 2004), was 
found to promote the reprogramming of normal cells to pluripotency by replacing two of 
the four critical factors previously identified:  Sox2 and c-Myc (Ichida, 2009).  In the 
context of the CSC theory, this observation seemed relevant for engineering patient-
specific anti-cancer therapies.  How might RepSox – a potent “reprogramming tool” – alter 
malignant cells?  Fortunately, when a patient's AML cells were exposed to RepSox in 
vitro, two effects were noted that could be useful for developing immuno-therapies:  The 
decline in the proportion of CD34+ cells is slowed, and the decline in Tim-3 surface 
expression is accelerated (Jajosky, 2014).  Thus, molecular tools that alter normal cells 
(Feng, 2009; Hou, 2013) may also alter tumor cells – and in ways potentially useful for 
engineering immune therapies.  
Perhaps students will find it informative to review the rationale for considering the 
potential relevance of chemical “reprogramming tools” for anti-cancer therapy-
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development.  In general, primary cancer cells tend to die or differentiate quickly in vitro.  
The ways RepSox affects normal cells (Ichida, 2009; Larsen, 2013) suggested RepSox 
might promote survival of primitive AML cells.  That is, the reprogramming-associated 
effects of molecular tools on normal cells might predict their effects on tumor cells.  
Primitive tumor cells are critical according to the “CSC theory” which suggests stem-like 
cancer cells must be eliminated – in addition to the more mature and prevalent “bulk” 
tumor cells – to prevent disease-relapse.  Thus, maintaining primitive tumor cells in vitro 
long enough to design, engineer, and test therapies was considered a vital technical goal.  
Given the ability of RepSox to promote cellular reprogramming, RepSox was evaluated 
as a “candidate tool” for AML therapy-development (Ichida, 2009).  After exposing AML 
cells from leukapheresis specimens to RepSox, two effects were chosen for initial study:  
the survival of the CD34+ subset of AML cells and AML-cell expression of Tim-3. 
AML stem cells (that can sustain disease and trigger relapse in patients – and 
engraft disease in immuno-deficient mice) are often enriched within the CD34+ subset 
(Bonnett, 1997; Eppert, 2011).  That is, the CD34+ subset of AML cells in a patient’s 
specimen generally contains the primitive LSCs that must be targeted to prevent relapse.  
Unfortunately, LSCs are difficult to study because they tend to rapidly die or differentiate 
in culture.  However, the actions of RepSox suggested RepSox, even when used alone, 
might inhibit differentiation and maintain “stemness” (Ichida, 2009; Larsen, 2013).  Thus, 
RepSox might facilitate engineering anti-AML immune therapies by helping to maintain 
primitive AML cells in vitro long enough so they can be used to identify therapeutic targets 
or evaluate immune-cell activation, antigen presentation, and candidate therapies. 
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When expressed on the surface of cancer cells, the immune-checkpoint receptor 
Tim-3 can promote tumor-cell immune evasion.  When expressed on the surfaces of the 
non-malignant antigen-presenting and immune-effector cells of cancer patients, Tim-3 
induces immune tolerance, and Tim-3 levels can increase on these non-malignant cells 
as they interact with tumor cells, stromal cells, immuno-suppressive factors, metabolic 
dysregulations, and other components of cancer microenvironments (Huang, 2010; 
Baghdadi, 2013).  In general, Tim-3 expression on cancer cells (Kikushige, 2010; Jan, 
2011; Kikushige, 2012), tumor-associated endothelial cells (Huang, 2010), and antigen-
presenting (Chiba, 2012) and immune-effector (Anderson, 2012) cells inhibits anti-tumor 
immune responses in patients with many types of cancers (see Tables 7.1 and 7.2).   
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Table 7.1. Human cancers that express Tim-3. 
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Table 7.2. Tim-3-expressing immune and stromal cells in the settings of cancer 
and chronic viral infections. 
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Tim-3 expression is linked to AML LSCs (Kikushige, 2010; Kikushige, 2012) and 
is a useful marker for distinguishing Tim-3+ LSCs to be targeted from the Tim-3- HSCs 
(normal cells) to be spared (Jan, 2011).  Tim-3 also highlights a potential confusion that 
can emerge concerning tumor-cell evolution and plasticity.  Most often, CSCs are viewed 
as being able to give rise to more mature tumor cells.  However, it has been found that 
tumor cells can evolve – even de-differentiate – into more stem-like cells in reaction to 
stresses like chronic inflammation (Landsberg, 2012) and immune-selection pressures 
(Noh, 2012b).  These same stresses also seem to trigger the de-differentiation of normal 
cells that precedes the regeneration of tissues in primitive animals after injuries like 
amputations.  Tumor cells have been found to acquire more stem-like phenotypes 
following serial rounds of “immune selection” in vivo (Lin, 2007; Noh, 2012a) and in vitro 
(Noh, 2012b).  The acquisition of CSC-like characteristics induced by immune selection 
was replicated in vitro by transfection with Nanog (Noh, 2012b).  That is, artificially 
induced Nanog signaling mimics the signaling induced when pathways are activated in 
tumor cells when they are attacked by immune cells – signaling that drives the tumor cells 
toward a stem-like, immune-resistant state (Noh, 2012b).  Regarding leukemia cells, 
Tim-3 expression by AML cells may distort immunologic synapses between immune and 
AML cells, suppress immune-cell activation, promote immune evasion, contribute to 
leukemogenesis, and may identify a highly evolved LSC phenotype that can emerge in 
advanced disease (Kikushige, 2010; Kikushige, 2012).  Thus, Tim-3 can be an important 
immuno-therapeutic target on both (malignant) AML cells and normal, but functionally 
impaired, immune cells.  Thus, molecular tools like RepSox that reduce Tim-3 surface 
levels may be valuable for engineering immune therapies. 
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History of leukemia therapy 
Hippocrates used arsenic to treat leukemia in ancient Greece; its use continued 
until the 20th century when it was replaced by radiation therapy.  More than 100 years ago 
it was noted that the cancers of some patients spontaneously disappeared, and this 
regression of tumors seemed to be linked to fever-inducing infections.  Thus, robust 
immune responses – induced by bacterial infections – were considered responsible for 
these spontaneous cures.  Although radiation could improve the condition of leukemia 
patients, it caused leukemia in the radiologists who treated them.  In 1913, the American 
Society for the Control of Cancer was founded to educate the public.  Malignant diseases 
were so lethal and feared, cancer diagnoses were often withheld, denied, or ignored (like 
the taboo now linked to ebola diagnoses in some nations).  In the 1930s, the Women’s 
Field Army of volunteers initiated “a war on cancer.”  Their poster included the “Sword of 
Hope” – a symbol which remains part of the logo of the American Cancer Society.  The 
handle of the sword consists of two intertwined serpents that symbolize medicine and 
science:  healing and creativity.  Regarding chemotherapy, soldiers exposed to the 
chemical warfare agent “mustard gas” during World War II were found to have low white 
blood cell counts.  That observation essentially invented modern chemotherapy.  Study 
of nitrogen mustard revealed it preferentially attacked rapidly dividing cells, including 
malignant cells. 
In the 1940s, the chemical aminopterin was discovered in leukemia patients 
experiencing remission.  So, Boston's Dr. Farber decided to use it therapeutically.  
Aminopterin is related to folic acid and blocks DNA replication in tumor cells.  By 1950, 
Hitchings and Elion had carefully designed the compound 6-mercaptopurin specifically to 
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disrupt DNA synthesis.  Although this drug often induced remissions, leukemia patients 
later relapsed and died. While these classic studies and some early agents are still 
important, better anti-leukemia treatments are needed to prevent relapse and death.  
Although many leukemia drugs with diverse mechanisms of action are now available, the 
survival of residual LSCs that trigger relapse remains a challenge. 
The potential of immunologic strategies was demonstrated when some leukemia 
patients were cured after being treated with monoclonal antibodies or bone-marrow cells 
from a donor who was not an identical twin of the patient (Thomas, 1999).  In the case of 
allogeneic bone marrow transplants, a donor's genetically distinct immune cells can 
induce a graft-versus-leukemia immune reaction that blocks re-emergence of the host’s 
LSCs (Thomas, 1999).  Elimination of tumor cells by (activated) immune cells is the same 
mechanism that had been proposed to explain the spontaneous cancer regressions 
observed in the 19th century (Coley, 1893). 
Currently, AML relapses are still lethal, but researchers seem confident they will 
be able to predictably cure even patients with advanced disease using rationally 
designed, multi-pronged therapies that include a patient-specific immune strategy.  In 
vitro cell-engineering techniques that exploit advances in cell reprogramming (Hou, 2013; 
Rais, 2013) and methods that repair dysfunctional antigen-presenting and immune-
effector cells can now generate immune cells that can be used therapeutically (following 
activation and expansion) (Hodi, 2010; Vizcardo, 2013; Themeli, 2013).  Technical 
breakthroughs and new insights into cancer immunology are rapidly advancing cell 
engineering (Hou, 2013; Kalos, 2011; Porter, 2011) and the design of immuno-therapies 
(Hodi, 2010; Tran, 2014).  As needed, even in the most problematic situations, these cell-
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engineering advances should enable researchers to manipulate mature cancer cells in 
routine specimens to generate the “CSC surrogates” that may be needed to develop 
patient-specific immune therapies.  Cancer-induced pluripotent stem cells (iPSCs) have 
been generated from primary chronic myeloid leukemia cells (Kumano, 2012).  Oct-4 has 
been shown to de-differentiate melanoma cells into CSC-like cells displaying reduced 
expression of melanocyte antigens, enhanced tumor-spheroid generation in vitro, and 
increased tumorigenicity in mice (Kumar, 2012).  The successful reprogramming of tumor 
cells has been reassuring since patient-specific LSC-targeted immunotherapies may be 
needed to save the lives of some patients and engineering these therapies may require 
generating LSCs in vitro.  That is, because some leukemia specimens contain few or no 
LSCs, a patient’s mature leukemia cells may need to be de-differentiated into LSC-like 
cells.  Thus, this project was influenced by the cell-repgrogramming breakthroughs 
achieved by tissue-regeneration researchers.  Also of great interest, cell-culture advances 
had demonstrated how tumor microenvironments (Kinugasa, 2014) and bone-marrow 
factors, such as hypoxia (Yoshida, 2009; Ng, 2014), bone-marrow stromal cells 
(Sutherland, 1990; Ailles, 1997), and adipocytes (Gletting, 2013), can help maintain stem 
and progenitor cells.  However, cell-culture advances have not yet been fully exploited 
by, for example, integrating them with new reprogramming methods and molecular tools 
(Feng, 2009).  The therapeutic vision for this project revealed how therapy-development 
may require not only the manipulation of primitive leukemia cells (to, for example, 
enhance immunogenicity and immune synapses in vitro) but also the manipulation of non-
malignant, but cancer-impaired, immune cells (to, for example, reverse defects 
responsible for immune tolerance).  That is, reprogramming may be necessary when 
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engineering therapies for some patients.  Tumor cells may need to be reprogrammed into 
relevant, LSC-like surrogates (that can be studied, manipulated, and serve as targets in 
vitro), and dysfunctional immune cells may need to be reprogrammed (to repair them 
before they are activated and expanded).  A possible cell-engineering strategy might 
involve repairing a leukemia patient's immune cells to restore cytolytic and/or antigen-
presentation function (via reprogramming), activating effector immune cells against AML 
LSC antigens in co-culture, and then expanding these tumor-targeted immune cells 
before infusing them as therapy. 
 Collectively, experimental findings and conceptual frameworks for cancer and 
immunology have directed the attention to the potential value of de-differentiation and cell 
engineering.  The technical obstacles encountered when with working with primary tumor 
cells in vitro have prompted cancer researchers to consider how regeneration scientists 
have successfully de-differentiated mature (normal) cells into pluripotent cells.  To 
develop effective immune therapies for some leukemia patients, we may need to maintain 
– or generate – LSCs to design patient-specific anti-LSC therapies.  That is, in response 
to the CSC theory and new data, attention has shifted from chemical warfare agents that 
target rapidly dividing bulk tumor cells to the stem cells and molecules involved in the 
regeneration of tissues in primitive animals.  Thus, although pursuing different agendas, 
cancer and regeneration researchers now share a strong interest in de-differentiation. 
Historically, advances in the conceptual frameworks for cancer seem to have 
driven progress.  However, current cancer-immunology concepts and theories are so 
reliably predicting outcomes, clinical successes now seem to depend on technical 
advances.  That is, current concepts seem adequate and comprehensive.  For example, 
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recent cancer “cures” induced by engineered T cells are validating the critical importance 
of “memory” T cells – as predicted.  Researchers are envisioning effective therapies but 
need the methods and tools to engineer these therapies. Progress now seems to be 
“driven” by the methodical development of new techniques in research labs. 
Finally, in retrospect, the history of cancer research is truly admirable and inspiring.  
It is comforting and reassuring to realize that efforts were not wasted:  Many treatments 
that originally seemed like disappointing failures were actually impressive, rational 
agendas that are currently being reconsidered.  Treatment “failures” have been 
informative.  We now realize that in the context of “immunoediting” and “tumor-cell 
plasticity” almost any therapeutic strategy has the potential to make matters worse.  To 
be effective long-term, anti-cancer therapies must be aggressive enough to eliminate a 
broad spectrum of tumor cells so that (1) CSCs do not have the opportunity to evolve into 
more lethal and death-resistant CSCs and (2) mature (“bulk”) tumor cells do not have the 
opportunity to de-differentiate into CSCs.  Thus, treatments initially considered ineffective 
may prove to be useful in the future as components of broader, multi-pronged strategies.   
Of note, many “conventional” or “non-immunologic” treatment options can induce 
beneficial immunologic effects.  For example, physical removal of malignant cells via 
surgery or leukapheresis can reduce tumor-cell-induced immune-suppression.  Radiation 
and some chemotherapies not only reduce the number of mature tumor cells but induce 
“immunogenic tumor-cell death” (Inoue, 2014; Ma, 2013) that can stimulate anti-cancer 
immune responses.  Thus, multi-pronged anti-cancer therapies are attractive because, 
by exploiting the unique actions of diverse agents, they may be able to eliminate both 
mature and stem-like tumor cells.  Of note, it is generally believed that patient-specific 
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immune strategies may be required to eliminate a patient’s CSCs.  That is, CSCs are so 
death-resistant, they can survive even when exposed to radiation and chemotherapeutic 
drugs.  Overall, the history of cancer research is truly inspiring:  Each valiant effort has 
been informative, and past “failures” are being reconsidered for their potential value in the 
context of more comprehensive conceptual frameworks and multi-pronged strategies.  
Conceptual frameworks 
As conceptual frameworks for cancer, immunology, and tissue regeneration have 
evolved, themes and “lessons” have emerged that can provide guidance.  For example, 
advances in diverse fields should be closely monitored so opportunities are not 
overlooked.  As noted, in vitro de-differentiation – pioneered by regeneration researchers 
– may prove useful for engineering anti-cancer immunotherapies.  De-differentiating a 
patient’s tumor cells and non-malignant (but dysfunctional) antigen-presenting and 
immune-effector cells (Vizcardo, 2013; Themeli, 2013) may sometimes be required to 
engineer effective therapies.  Interestingly, in humans, malignant cells may be the only 
cells that spontaneously de-differentiate – a mechanism that helps cancer cells survive 
when subjected to therapeutic or immunologic attack (Landsberg, 2012; Reiman, 2010).   
Certain genes and signaling pathways seem especially critical for the generation, 
or survival, of normal stem cells and CSCs – and markedly different factors can induce 
activation of these genes and signaling pathways.  Cell de-differentiation during in vitro 
reprogramming and amputation-induced limb regeneration in vivo are linked to the Wnt, 
Notch, and Hedgehog signaling pathways as well as activation of the Sall4 gene (Neff, 
2011; Hou, 2013).  Surface antigens like Tim-3 can be highly expressed on diverse cell 
types – including tumor (Wiener, 2007; Dorfman, 2010; Kikushige, 2010; Kikushige, 2012; 
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Cao, 2013; Shang, 2013), endothelial (Huang, 2010), antigen-presenting cells (Chiba, 
2012), and immune-effector cells (Anderson, 2012) in patients with a variety of cancers 
(see Tables 7.1 and 7.2).  Furthermore, CAFs may also actively suppress immune cells 
(Silzle, 2004; Gieseke, 2013) as shown in Figure 3.6.  Tim-3 is also expressed by 
functionally “exhausted” immune cells in patients with chronic viral infections (see Table 
7.2) (Jones, 2008; Golden-Mason, 2009; Ju, 2010; McMahan, 2010; Vali, 2010; Finney, 
2013).  Thus, Tim-3 modulation may be a therapeutic strategy that may be useful for a 
variety of cancers and (chronic) viral diseases. 
As emphasized previously, the most lethal tumor cells are stem-like cells that are 
hard to kill in vivo – but are hard to keep alive in vitro.  Cancer cells that robustly grow in 
culture (that are like “HeLa cells”) are extremely rare.  Thus, researchers are working to 
find simple ways to maintain, or generate, a patient’s lethal tumor stem cells in vitro in 
order to design, and test, strategies that can target them.  That is, developing better in 
vitro ways to maintain a patient’s CSCs – or generate CSC-like surrogates when 
necessary – is a major goal.  Of note, in response to stress, normal stem and progenitor 
cells are protected by inflammation- and regeneration-related mechanisms that have 
been conserved during evolution.  These same mechanisms are thought to protect 
primitive malignant cells that are exposed to chronic inflammation or therapeutic attack 
(Landsberg, 2013), and may provide guidance for maintaining primitive tumor cells in 
vitro.  Of note, cancer’s “unholy trinity” refers to three environmental conditions that 
support cancer cells:  chronic inflammation, cytokines, and the transcription factor STAT3 
(Li, 2011).  These factors are thought to sustain the CSCs that maintain disease and 
trigger relapse following treatments that predominantly target bulk tumor cells.  As the 
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underlying mechanisms by which the “unholy trinity” (Li, 2011) maintains CSCs are 
clarified, they may be exploited to improve cell-culture techniques and guide the 
engineering of CSC-targeted immune therapies.  However, the relationship between 
tumor cells and inflammation may be context-dependent.  Chemotherapies that induce 
ICD are considered valuable components of anti-cancer therapies by inducing 
inflammation-related anti-cancer immune responses (Inoue, 2014; Ma, 2013). 
Although finding better ways to maintain or generate a patient’s stem-like cancer 
cells is still a challenge, recent successes with patient-specific anti-cancer immune 
therapies have validated current conceptual frameworks, and dramatic advances in cell 
engineering suggest all technical obstacles can eventually be overcome.  Patients have 
achieved long-lasting remissions following adoptive transfer of their own T cells that have 
been engineered to express tumor-targeted chimeric-antigen receptors (CARs) ex vivo 
(Kalos, 2011; Porter, 2011; Kochenderfer, 2012; Brentjens, 2013).  Following isolation, 
expansion, and reinfusion of cancer-reactive tumor-infiltrating T cells, tumors regressed 
in a patient with metastatic cholangiocarcinoma (Tran, 2014).  Immune-checkpoint 
blockade of CTLA4 stimulated immune responses and improved survival of patients with 
metastatic melanoma (Hodi, 2010).  A genetically engineered oncolytic (cancer-lysing) 
strain of measles virus eliminated tumors in a patient with advanced “incurable” multiple 
myeloma (Russell, 2014).  Although a patient's immune cells can become impaired 
(“exhausted” or unresponsive) as a cancer progresses, functionality can be restored after 
de-differentiating these cells (Vizcardo, 2013; Themeli, 2013; Nishimura, 2013), 
modulating immunoreceptors to unleash anti-tumor activity (Hodi, 2010), or manipulating 
the cells in other ways described in Chapter IV.  Following reprogramming to pluripotency 
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and re-differentiation, T cells were functionally “rejuvenated” and acquired elongated 
telomeres along with the capacity for significant expansion (Vizcardo, 2013; Themeli, 
2013; Nishimura, 2013).  Although conceptual frameworks highlight the complexity of 
malignant disease and the diverse dysregulations of local tumor microenvironments and 
the global immune system, dramatic clinical and cell-engineering successes have been 
achieved. 
Also encouraging, in vitro techniques are effectively completing more tasks.  Highly 
controlled in vitro conditions provide the opportunity to manipulate cells in diverse ways 
not possible in vivo where cancer-distorted microenvironments suppress anti-tumor 
immune responses via recruitment of myeloid-derived suppressor cells, release of soluble 
factors, and upregulation of inhibitory immune-checkpoint receptors that induce immune 
tolerance (Rabinovich, 2007).  The in vitro evaluation and manipulation of cells in different 
contexts can be highly informative and inspire new treatment strategies.  Methods for 
testing candidate anti-cancer therapies in vitro have correctly predicted their success in 
animals and humans (Peng, 2001; Carpenito, 2009; Milone, 2009; Noh, 2012b; Grosso, 
2013).  Also encouraging, although a patient’s CSCs may be rare and elusive, in vitro 
engineered stem-like tumor cells that are not “bona fide CSCs” may be similar enough to 
the CSCs in vivo that they can serve as relevant therapeutic targets by virtue of 
immunologic cross-reactivity (Noh, 2012b).  
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Worst-case clinical scenario:  advanced disease with highly evolved, death-
resistant, and treatment-refractory cancer cells 
Before planning experiments, it was considered prudent to consider the “worst-
case clinical scenario” when envisioning the engineering of a patient-specific anti-cancer 
immune therapy.  What cell types might need to be altered, repaired, or activated?  What 
cell manipulations and which methods might be required?  The latest conceptual 
frameworks for cancer and immunology propose an evolving distribution of cancer cells 
ranging from death-resistant stem-like cells to their more mature progeny as well as an 
evolving distribution of dysfunctional antigen-presenting (Gabrilovich, 2004) and immune-
effector cells (Radoja, 2000; Frey, 2008; Lion, 2012; Stringaris, 2014).  That is, both tumor 
and immune cells evolve as malignant disease advances, and the immune system 
becomes progressively dysregulated via a combination of tumor-cell immune evasion and 
immune-system tolerance that prevents adequate clearance of cancer cells (Kim, 2006).  
In highly evolved cancers, this emergence of multiple immunologic dysfunctions may 
require a multi-pronged therapy that combines patient-specific immune strategies with 
“conventional treatments.”  That is, a personalized approach may be required to 
effectively target each patient’s unique immune-cell dysfunctions and CSC antigens.  The 
“Immunoscore” cancer classification system proposes carefully examining the immune 
infiltrate within a patient’s tumor to predict outcomes and guide therapeutic decisions 
(Galon, 2012; Fridman, 2012).  As conceptual frameworks have improved, they have 
identified new mechanisms that explain how non-malignant antigen-presenting and 
immune-effector cells become dysfunctional in cancer (Radoja, 2000; Gabrilovich, 2004; 
Frey, 2008; Lion, 2012; Stringaris, 2014).  Remarkably, dysfunctional immune cells can 
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be “repaired” (Reiners, 2013; Vizcardo, 2013), reactivated (Hodi, 2010), and skillfully 
engineered (Themeli, 2013; Kalos, 2011; Porter, 2011) in vitro so they can be used 
therapeutically.  For example, a melanoma patient's exhausted, tumor-infiltrating CD8+ 
cytotoxic T cells were functionally “rejuvenated” by first reprogramming them to 
pluripotency and then re-differentiating them back into T cells (Vizcardo, 2013; Themeli, 
2013).  The successful generation of normal HSCs from iPSCs (Lim, 2013; Suzuki, 2013; 
Amabile, 2013) suggests a cancer patient’s non-malignant blood cells can be used to 
repopulate a patient’s bone marrow with normal HSCs as needed.  Of note, the latest 
findings and conceptual frameworks for cancer and immunology not only direct attention 
to the critical importance of the non-malignant cells of the immune system, but they help 
explain how these cancer-impaired cells can be repaired via de-differentiation (Vizcardo, 
2013; Themeli, 2013).  In general, as conceptual frameworks have advanced, they have 
identified new therapeutic options along with the technical tasks these strategies require.  
As noted, a “worst-case clinical scenario” (an advanced, highly evolved, and treatment-
refractory malignant disease) suggests a cancer patient's antigen-presenting and 
immune-effector cells may need to be reprogrammed to restore functionality (such as 
cytolytic activity and cytokine production) using techniques pioneered by regeneration 
researchers (Vizcardo, 2013; Themeli, 2013; Nishimura, 2013). 
Worst-case leukemia specimen:  LSCs are rare and immunoevasive and the 
immune cells are dysfunctional 
In general, the blood or bone-marrow specimens taken from leukemia patients who 
are not severely immuno-compromised should contain the tumor and immune cells that 
are needed to engineer a patient-specific immunotherapy.  However, it seems prudent to 
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consider “the worst-case cancer specimen” and the challenges associated with 
maintaining primary cells ex vivo.  Researchers should be aware, for example, that 
marked changes in the phenotypes of AML cells can occur as soon as the AML cells 
leave the bone marrow.  Exposure to oxygen concentrations that are higher than the 
hypoxic levels in the bone marrow can reduce expression of CXCR4 and activate the AhR 
pathway.  This may explain why the maintenance of primitive AML cells in vitro is 
improved by RepSox which may, conceivably (at least in some cells), induce CXCR4 
expression via CXCL12 upregulation or via AhR pathway antagonism.  In some studies, 
activation of the CXCL12/CXCR4 axis has been found to activate the PI3K/Akt “survival 
pathway” and to affect the AhR pathway.  In general, the effects of the AhR pathway are 
cell-specific.  Regarding AML, inhibition of the AhR pathway has been shown to improve 
the survival of primitive AML cells in vitro (Pabst, 2014). 
Regarding the specimens from different AML patients, there is marked variation in 
the proportions and functionality of various immune cells as well as the proportions and 
phenotypes of CSCs.  The proportions of LSCs, normal HSCs, antigen-presenting cells, 
immune-effector cells, and CAFs vary by AML subtype and stage, and by treatment 
history (Sarry, 2011; Wiseman, 2013; Kasper, 1999).  Ideal specimens will contain 
adequate numbers of the CSCs to be targeted, normal HSCs to be spared, and functional 
APCs and tumor-reactive immune-effector cells – that is, cells that can simplify the 
engineering of a patient-specific therapy.  In contrast, problematic specimens may contain 
few or no stem-like tumor cells (and immune cells that are highly dysfunctional).  In that 
case, mature tumor cells may need to be de-differentiated into tumor cells that are 
sufficiently stem-like (Noh, 2012b; Kumar, 2012) to serve as in vitro surrogate targets for 
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CSCs when engineering and evaluating candidate therapies.  Figure 7.1 and Table 7.3 
outline strategies and conditions that trigger cell de-differentiation.  Immune-selection 
pressures (Reiman, 2010; Noh, 2012b); tumor-microenvironment conditions such as 
hypoxia (Sahlgren, 2008), CXCL12, and inflammation (Landsberg, 2012); and exposure 
to chemotherapy and radiation (Saxena, 2011; Sun, 2012; Chang, 2013) may drive tumor 
cells to undergo epithelial-to-mesenchymal transition (EMT) and/or acquire stem-like and 
immune- and death-resistant phenotypes.  As immunogenic tumor cells are eliminated by 
the immune system, immune- and death-resistant cancer cells (“escape variants”) can 
emerge and become predominant via natural selection (Dunn, 2002).  Thus, tumor cells 
may need to be manipulated in vitro to increase their immunogenicity (to facilitate 
immune-cell activation in vitro) or modified in vivo using a (safe, non-toxic) systemic agent 
to decrease their death-resistance so they are susceptible to immunologic attack in vivo. 
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Figure 7.1. Spectrum of ways to induce de-differentiation. 
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Table 7.3. Potential ways to induce cellular de-differentiation. 
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As noted previously, when a patient-specific immune therapy is considered the 
best strategy, de-differentiation may be needed to repair a patient’s defective immune 
cells (as well as generate CSC-like cells that can serve as surrogate targets in vitro).  
Immune-cell function might also be enhanced by increasing mTOR activity (via 
upregulation of the PI3K/Akt pathway) since mTOR has been found to improve immune-
cell function (Schmitz, 2008; Powell, 2012).  Of note, RepSox can upregulate CXCL12, 
and CXCL12 can activate the PI3K/Akt/mTOR axis (Chen, 2012). 
When a problematic cancer specimen contains few or no CSCs, more mature 
(more differentiated) tumor cells may need to be reprogrammed into stem-like cells.  
However, it is not clear how similar the CSC-like surrogates (to be used in vitro) must be 
to the actual disease-sustaining CSCs in vivo.  Presumably, the more closely the CSC-
like cells used in vitro resemble the CSCs in vivo, the more relevant these cells will be 
when serving as surrogate targets for therapy-development.  Of note, Noh found that a 
spectrum of stem-like cells having different degrees of “stemness” shared the same 
Nanog-mediated death-resistance to T-cell attack – and the greater their “stemness,” the 
greater their death-resistance (Noh, 2012b).  That is, although the “stemness” of these 
CSC-like cells varied, they shared the same therapeutic vulnerability as the most stem-
like CSC.  Furthermore, the less stem-like tumor cells could be made more stem-like (and 
more resistant to immune-cell attack) either through serial rounds of in vitro immune-
selection pressure (via exposure to activated immune cells) or, more directly, by 
transfection with Nanog (Noh, 2012b).  These observations suggest that the patient’s 
most evolved and lethal CSCs may not be needed to design effective immune therapies 
– stem-like surrogates engineered in vitro may suffice. 
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In general, if the reprogramming of cancer cells is needed (when only mature 
cancer cells are available in a specimen), the goal is to de-differentiate them into stem-
like (CSC-like) cancer cells that adequately resemble the CSCs that can sustain disease 
and cause relapse.  That is, the goal is not to de-differentiate mature cancer cells all the 
way to pluripotency.  When salamanders regenerate tissues, the de-differentiation of cells 
is “partial” or “limited” in that the stem-like cells generated (to form the blastema) are 
“restricted progenitors” – not pluripotent stem cells (Christen, 2010; Garza-Garcia, 2010).  
Table 7.4 compares the partial, spontaneous (natural) de-differentiation of normal cells 
that occurs in vivo during regeneration with “full” de-differentiation (“artificially”) induced 
in vitro by regeneration researchers when they generate pluripotent stem cells.  Also 
notable, when human cancer cells are stressed – such as when exposed to toxic 
chemotherapeutic agents – they can de-differentiate into more death-resistant, stem-like 
phenotypes.  That is, both normal cells (in primitive animals) and malignant cells (in 
humans) can spontaneously (and “partially”) de-differentiate in vivo. 
When considering conceptual frameworks and “worst-case scenarios” relevant for 
therapy-development, the potential need for, and value of, de-differentiating a patient’s 
malignant cells and/or cancer-impaired immune cells in vitro becomes apparent.  As 
noted, spontaneous cellular de-differentiation in primitive animals can generate critically 
important (normal) stem-like cells via mechanisms that can be exploited by human cancer 
cells to generate death-resistant CSCs.  That is, de-differentiation is exploited by human 
tumor cells stressed by immunologic or therapeutic attack (cancer-cell immunoediting as 
a survival mechanism) and by normal cells stressed by injury (tissue regeneration as a 
survival mechanism).  As noted, for in vitro therapy-development, de-differentiating both 
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(malignant) tumor and (non-malignant) immune cells of a cancer patient may be required 
when dealing with problematic clinical scenarios and specimens.  When the potential 
value of de-differentiation for therapy-development was considered, attention was 
directed to how a reprogramming tool like RepSox (Ichida, 2009) might alter AML cells. 
 
Table 7.4. Comparison of de-differentiation processes:  the two extremes. 
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Most complex, unassuming therapeutic strategy 
 In general, for patients with advanced cancers, complex, multi-pronged therapies 
may be needed that combine “conventional treatments” with immunologic strategies.  
Multi-pronged therapies might involve combinations of radio- and chemo-therapies, 
antibodies, activated antigen-specific anti-CSC immune cells, immune-stimulating 
agents, inhibitors of anti-apoptotic factor transcription, and/or many other potentially 
useful factors.  These combination therapies will seek to target the entire spectrum of 
tumor cell phenotypes (in multiple ways) and immuno-suppressive microenvironments for 
problematic patients with advanced cancers (see Figure 4.1).  Of course, physically 
removing tumor cells (via surgery or leukapheresis) can reduce immune suppression as 
well as reduce mechanical and/or hemodynamic problems caused by the presence of 
large numbers of malignant cells.  Creating the patient-specific, anti-CSC immunologic 
components of multi-pronged strategies is a formidable challenge that may require 
extensive in vitro cell engineering that alters tumor cells and repairs, activates, and 
expands cancer-impaired immune cells.  In the case of leukemias like AML, large 
numbers of tumor cells can be removed by leukapheresis which reduces the immuno-
suppression induced by these malignant cells.  Chemotherapies that induce ICD should 
be beneficial (Zitvogel, 2008; Hodge, 2013; Ma, 2013; Inoue, 2014) via immune 
stimulation.  Regarding cell engineering, developing immune strategies that can eliminate 
relapse-causing LSCs may require manipulating a patient's cells in different ways during 
different phases of therapy-development.  In the most problematic leukemia scenario, 
none of the available malignant cells will be primitive enough to adequately represent the 
lethal disease-sustaining LSCs, and specimens will not contain sufficient numbers of 
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normal HSCs.  Because immune therapies with “immunological memory” must not 
destroy normal HSCs, LSCs and normal HSCs need to be compared and the status of 
each should be monitored when evaluating candidate therapies preclinically in vitro.  
These tasks require the ability to maintain pre-existing – or generate de novo – 
(malignant) CSCs and (normal) HSCs which may be the most challenging in vitro 
agendas.  Fortunately, advances in cell engineering suggest this is feasible.  A 
remarkable example is a process by which cancer-impaired T cells are functionally 
“rejuvenated” via reprogramming and then expanded (Vizcardo, 2013; Themeli, 2013).  
Also, antigen-presenting cells have been successfully repaired and loaded with tumor 
antigens so they can be used therapeutically (Smits, 2009; Kantoff, 2010).  In general, 
antibodies can be designed once suitable tumor-specific antigens have been identified.  
As emphasized, recent technical advances suggest that even the most challenging tasks 
related to immunotherapy-development can eventually be completed. 
Despite dramatic advances in the engineering of therapeutic immune cells, studies 
suggest immune therapies may be inadequate when primitive tumor cells have evolved 
into extremely death-resistant cells.  In that case, systemic agents may need to be 
administered that target the specific pro-survival mechanisms that protect these highly 
evolved CSCs (Igney, 2002; Vanneman, 2012).  The death-resistance of tumor cells may 
involve changes in cell-surface antigens or changes in the intracellular transcription of 
critical molecules.  For example, some death-resistant melanoma cells express CTLA-4.  
Thus, systemic administration of anti-CTLA-4 antibodies may increase the susceptibility 
of these cancer cells to immunologic attack – as well as enhance the function of immune 
cells that express CTLA-4 (Laurent, 2013).  Regarding the transcription problems inside 
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cancer cells that increase their death-resistance, systemic agents can reduce the 
intracellular transcription of those anti-apoptotic factors that block immune-mediated 
killing, especially the killing of highly evolved CSCs (Vanneman, 2012).  Another option 
is to use systemic agents that increase tumor-cell transcription of proapoptotic factors or 
factors like RIG-I that promote immune-mediated killing of tumor cells.  Fortunately, 
processes like oligonucleotide production are highly advanced and can be used to 
produce agents that can be administered systemically to modulate the transcription of 
tumor-cell factors like RIG-I as well as antiapoptotic and proapoptotic factors.  Cancer 
research now includes the study of intracellular mechanisms and transcription, and such 
studies are now explaining the anti-cancer actions of some agents for the first time.  For 
example, one herb-derived anti-cancer chemical has been found to modulate 
transcription of the anti-apoptotic factor XIAP.  Some malignant cells are death-resistant 
via XIAP overexpression, and by down-regulating XIAP, this herb isolate was able to 
promote the apoptosis of human cancer cells (Fang, 2012).  In general, new insights have 
been gained regarding how herb-derived chemicals improve anti-cancer immunity or 
reduce tumor-cell death-resistance via studies that assessed cytokine production, 
immune-cell development, or the transcription of antiapoptotic or proapoptotic factors 
(Cheng, 2010; Peng, 2013).  Herb-derived chemicals that favorably modulate key 
transcription mechanisms in tumor cells are candidates for systemic use since they have 
been used safely for centuries.  In addition to the targeting of immune and tumor cells, 
agents have been evaluated that can be administered systemically to counteract a variety 
of immuno-suppressive factors within the tumor microenvironment (van den Boorn, 2013).  
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Obviously, the expanding number of systemic options should promote the development 
of effective multi-pronged therapies. 
Considering “worst-case scenarios” and the possible need for complex therapies 
helped guide this project.  Current conceptual frameworks, past treatment failures, and 
the immunoediting and CSC theories identified potential therapy-development challenges 
in advance.  For example, “working backwards” from a patient-specific therapeutic vision 
directed attention to the critical importance of maintaining and manipulating primitive 
tumor cells.  CSCs available in specimens need to be maintained.  If only mature cancer 
cells are available, they may need to be converted to CSC-like cells via chemical or 
genetic engineering or by in vitro use of immune-selection (Noh, 2012b) or chemo-
therapeutic pressures.  Presumably, partial reprogramming of tumor cells is always an 
option.  Furthermore, some specific genetic-engineering tasks might be among the 
options:  for example, Nanog transfection – in the case of some cancers – might render 
tumor cells more stem-like by inducing the same cell changes induced by immune-cell 
attack (Noh, 2012b).  In general, complex in vivo processes that protect and maintain 
normal and malignant stem cells are being replicated in vitro via skillful use of new cell-
engineering and cell-culture techniques.  Learning how to generate and nurture the most 
lethal tumor cells may be necessary (so they can be studied) in order to find ways to kill 
them.  Thus, factors and conditions considered “detrimental” because they sustain tumor 
cells in vivo are useful (for therapy-development) if they are also able to maintain cancer 
cells in vitro.  For example, because “the unholy trinity” – STAT3, cytokines, and chronic 
inflammation (Li, 2011) – supports primitive tumor cells in vivo, these “unholy” factors may 
provide clues for how to maintain tumor cells effectively in vitro.  Also, the same injury-
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induced and inflammation-related mechanisms that activate the genes and signaling 
pathways that protect the (normal) primitive cells (needed for regeneration after injury) 
may also generate and protect stem-like tumor cells in vitro.  Thus, tumor necrosis factor 
(TNF)-α and other pro-inflammatory factors within tumor microenvironments that protect 
melanoma (and other types of tumor cells) from immune-cell attack by inducing their de-
differentiation (Landsberg, 2012) may prove to be useful for in vitro cell engineering. 
In general, a cancer patients cells may need to be expanded in order to have 
adequate numbers of cells for in vitro studies and for the evaluation of candidate therapies 
preclinically.  When engineered T cells, NK cells, and/or dendritic cells are to be infused 
as therapy, having sufficient numbers of these cells may require expanding these cell 
populations in vitro (Tran, 2014).  In general, when considering multi-pronged immune 
therapies, both the technical challenges and therapeutic opportunities are numerous. 
Future directions related to RepSox 
Exploring how RepSox may affect immune-cell activation and Tim-3 expression 
As emphasized, the actions of RepSox suggest this reprogramming tool might 
facilitate the engineering of patient-specific anti-cancer immune therapies.  Questions to 
be answered are straightforward:  How does RepSox affect Tim-3 expression on a cancer 
patient’s non-malignant – but cancer-impaired – dendritic, NK, and T cells?  Can reducing 
Tim-3 on AML cells improve immune-cell activation such as the spontaneous activation 
of γδ T cells via co-culture of these cells?  If so, by virtue of immunologic cross-reactivity 
and the existence of multiple tumor-cell antigens, will immune cells activated against 
RepSox-treated AML cells (whose Tim-3 expression has been eliminated) also be 
reactive against (lyse) the original AML progenitors (that were not exposed to RepSox)?  
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Can RepSox help restore the function of cancer-impaired antigen-presenting and 
immune-effector cells? 
How RepSox affects cancer-impaired immune cells, antigen presentation, and 
immune-cell activation warrants study for two reasons:  (1) combined with other tools, 
RepSox can induce reprogramming (a process that can be used to restore the function 
of immune cells) and (2) used alone, RepSox can reduce expression of Tim-3 (a surface 
receptor that can disrupt the function of immune cells and inhibit immune-cell activation 
via distortion of immune synapses).  As emphasized previously, the function of 
“exhausted” T cells from cancer patients can be restored (“rejuvenated”) in vitro following 
reprogramming to pluripotency (Vizcardo, 2013; Themeli, 2013).  Conceivably, 
combinations of RepSox and other chemicals could be used instead of genetic 
engineering to improve immune-effector-cell activity and antigen presentation just as 
combinations of RepSox and other chemical tools can replace genetic engineering when 
generating pluripotent stem cells (Hou, 2013).  Perhaps “7-factor chemical 
reprogramming” (that fully de-differentiates normal cells) may provide guidance as to how 
RepSox and other chemicals can be used to alter a cancer patient’s malignant cells and 
non-malignant immune cells in ways useful for therapy-development (Hou, 2013).  It 
seems reasonable to conclude that since chemical engineering (Hou, 2013) and genetic 
engineering (Takahashi, 2007) have successfully de-differentiated (normal) cells to 
pluripotency, it should be possible to complete any desired in vitro cell-manipulation task.  
That is, since full reprogramming to pluripotency can be induced in vitro, what cell-
engineering task is not feasible?  To promote cancer therapy-development, RepSox might 
be combined with some of the same factors that are already being used by regeneration 
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researchers to manipulate normal cells (Feng, 2009).  In general, new culture methods 
and research findings have identified a variety of potentially useful factors:  the chemical 
reprogramming tools and “boosters” already being used with RepSox (Feng, 2009; Hou, 
2013), physical conditions like hypoxia (Yoshida, 2009) and 3-D geometries, and 
cytokines and growth factors as well as a variety of support cells including adipocytes, 
osteoblasts, stromal cells, and even CAFs.  Guidance is being provided by the steady 
flow of new advances.  Although the possible combinations may seem overwhelming and 
unlimited, the opportunities are also numerous. 
In this project, the effects of RepSox – and other reprogramming tools (Feng, 2009; 
Hou, 2013) – on antigen-presenting and immune-effector cells and on immune-cell 
activation were not studied, but warrant investigation.  In vitro ways to measure immune-
cell activation are reviewed in Table 7.5.  When evaluating how well immune cells react 
against tumor cells in vitro, adding chemotherapeutic agents like anthracyclines that 
induce “immunogenic” tumor cell death (Zitvogel, 2008; Ma, 2013; Inoue, 2014) might 
indicate whether some “conventional” anti-cancer drugs can further activate the immune 
system and work synergistically with immune strategies.  
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Table 7.5.  Measures of immune cell activation. 
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Regarding Tim-3, functionally exhausted Tim-3+ immune cells can (eventually) 
appear in advanced malignant diseases and chronic viral infections.  Impaired Tim-3-
expressing immune cells are associated with many cancers including melanoma (da 
Silva, 2014), AML (Zhou, 2011), and follicular B-cell non-Hodgkin’s lymphoma (Yang, 
2012).  Exhausted Tim-3+ immune cells have been found in patients with chronic viral 
infections such as HIV (Jones, 2008; Finney, 2013), hepatitis B (Ju, 2010), and hepatitis C 
(Golden-Mason, 2009; McMahan, 2010; Vali, 2010).  Of note, when expressed by 
endothelial cells isolated from human lymphoma tumors, Tim-3 was shown to suppress 
CD4+ helper T-cell activation by stimulating the IL-6/STAT3 pathway (Huang, 2010).  
Mesenchymal stem cells expressing galectin-9 (a Tim-3 ligand) have been shown to 
suppress T-cell proliferation (Gieseke; 2013).  In general, Tim-3 signaling within tumor 
microenvironments is believed to promote tumor progression by suppressing the activity 
of infiltrating immune cells.  That is, the Tim-3 receptor is not simply a marker of impaired 
(“exhausted”) immune cells, but directly suppresses their activity.  Because Tim-3 
expression is a conserved molecular defect on the immune cells of patients with a variety 
of cancers and chronic infections, the ability of RepSox to reduce Tim-3 receptor levels 
in vitro (and, thereby, potentially restore and activate dysfunctional immune cells) may 
help researchers engineer therapies against a variety of diseases. 
Exploring how RepSox may maintain primitive (normal) hematopoietic stem cells 
Chapter VI discusses mechanisms that might explain how RepSox slows decay 
of CD34+ AML cells via its actions on c-Myc and CXCL12 (see Figure 7.2).  Of note, 
CXCL12 is also known as “stromal cell-derived factor 1” (SDF-1).  Considering the actions 
of RepSox on TGF-β signaling and CXCL12, RepSox might also help maintain primitive 
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(normal) hematopoietic stem cells in specially designed culture systems.  For example, 
regarding the method developed by Khan, et al (Ali, 2014) – that is able to maintain and 
expand HSCs/HPCs in vitro – perhaps RepSox could replace use of “hKirre stromal-cell 
engineering” in their co-culture system.  Why consider incorporating RepSox?  RepSox 
seems potentially useful because Khan proposed that hKirre may promote the stemness 
and multipotency of umbilical cord blood cells (when co-cultured with stromal cells) via 
two hKirre-induced effects:  promotion of CXCL12 and inhibition of TGF-β.  Because 
RepSox can increase CXCL12 (Larsen, 2013; Jajosky, 2014) and inhibit TGF-β signaling 
(Gellibert, 2004), RepSox might replace the hKirre manipulation of stromal cells in their 
co-culture system and, thereby, help maintain and expand HSCs/HPCs more easily.   
Regarding RepSox-related mechanisms, exposing cells to RepSox in vitro might – 
via CXCL12 upregulation – inhibit the death and differentiation of stem-like cells (that 
occurs spontaneously ex vivo) by inhibiting the AhR pathway.  Of note, hypoxic 
microenvironments can preferentially sustain stem-like cells in vivo.  Perhaps RepSox 
(via CXCL12) can enhance hypoxia inducible factor (HIF) activity in vitro, and increased 
HIF activity, in turn, has been shown to inhibit the AhR pathway.  Of note, CXCL12 is a 
“hypoxia-inducible gene,” and the CXCL12 promoter contains hypoxia inducible factor-1α 
(HIF-1α) binding sites.  Also, CXCL12 has been found to activate the PI3K/Akt pathway, 
and PI3K/Akt signaling contributes to activation of HIF-1α in the context of hypoxia.  
Research findings suggest CXCL12, HIF, and the AhR pathway are closely related. 
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Figure 7.2: Potential mechanisms of RepSox action on AML cells. 
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Of note, scientists feel “the balance” of CXCL12 and TGF-β (or the “cross-talk” 
between these factors) controls a “cell-fate switch” that determines whether cells remain 
stem-like or differentiate.  Researchers are interested in the mechanisms for cell-cycle 
regulation and self-renewal (how “the balance of cycling/quiescence” is controlled) 
because a more comprehensive understanding of these mechanisms will advance cell 
engineering (Lataillade, 2002; Chabanon, 2008).  The existence of this 2-factor “cell-fate 
switch” is suggested by experimental observations (Chabanon, 2008) and may explain 
why RepSox is proving to be an especially useful and potent cell-engineering tool.  
Perhaps RepSox is unique:  RepSox not only inhibits TGF-β, RepSox upregulates 
CXCL12 in (normal) mouse embryonic fibroblasts (Larsen, 2013) and in (malignant) AML 
cells (Jajosky, 2014).  Of note, in this AML study, other TGF-β inhibitors did not increase 
CXCL12 (Jajosky, 2014).  By increasing CXCL12 mRNA levels, RepSox may be a unique 
TGF-β inhibitor that can serve as a useful, and convenient, “CXCL12 research tool” that 
might replace, in some situations, use of expensive recombinant CXCL12 (aka SDF-1). 
Clarifying how RepSox affects CXCL12 and c-Myc 
One specific, potentially informative RepSox-related study could assess the effects 
of exposing AML cells to a combination of RepSox and the CXCR4 antagonist “AMD3100” 
for less than 5 days.  Of note, short-term exposure (less than 5-days) to AMD3100 may 
be critical clinically.  A “5-day cut-off” for AMD3100-exposed leukemia cells was identified 
by Kim, et al who observed two very different net effects induced by AMD3100 in vitro 
depending on whether the duration of AMD3100 exposure was greater than 5-days or 
less than 5-days (Kim, 2011).  Of note, AMD3100 can be used clinically to mobilize 
primitive (normal or leukemic) blood cells from the bone marrow into the peripheral blood 
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(Liles, 2003; Broxmeyer, 2005).  AMD3100 reduces the ability of the CXCL12/CXCR4 
axis to chemotactically retain primitive blood cells within the bone marrow where CXCL12-
secreting stromal cells attract CXCR4-expressing cells.  AMD3100 reduces CXCL12 
binding to CXCR4 by competitively binding to the CXCR4 surface receptor (Donzella, 
1998; Rosenkilde, 2004).  Thus, AMD3100 reduces the effects of CXCL12 mediated by 
the CXCL12/CXCR4 axis and is considered a CXCR4 antagonist, although it has some 
partial agonist activity in vitro (Zhang, 2002).  However, a second CXCL12 receptor, 
CXCR7, has recently been discovered, and AMD3100 also binds to this receptor – but at 
a separate allosteric site not used by CXCL12 (Kalatskaya, 2009).  The net effect is that 
during the first 5-days of exposure, AMD3100 (an “antagonist”) may actually enhance the 
CXCL12-related effects induced by RepSox because AMD3100 can independently (non-
competitively) activate the CXCL12/CXCR7 axis.  If activation of the CXCL12/CXCR7 
axis (vs. the CXCL12/CXCR4 axis) is the key mechanism by which stem-cell maintenance 
and self-renewal are promoted, then AMD3100 might – during the first 5-days of 
combined exposure – enhance (instead of reduce) the ability of RepSox to maintain 
primitive AML cells.  Of note, the ability of AMD3100 to potentially promote the 
maintenance and proliferation of primitive leukemia cells (via CXCL12/CXCR7 axis 
activation) is an issue – a warning – prudently raised by Kim et al because AMD3100 is 
used clinically to mobilize leukemia cells.  They are concerned because AMD3100 has 
been assumed to be safe when viewed as a CXCL12 antagonist – before CXCR7, 
AMD3100-CXCR7 binding, and the actions of the CXCL12/CXCR7 axis had been 
identified (Kalatskaya, 2009).  Based on their insights into CXCR7, Kim, et al have 
cautioned that use of AMD3100 could, conceivably, promote the maintenance or 
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proliferation of primitive myeloid leukemia cells (Kim, 2011).  If the addition of AMD3100 
were to further enhance RepSox-induced maintenance of CD34+ AML cells (during the 
first 5 days of combined exposure), this would suggest that promoting CXCL12 in AML 
cells (or in both the stromal and AML cells) helps maintain primitive AML cells in vitro via 
the CXCL12/CXCR7 axis (since AMD3100 inhibits the CXCL12/CXCR4 axis).  Of note, 
studies of normal endothelial cells suggest CXCL12 may maintain normal CD34+ 
hematopoietic stem/progenitor cells via the CXCL12/CXCR7 axis (Torossian, 2014).  
Thus, RepSox may promote AML CD34+ cell survival in part, or entirely, via the 
CXCL12/CXCR7 axis.  The extent to which a patient’s CD34+ AML cells express CXCR4 
and/or CXCR7 may determine how well RepSox slows the decay of these AML cells.  
Exposing AML cells to combinations of AMD3100 and RepSox could clarify this issue. 
To explain how the effects of RepSox on AML cells may be related to c-Myc, the 
CXCL12/CXCR4 axis, or the CXCL12/CXCR7 axis, normal stromal cells (from a healthy 
donor) and an AML patient's leukemia cells and CAFs can be exposed to combinations 
of (1) RepSox and c-Myc inhibitors such as 10058-F4 (Huang, 2006) and (2) RepSox and 
CXCR4 and CXCR7 agonists and antagonists.  Since these research tools are available, 
it should be possible for interested researchers to clarify, in detail, RepSox-induced 
effects that are due to changes in CXCL12 and/or c-Myc. 
RepSox studies may also be able to clarify how CAFs support tumor cells.  Of note, 
Kojima, et al identified CXCL12 and TGF-β as two factors critical for the evolution of 
stromal cells into tumor-promoting CAFs (Kojima, 2010):  the same two factors believed 
to control the “cell-fate switch” (Chabanon, 2008).  Activation of autocrine TGF-β and 
CXCL12 signaling promotes conversion of stromal cells into tumor-promoting CAFs 
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(Chabanon, 2008).  Regarding fibroblasts from healthy animals (fibroblasts not exposed 
to cancer microenvironments), RepSox upregulates CXCL12 in mouse embryonic 
fibroblasts (Larsen, 2013) and inhibits TGF-β signaling (Gellibert, 2004; Ichida, 2009).  
Thus, a potentially informative in vitro study might involve comparing how three different 
populations of stromal cells can support a patient's AML cells in vitro:  (1) the cancer-
altered CAFs obtained from the (same) AML patient, (2) normal stromal cells (from a 
healthy source) that had been exposed to RepSox, and (3) normal stromal cells that had 
not been exposed to RepSox.  In general, the actions of TGF-β on stromal cells and 
cancer cells are complex and time-dependent.  As noted by Caestecker, et al, during 
cancer progression, tumor cells often escape from the anti-proliferative effects of TGF-β 
through acquired mutations or dysregulation of the TGF-β signaling pathway (de 
Caestecker, 2000).  Furthermore, Kojima, et al noted that some interactions between 
TGF-β and CAFs involve the CXCL12/CXCR4 axis:  In stromal fibroblasts, TGF-β 
promotes TGF-β and CXCL12 autocrine signaling loops (by promoting TGF-β and 
CXCL12 production and inducing CXCR4 expression) which reciprocally cross-stimulate 
each other in a positive feedback manner to maintain the CAF phenotype (Kojima, 2010).  
Thus, experiments that compare how tumor cells are influenced by CAFs, normal stromal 
cells, and RepSox-treated stromal cells – and that skillfully exploit CXCR4 and CXCR7 
antagonists, blocking antibodies, inhibitors, and other tools – may clarify how support cells 
promote the survival of CSCs.  Learning how RepSox affects support cells may be as 
valuable as learning how RepSox can alter a cancer patient's tumor and immune cells.  
The evolution of support cells in cancer patients warrants study because 
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microenvironments protect and sustain the primitive tumor cells that trigger cancer 
relapses. 
Investigating how RepSox might help generate anti-AML immune-cell therapies 
Since RepSox maintains primitive AML cells, upregulates CXCL12, and decreases 
Tim-3, RepSox may promote the activation of immune cells by leukemia-cell antigens that 
could, under the proper circumstances, directly bind to immune-cell receptors.  This 
seems feasible when the immunologic synapse between immune cells and AML cells is 
visualized in the context of prior research findings.  One way to help readers visualize 
how RepSox may enhance the direct synapse between AML and immune cells involves 
the method developed by Gertner-Dardenne and colleagues (Gertner-Dardenne, 2012).  
In their co-culture system (which includes a “TCR agonist”), a patient’s AML cells directly 
present antigens to immune cells, and this spontaneously activates the patient’s γδ T cells 
against “tumor-associated” AML antigens (Gertner-Dardenne, 2012).  This spontaneous 
activation of T cells triggered by the co-culture of AML and immune cells highlights the 
structure of the immunologic synapse.  AML surface-antigens bind to (and activate) T-cell 
receptors like TCR and DNAM1 (Gertner-Dardenne, 2012).  In the context of this AML-
cell/immune-cell synapse, the actions of RepSox seem especially relevant and potentially 
useful.  First, RepSox could promote the activation of immune cells against critically 
important stem-cell antigens by helping to maintain (in vitro) primitive CD34+ AML cells 
that are more likely to display LSC antigens than more mature AML cells.  For those 
immune cells expressing the CXCR4 receptor, RepSox could enhance the physical 
aggregation of AML cells and immune cells via upregulation of AML-cell CXCL12 (Smith, 
2013).  That is, RepSox might promote chemoattraction and increase the number of 
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immunologic synapses that form during co-culture of AML and immune cells.  By 
decreasing Tim-3 expression, RepSox could reduce the distortion and dysfunction of the 
immunologic synapse that results when the Tim-3 receptor is present (Clayton, 2014).   
Of note, it seems prudent to address a potential confusion that can emerge when 
Tim-3 is simply called an “LSC antigen.”  It is suggested here that Tim-3 on leukemia cells 
should, instead, be viewed as an “antigen on highly evolved LSCs.”  That is, LSCs that 
originally did not express Tim-3 may eventually display Tim-3 after leukemic disease has 
advanced and LSCs have evolved into more problematic and death-resistant LSCs.  By 
simply referring to Tim-3 as an “LSC antigen,” some AML cells that do not express Tim-3 
might not be viewed as LSCs even though they are LSCs that have not yet evolved 
substantially and represent “early versions” of the original (disease-initiating) LSCs.  It is 
assumed here that LSCs, like immune cells, evolve as malignant disease progresses, 
and that the more highly evolved LSCs can display Tim-3 (Zhou, 2011).  Of note, the 
RepSox-treated AML cells whose Tim-3 expression was eliminated in this study still 
exhibited aldehyde dehydrogenase activity.  If it is assumed that only Tim-3-expressing 
AML cells should be used to activate immune cells (by assuming only these AML cells 
are LSCs and only these cells express relevant stem-like tumor antigens), this could be 
counter-productive since Tim-3 can disrupt the immunologic synapse and, thereby, 
prevent in vitro immune-cell activation (Clayton, 2014). 
Also for clarity, it is assumed here that the expression of AML cell-surface antigens 
is, in general, influenced by both the differentiation and evolution of AML cells.  Noh and 
colleagues showed how cancer cells can change in response to “immune-selection 
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pressures” and that a range of tumor cells with different phenotypes – reflecting different 
stages of evolution – could engraft disease in mice (Noh, 2012). 
Regarding Tim-3 on tumor cells, Tim-3 has been linked to advanced stages of 
cancer and poor patient prognosis (Zhuang, 2012).  This suggests Tim-3 expression 
emerges via tumor-cell immunoediting (cell plasticity and evolution) as malignant disease 
progresses (Zhou, 2011).  Tim-3 receptors, in turn, can disrupt the immunologic synapse 
(Clayton, 2014), and this may explain how the more highly evolved cancer cells are better 
able to evade immune-cell attack. 
The RepSox-related research option suggested here assumes that critical tumor-
associated antigens on stem-like RepSox-exposed AML cells (that do not display Tim-3 
surface receptors) can activate immune cells against primitive relapse-causing AML cells 
because expression of some LSC antigens should be unrelated to Tim-3 expression.  
Thus, exposing AML cells to RepSox may enhance immune-cell activation (by reducing 
AML-cell Tim-3 expression) as well as the aggregation (chemoattraction) of AML and 
CXCR4-expressing immune cells (by upregulating CXCL12).  Of note, it is generally 
agreed that (1) the immunologic synapse is disrupted by Tim-3 and (2) chemoattraction 
involving CXCR4-expressing cells is enhanced by CXCL12 (Clayton, 2014; Kumar, 2006; 
Braza, 2010).  Thus, RepSox may simultaneously enhance immune-cell activation and 
increase the number of immunologic synapses in co-culture systems (Smith, 2013). 
As a specific example, RepSox might help generate therapeutic immune cells 
when incorporated into the co-culture system developed by Gertner-Dardenne and 
colleagues (Gertner-Dardenne, 2012).  When their method is used to co-culture a patient’s 
AML and immune cells – which exploits the “TCR agonist” bromohydrin pyrophosphate 
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(BrHPP) – AML cells present AML-associated antigens to γ9δ2 T cells and spontaneously 
activate them (Gertner-Dardenne, 2012).  F1F0-ATPase, PVR (CD155), and Nectin-2 
(CD112) are some of the AML surface antigens thought to bind to, and activate, the 
γδTCR or DNAM1 (CD226) receptors on the T cells (Gertner-Dardenne, 2012; Wen-Li, 
2012; Scotet, 2005).  After expanding and infusing these activated γ9δ2 T cells, survival 
improved in an animal model of AML (Gertner-Dardenne, 2012).  Especially encouraging, 
these activated T cells had “memory” features which, potentially, can very effectively 
prevent cancer relapses (Gertner-Dardenne, 2012). 
In the study by Gertner-Dardenne and colleagues, the phenotypic profile of the 
AML blasts was not specified.  Thus, it is not known whether the patient-derived AML cells 
used to present tumor antigens to the immune cells were mature or stem-like.  It seems 
prudent to assume that the phenotype of the AML cells can affect T-cell activation.  That 
is, it seems reasonable to expect that the specific AML cell antigens presented to immune 
cells (to activate them) will depend on how stem-like the AML cells are.  Presumably, the 
more stem-like the AML cells are, the more likely the activated immune cells will be 
reactive against those stem-like AML cells (the “minimal residual disease” cells) that can 
trigger disease-relapse.  Thus, it seems prudent to exploit methods that can isolate, 
generate, and/or maintain stem-like AML cells so LSC-like AML cells are used to present 
antigens when activating immune cells.  By first helping to maintain primitive CD34+ AML 
cells, RepSox should increase the likelihood that LSC antigens are presented to immune 
cells (by the RepSox-treated AML cells) when the immune cells are activated during co-
culture.  That is, RepSox might enhance the γ9δ2 T-cell activation method of Gertner-
Dardenne by supplying LSC-like AML cells for co-culture with the patient’s immune cells.  
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Remarkably, the γ9δ2 T cells activated by AML-cell/immune-cell co-culture have 
the potential, in turn, to present antigens to, and activate, αβ T cells (Brandes, 2009; 
Anderson, 2012).  Exploring this technique for activating αβ T cells – as well as other 
ways to activate NK cells and other γδ T cells (not just γ9δ2 T cells) – seems especially 
appropriate for anti-AML therapy-development since AML cells can directly activate γ9δ2 
T cells.  If RepSox can enhance γ9δ2 T-cell activation, this may, in turn, facilitate the 
activation of other immune cells in subsequent phases of therapy-development. 
Regarding molecular mechanisms, the “tumor-associated antigens” on AML cells 
thought to spontaneously activate γ9δ2 T cells include Nectin, PVR, and F1F0-ATPase.  
Of course, when AML cells spontaneously activate γ9δ2 T cells, other unknown AML cell-
surface antigens may be involved.  By eliminating synapse-disruption by Tim-3, perhaps 
RepSox can enable AML cells to more directly present AML antigens (like Nectin, PVR, 
and F1F0-ATPase) to receptors on immune cells.   
Overall, it seems reasonable to investigate how RepSox might enhance the 
spontaneous activation of immune cells by AML cells in co-culture systems.  Exploring 
diverse AML co-culture options might identify ways that a broad spectrum of αβ T cells, 
NK cells, and other γδ T cells (not just γ9δ2 T cells) can be activated against AML cells.  
As noted, just as AML cells serve as antigen-presenting cells to activate immune cells, 
γ9δ2 T cells activated by AML cells can, in turn, serve as antigen-presenting cells that 
can activate αβ T cells (Deniger, 2013).  Perhaps combinations of activated γ9δ2 T cells, 
AML cells, and chemical factors can be found that are able to activate a broad range of 
immune cells for therapeutic purposes (a spectrum of NK, γδ T cells, and αβ T cells) 
without, for example, using genetic engineering to insert chimeric antigen receptors 
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(CARs).  If genetic engineering cannot be avoided, it is reassuring that Deniger and 
colleagues have successfully activated polyclonal γδ T cells with broad anti-tumor 
capability using CAR technology and “artificial” antigen-presenting cells (Deniger, 2013).  
However, in view of the great diversity of AML cells among patients, co-culture methods 
that can exploit spontaneous immune-cell activation may eliminate the need to identify, 
in advance, specific AML “tumor-associated” surface-antigens – a task required when, for 
example, deciding what CAR insertions are to be genetically engineered. 
To summarize this research option, the unique actions of RepSox might help 
generate anti-AML γ9δ2 T-cell therapies by, first, maintaining LSC-like AML cells that 
could be used to present stem-like AML antigens in co-culture systems that activate a 
patient’s γ9δ2 T cells.  Then, either simultaneously or in a separate in vitro process, 
RepSox might improve γ9δ2 T-cell activation when a patient’s immune and (LSC-like) 
AML cells are co-cultured.  That is, since RepSox maintains primitive CD34+ AML cells 
(that may display LSC-like tumor antigens), reduces Tim-3 expression (which disrupts 
immunologic synapses), and upregulates CXCL12 (that may increase chemoattraction 
and the number of immunologic synapses), RepSox may promote the co-culture 
activation of γ9δ2 T cells against those primitive AML cells that trigger AML relapse.  
RepSox may be especially useful in advanced AML disease when LSCs have evolved to 
express Tim-3 cell-surface receptors which, in turn, disrupt immunologic synapses and 
inhibit immune-cell activation. 
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Future directions not involving RepSox 
Students should enjoy and embrace the improvements in conceptual frameworks 
for cancer, immunology, and tissue regeneration as well as the steady clarification of 
molecular mechanisms and signaling pathways.  This progress is inspiring innovative 
therapeutic strategies which, in turn, are identifying key technical challenges and exciting 
research options.  Immunology and regeneration research are directing attention to new 
tools and methods that can be used to engineer immunotherapies in vitro. 
“7-factor” (chemical) reprogramming to pluripotency directs attention to the six 
other reprogramming factors that were used with RepSox (Hou, 2013).  Perhaps these 
molecules can alter tumor-cell survival, differentiation status, immunogenicity, or other 
cellular features in ways useful for therapy-development.  Like RepSox, three other 
chemicals were described as being especially useful:  CHIR99021 (a glycogen synthase 
kinase 3 [GSK3-β] inhibitor), Forskolin (a cAMP agonist), and 3-deazaneplanocin A 
(“DZNep”; an S-adenosyl-homocysteine hydrolase inhibitor) (Hou, 2013).  Perhaps 
combining one or more of these tools with RepSox would enhance the ability of RepSox 
to maintain the survival of primary CD34+ AML cells.  The remaining three factors included 
valproic acid (a histone deacetylase [HDAC] inhibitor), tranylcypromine (a monoamine 
oxidase inhibitor), and “2i” treatment involving dual inhibition of mitogen-activated protein 
kinase signaling and GSK3-β.  “Reprogramming boosters” were also identified including 
D4476 (an inhibitor of casein kinase I), 2-methyl-5-hydroxytryptamine (closely related to 
the neurotransmitter serotonin), basic fibroblast growth factor, prostaglandin E2, 
SRT1720 (a sirtuin 1 activator), and sodium butyrate (a HDAC inhibitor) (Hou; 2013).  In 
general, because these agents and other molecular tools (Feng, 2009) promote cellular 
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reprogramming (like RepSox), they may also alter the tumor and immune cells of AML 
patients in ways that can facilitate therapy-development. 
Perhaps co-culturing a leukemia patient's tumor cells with support cells such as 
adipocytes, osteoblasts, stromal cells, or the patient's own CAFs would be helpful – or 
use of a 3-D cell-culture system.  A trial-and-error approach may be unavoidable when 
trying to identify combinations of factors that might better maintain or alter the cells of 
AML patients.  However, insights into signaling pathways and molecular mechanisms 
may predict worthwhile combinations.  Regarding the activation of immune cells by tumor 
cells in vitro, adding chemotherapeutic agents like anthracyclines that induce 
immunogenic tumor-cell death (Inoue, 2014) may demonstrate whether or not some 
“conventional drugs” can enhance immune responses and work synergistically with 
immunologic strategies.  In general, promising research options are unlimited due to the 
dramatic advances generated by cancer and regeneration research.  When evaluating 
cell-engineering tools, effects will depend on the concentrations and combinations of 
factors and whether they are used simultaneously or sequentially.  The steady discovery 
of new and exciting tools means setting priorities will be challenging.  The ability to more 
predictably alter tumor and immune cells is increasing as evidenced by the impressive, 
rational design of “7-factor chemical de-differentiation” (Hou, 2013) along with 
reprogramming efficiencies near 100% (Rais, 2013).  Because mature cells have been 
chemically reprogrammed to pluripotency (Hou, 2013), any desired in vitro cell 
manipulation now seems feasible.  Still, despite dramatic advances, a basic challenge is 
likely to persist for years:  the development of simple techniques that can maintain – or 
generate as needed – a patient's CSCs in vitro for therapy-development purposes.   
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Practical considerations for students 
In addition to describing specific ways RepSox might be used for in vitro cell 
engineering, therapy-development, and the clarification of mechanisms, this dissertation 
seeks to provide a useful overview.  Although interactions between cancer cells and the 
immune system are numerous, complex, and even intimidating, students should 
appreciate how each newly identified mechanism provides an opportunity for intervention 
and therapeutic synergy.   
When planning to engineer anti-cancer immune therapies in vitro, it seems 
worthwhile to consider those in vivo mechanisms that very effectively support tumor cells.  
In general, in vivo cancer microenvironments promote the maintenance and proliferation 
of CSCs while inhibiting the activation of immune cells.  In contrast, in vitro conditions are 
“the reverse” in that it is difficult to maintain stem-like cancer cells ex vivo but effective 
immune-cell activation is possible in the absence of the immunologic restraints that exist 
in vivo.  Understanding these differences can provide guidance for generating and/or 
maintaining (in vitro) the stem-like cancer cells that can serve as relevant “target cells” 
when designing antibody or immune-cell therapies. 
Considering conceptual frameworks – like the CSC and immunoediting theories –
is also worthwhile.  They explain why the immune-evasive and immune-suppressing 
CSCs that trigger relapse must be eliminated (as well as the more mature and prevalent 
“bulk” tumor cells) and that, because CSCs evolve, the sooner the better.  To cure some 
patients, their own immune cells may need to be activated against CSC antigens and 
administered along with other personalized and conventional therapeutic strategies such 
as antibodies, immuno-modulating agents, surgery, chemotherapies, etc.   
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Another worthwhile exercise is visualizing how the immunologic synapse is 
involved in immune-cell activation.  When a cancer is highly advanced and a patient’s 
specimens lack CSCs and immune cells that are functional (”reactive”), generating 
immune cells in vitro that are reactive against CSC antigens may be difficult.  In this 
problematic scenario, it can be instructive to visualize how RepSox might enhance 
immunologic synapses in the specific context of co-culture systems that use a patient’s 
AML cells to activate γ9δ2 T cells.  The actions of RepSox suggest RepSox could facilitate 
in vitro activation of γ9δ2 cells against AML LSCs by enhancing (1) chemoattraction, 
(2) presentation of LSC antigens, and/or (3) activation of immune cells (by eliminating the 
adverse influence of Tim-3).  That is, RepSox might enhance immunologic-synapse 
formation between AML and γδ T cells.  RepSox seems especially useful because AML 
cells directly present antigens to, and activate, γδ T cells.  Thus, because RepSox (alone 
or in combination with other culture conditions and factors) may help maintain, or 
generate, primitive AML cells, RepSox may, thereby, help supply the primitive AML cells 
that can present (to immune cells) the LSC antigens that need to be targeted to prevent 
relapse.  That is, by helping to provide LSC-like AML cells, RepSox may help activate 
immune cells so they are reactive against relapse-causing AML cells.  During co-culture, 
RepSox may promote immunologic synapse formation and immune-cell activation by 
upregulating CXCL12 and/or by decreasing Tim-3 expression.  Perhaps RepSox may 
enhance immune-cell activation against LSC antigens when incorporated into the co-
culture method developed by Gertner-Dardenne, et al (Gertner-Dardenne, 2012). 
In addition to considering ways to improve the activation of T cells by AML cells, 
students should consider other challenges.  It seems prudent to anticipate “worst-case 
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scenarios” involving (1) tumor cells that are highly evolved and immune-resistant, 
(2) antigen-presenting and immune-effector cells that are markedly dysfunctional, and 
(3) specimens that may not contain adequate numbers of HSCs or primitive tumor cells.  
Fortunately, many new methods are becoming available, but students may still need to 
develop their own special techniques to accommodate the novel therapies they envision.   
In the case of leukemia, for example, students may need to consider how they can best: 
1. Obtain useful patient specimens that, ideally, contain the cells needed to engineer 
immunotherapies:  primitive tumor cells to be targeted, normal HSCs to be spared, 
and dysfunctional antigen-presenting and immune-effector cells to be repaired.  
Leukapheresis specimens, obtained from patients with high white blood cell 
counts, contain billions of cells that are often discarded as waste.  Aldefluor 
staining is a simple technique that distinguishes normal (ALDHbright) from AML 
(ALDHintermediate) stem/progenitor cells based on their unique staining patterns 
(Pearce, 2005; Gerber, 2012).  
2. Maintain and manipulate tumor, antigen-presenting, and immune-effector cells as 
well as isolate normal HSCs for comparison purposes.  The bone marrow stromal 
cells that have evolved in a cancer patient (CAFs) may help to maintain that 
patient’s tumor and immune cells in vitro. 
3. Develop co-culture methods that use primitive leukemia cells to activate immune 
cells so these immune cells are reactive against the stem-like leukemia cells that 
can trigger disease-relapse. 
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4. Identify those anti-apoptotic factors in a patient's primitive tumor cells that inhibit 
tumor-cell killing when a candidate immune-cell therapy is tested in vitro. 
5. Identify therapeutic agents (such as small molecules or oligonucleotides) that 
could safely be administered to patients to inhibit transcription of problematic anti-
apoptotic factors (or promote transcription of apoptotic factors) within tumor cells 
without harming normal HSCs. 
6. Repair, activate, and/or expand cancer-impaired antigen-presenting and/or 
immune-effector cells (by, for example) reprogramming these cells, altering cell-
surface antigens, enhancing tumor-antigen presentation, co-culturing immune and 
cancer cells with “TCR agonists” or via other strategies reviewed in Chapter IV.    
7. Compare leukemia cells and normal HSCs to identify tumor-specific (or LSC-
specific) cell-surface antigens or even notable intracellular differences. 
8. Determine if some immune cells in a patient's specimen already react against 
tumor antigens.  If so, select, or develop, a way to expand these cells.  If reactive 
immune cells are not available, engineer (repair, activate, and expand) immune 
cells to be reactive against a suitable tumor-specific antigen. 
9. Modulate tumor cells so they are more immunogenic or, more generally, improve 
immunologic-synapse formation in vitro to promote antigen-presentation and the 
activation of immune cells.    
10. Identify how tumor cells impair immune-cell activation and acquire death-resistant 
phenotypes when attacked by immune cells or antibodies.    
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11. Render tumor cells more stem-like in vitro, if needed, so they can serve as suitable 
in vitro therapeutic targets (by resembling the disease-sustaining LSCs that reside 
in vivo).  This conversion into stem-like tumor cells may require chemical or genetic 
engineering or exposure to stresses involving serial rounds of immune-selection 
or chemotherapeutic “pressure.” 
12. Design multi-pronged immune therapies:  combinations of antibodies, activated 
immune cells, agents that render tumor cells less death-resistant, factors that 
enhance immune responses (such as cytokines like IL-2), cytotoxic agents that 
induce immunogenic tumor cell death, and/or agents that mitigate the adverse 
impact of cancer-supporting microenvironmental cells and molecular factors that  
emerge as malignant disease progresses. 
13. Evaluate candidate immune therapies pre-clinically in vitro. 
 
Finally, students may find it instructive – and motivating – to consider how some 
therapeutic options that have already been developed might be combined to create 
rational, multi-pronged anti-cancer therapies.  As noted previously, anti-cancer options 
are diverse and range from traditional in vivo tasks (the physical removal of malignant 
cells or systemic modulation of tumor cells, support cells, and the immune system) to 
new, more technically complex in vitro tasks (such as the skillful engineering of a patient’s 
immune cells).  For a blood cancer like AML, bulk tumor-cell removal is accomplished by 
leukapheresis which reduces the immune suppression induced by malignant cells.  
“Conventional chemotherapeutic drugs” that induce ICD (cytarabine, daunorubicin, 
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mitomycin, etc.) not only kill cancer cells, but also enhance anti-cancer immune 
responses and promote tumor-cell apoptosis (Fredly, 2011).  Cytokines like IL-2 can be 
administered systemically to enhance immunologic responses, and the impact of IL-2 
may be enhanced by histamine dihydrochloride (Romero, 2009).  Regarding immune-cell 
strategies, a patient’s γ9δ2 T cells can be directly activated against a patient’s stem-like 
AML cells via a co-culture system that exploits a TCR agonist (Gertner-Dardenne, 2012) 
– an in vitro process that might be enhanced by RepSox.  After expansion, these T cells 
could serve as the anti-LSC component of a multi-pronged therapy and provide long-term 
protection by functioning as “memory effector” immune cells.  Ideally, NK cells, DCs and 
a broad spectrum of γδ and αβ T cells would be exploited.  Regarding the death-
resistance of stem-like cancer cells, primitive tumor cells might be rendered more 
susceptible to immune-cell attack by administering systemic agents that reduce the levels 
of key anti-apoptotic factors.  For example, the antisense oligonucleotide “AEG35156” 
has been shown to reduce the levels of anti-apoptotic factor XIAP and, thereby, promote 
apoptosis of AML stem cells (Carter, 2011).  Regarding systemic immune suppression 
induced by Tregs, IL-2 diphtheria toxin fusion protein has promoted clearance of AML cells 
via depletion of Tregs (Bachanova, 2014).  Regarding MDSCs, the agent “sunitinib,” a 
receptor kinase inhibitor, has, in some cancer patients, enhanced the effectiveness of 
immune-based strategies and reversed immune suppression by reducing the numbers of 
MDSCs as well as Tregs (Ozao-Choy, 2009).  An anti-CTLA-4 antibody (MDX-010) 
improved the ability of AML-derived DCs to activate T cells against AML cells in an 
autologous culture system (Zhong, 2006).  Envisioning such options illustrates how the 
complexity of malignant disease provides many opportunities for intervention. 
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Summary 
The interactions between cancer cells and the immune system are complex and 
fascinating.  Remarkably, valuable insights into cancer and immunology have been 
prompted by very diverse and unusual observations.  For example, infections, chemical 
warfare agents, and limb regeneration in salamanders have suggested that immune 
stimulation, immunogenic tumor-cell death, and cellular de-differentiation are biological 
phenomena worth considering when treating cancer patients.  Perhaps some will find it 
counter-intuitive that the non-malignant cells of cancer patients are attracting intense 
attention:  current therapeutic cell-engineering agendas involve (non-malignant) antigen-
presenting and immune-effector cells, and researchers are also identifying the critical 
roles played by CAFs and other micorenvironmental factors that so effectively support 
malignant cells.  Immune-cell therapies can be created in vitro using genetic engineering 
techniques (like CAR insertion) or co-culture methods that promote the spontaneous 
activation of immune cells by cancer cells.  Multi-pronged therapies may be required that 
can simultaneously exploit diverse ways to promote the killing of tumor cells, enhance the 
immune system, or reverse the cancer-promoting features of cancer microenvironments.   
More than 100 years after spontaneous tumor regressions were linked to 
concomitant infections, cancer researchers are now rationally engineering therapies that 
are predictably saving the lives of cancer patients (Kalos, 2011; Porter, 2011).  Successful 
therapies include immune-based components (passively administered or actively 
induced) that eliminates those problematic, primitive cancer cells that can trigger relapse.  
Despite the complexity of malignant diseases, this is an historic era of cancer cures.  
Fantastic advances in cell engineering have facilitated the development of life-saving 
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therapies.  Given this historic context, students should feel fortunate.  Students should 
confidently envision innovative therapies, eagerly confront technical challenges, and 
creatively exploit new tools and methods.  
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